flutamide has been researched along with Cancer of Prostate in 979 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effectiveness and safety of tamsulosin combined with androgen deprivation therapy (ADT) for lower urinary tract symptoms (LUTS) in advanced prostate cancer (PC) patients." | 9.24 | Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients. ( Ding, K; He, W; Liu, S; Wu, H; Zhang, T, 2017) |
| "To determine whether the nonsteroidal antiandrogenic drug flutamide is a clinically relevant inducer of methemoglobinemia in patients with prostatic cancer." | 9.09 | Lack of methemoglobinemia with flutamide. ( Becker, H; Donn, F; Schmoldt, A; Schulz, M, 2001) |
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 9.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| "This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma." | 9.07 | The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991) |
| "Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma." | 8.78 | Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991) |
| " This paper demonstrated that flutamide combined with leuprorelin acetate produced a significant reduction in the growth rate of Dunning R3327-H prostatic adenocarcinoma." | 7.70 | [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats]. ( Abe, F; Kuroiwa, S; Okada, M; Tomura, A, 1998) |
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 7.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 7.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "To assess the effectiveness of palladium-103 brachytherapy in stage T1 and T2 adenocarcinoma of the prostate." | 7.70 | Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. ( Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C, 2000) |
| "We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate." | 7.69 | Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. ( Braslis, KG; Civantos, F; Davi, RC; Nelson, E; Soloway, MS, 1995) |
| "Three of 34 patients treated with a TAS regimen incorporating flutamide developed significant hepatic abnormalities: elevated transaminases [2] and fatal hepatic necrosis [1]." | 7.69 | Flutamide-induced liver toxicity including fatal hepatic necrosis. ( Chen, A; Crownover, RL; Fu, KK; Holland, J; Krieg, R; Roach, M; Young, BK, 1996) |
| "Six men being treated for advanced prostate carcinoma with flutamide/finasteride combination therapy developed painful gynecomastia, which was treated with tamoxifen 10 to 30 mg/day for 1 month." | 7.69 | Tamoxifen for flutamide/finasteride-induced gynecomastia. ( Lowe, FC; Staiman, VR, 1997) |
| "A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3." | 7.68 | Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993) |
| "The authors report a case of clinical methemoglobinemia occurring one year after a patient began receiving flutamide 750 mg/d for prostate cancer with bone metastasis." | 7.68 | Flutamide-induced methemoglobinemia. ( Chareyre, S; Delmas, PD; Gozzo, I; Schott, AM; Vial, T, 1991) |
| "The histopathology of 23 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for 3-6 months with combination therapy including a luteinizing hormone-releasing hormone agonist and the antiandrogen drug flutamide was reviewed and compared with the pretreatment biopsies or transurethral resection material." | 7.68 | Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. ( Boivin, JC; Dupont, A; Labrie, F; Monfette, G; Pinault, S; Srigley, JR; Têtu, B, 1991) |
| "High-grade prostatic intraepithelial neoplasia (HGPIN) appears to represent an ideal target for chemoprevention of prostate cancer (PCa)." | 6.73 | Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. ( Wenlu, S; Zhigang, Z, 2008) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 6.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide)." | 5.40 | [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)]. ( Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A, 2014) |
| "High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma." | 5.31 | Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. ( Alberts, SR; Blute, ML, 2001) |
| "A seventy-three year-old patient with prostate cancer underwent radical prostatectomy, followed by total androgen brocking therapy using flutamide and LH-RH agonist." | 5.30 | [Fatal hepatic failure following hepatitis caused by flutamide: a case report]. ( Kinebuchi, Y; Murata, Y; Okaneya, T, 1999) |
| "Flutamide was administered to a patient in conjunction with orchiectomy for stage D2 prostate cancer." | 5.29 | Severe reversible neutropenia following treatment of prostate cancer with flutamide. ( Livingston, RB; McDonnell, ND, 1994) |
| "To assess the effectiveness and safety of tamsulosin combined with androgen deprivation therapy (ADT) for lower urinary tract symptoms (LUTS) in advanced prostate cancer (PC) patients." | 5.24 | Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients. ( Ding, K; He, W; Liu, S; Wu, H; Zhang, T, 2017) |
| "Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3." | 5.24 | Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. ( Bedi, M; Brereton, HD; Dignam, JJ; Grignon, DJ; Hanks, GE; Horwitz, EM; Kim, H; Kwok, Y; Lawton, CAF; Lepor, H; Lin, X; Parliament, MB; Pisansky, TM; Rabinovitch, R; Roach, M; Rosenthal, SA; Sandler, HM; Venkatesan, VM; Zeitzer, KL, 2017) |
| "To compare the efficacy of orchiectomy alone and orchiectomy plus flutamide in treating patients with advanced carcinoma prostate." | 5.11 | Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach. ( Ansari, MS; Dogra, PN; Gupta, NP; Hemal, AK; Seth, A, 2004) |
| "To determine whether the nonsteroidal antiandrogenic drug flutamide is a clinically relevant inducer of methemoglobinemia in patients with prostatic cancer." | 5.09 | Lack of methemoglobinemia with flutamide. ( Becker, H; Donn, F; Schmoldt, A; Schulz, M, 2001) |
| "In a recent study by the Casodex Combination Study Group, USA, patients in a flutamide (750 mg/day) plus LH-RH agonist group showed a high treatment failure rate, mainly due to flutamide-induced diarrhea and hepatotoxicity." | 5.08 | Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. ( Akaza, H; Aso, Y; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Usami, M, 1996) |
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 5.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| "Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis." | 5.08 | PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. ( Casselman, J; Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W; Van Velthoven, R, 1997) |
| "We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo." | 5.08 | Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. ( Blumenstein, BA; Bueschen, AJ; Crawford, ED; Culkin, DJ; Eisenberger, MA; Loehrer, PJ; Lowe, BA; McLeod, DG; Miller, G; Sears, K; Thompson, IM; Wilding, G, 1998) |
| " Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = ." | 5.08 | Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. ( Blumenstein, BA; Crawford, ED; Eisenberger, M; Higgins, B; Lovato, LC; Meyskens, FL; Moinpour, CM; Savage, MJ; Skeel, R; Troxel, A; Veith, RW; Yee, M, 1998) |
| "In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double-blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo." | 5.07 | The use of flutamide in hormone-refractory metastatic prostate cancer. ( Benson, RC; Blumenstein, BA; Crawford, ED; Eisenberger, MA; McLeod, DG; Spaulding, JT; Spicer, D, 1993) |
| "This prospective trial was undertaken to determine the benefits of the combination of bilateral orchidectomy with flutamide, both in terms of survival and quality of life for patients with advanced prostatic carcinoma." | 5.07 | The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico. ( De-la-Garza, J; Mendoza-Valdés, A; Ocampo-del-Carpio, O, 1991) |
| " UFT (a compound of tegafur and uracil) is said to be effective for bladder cancer." | 4.80 | [Progress in oral anti-cancer drug therapy for urological cancer]. ( Akaza, H; Tsukamoto, S, 1999) |
| "MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination with prostatic neoplasms." | 4.79 | Nilutamide: an antiandrogen for the treatment of prostate cancer. ( Dole, EJ; Holdsworth, MT, 1997) |
| "Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma." | 4.78 | Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. ( Delaere, KP; Van Thillo, EL, 1991) |
| "Standard therapies for locally advanced prostate cancer have resulted in suboptimal disease control rates." | 3.80 | Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. ( Stock, RG; Stone, NN, 2002) |
| "One hundred and seventeen elderly male subjects [60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa)] treated with finasteride or flutamide were included." | 3.78 | Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. ( Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A, 2012) |
| " A large randomized study comparing the non-steroidal antiandrogen, bicalutamide, with flutamide, each in combination with luteinizing hormone-releasing hormone (LHRH) analogs, showed that after a median follow-up of 49 weeks, the time to treatment failure was significantly longer for the bicalutamide patients compared with the flutamide patients (p = 0." | 3.78 | Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. ( Blackledge, G; Kolvenbag, G; Nash, A, 1996) |
| "However, most clinically localized prostatic cancers have pathologic evidence of extracapsular spread, limiting the effectiveness of radical surgery in curing this disease." | 3.77 | Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. ( Aprikian, AG; Cohen, D; Fair, WR; Reuter, V; Sogani, P, 1993) |
| "Only Flutamide has been studied in monotherapy of prostatic cancer patients." | 3.76 | Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. ( Schröder, FH, 1990) |
| "Flutamide, a nonsteroidal antiandrogen used for treatment of prostate cancer, causes a temporary increase in transaminase and in some cases severe liver dysfunction." | 3.73 | Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. ( Doi, M; Goda, R; Ichimura, E; Matsuzaki, Y; Nagai, D; Nishikawa, K; Tomura, A, 2006) |
| " We investigated the effects of the proteasome inhibitors MG115 and PSI alone or in combination with different concentrations of the antiandrogen hydroxyflutamide on the cellular proliferation, apoptosis and viability of 10 prostatic adenocarcinoma cell cultures." | 3.72 | Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures. ( Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U, 2004) |
| "One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid)." | 3.72 | Anemia in patients on combined androgen block therapy for prostate cancer. ( Cheng, SG; Hua, LX; Li, J; Qian, LX; Sui, YG; Wang, XR; Wu, HF; Zhang, W, 2004) |
| " Here we report AR gene mutations identified in human prostate cancer and the autochthonous transgenic adenocarcinoma of the mouse prostate model that colocate to residues (668)QPIF(671) at the boundary of the hinge and ligand-binding domain, resulting in receptors that exhibit 2- to 4-fold increased activity compared with wild-type AR in response to dihydrotestosterone, estradiol, progesterone, adrenal androgens, and the AR antagonist, hydroxyflutamide, without an apparent effect on receptor levels, ligand binding kinetics, or DNA binding." | 3.71 | Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. ( Bentel, JM; Buchanan, G; Greenberg, NM; Han, G; Harris, JM; Horsfall, DJ; Marshall, VR; Matusik, RJ; Moore, N; Nahm, HS; Tilley, WD; Yang, M, 2001) |
| "To prevent treatment withdrawal due to flutamide-induced liver dysfunction, we performed maximum androgen blockade (MAB) therapy by combining a luteinizing hormone-releasing hormone agonist or orchiectomy with low-dose flutamide (125 mg x 2/day) in patients with prostate cancer." | 3.71 | [Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy]. ( Fujii, T; Hosomi, M; Kiyohara, H; Nakayama, J; Shimizu, K, 2001) |
| " In 8 male patients, mean age 75 years (range 65-83), flutamide was indicated for palliative therapy of disseminated prostatic carcinoma, and in one young female (14 years) was given for the treatment of facial hirsutism." | 3.71 | Flutamide-induced hepatotoxicity: report of a case series. ( Alcántara, R; Andrade, RJ; Camargo, R; Fernández, MC; Ferrer, T; Fraga, E; García Cortés, M; García-Ruiz, E; Lucena, MI; Martín-Vivaldi, R; Montero, JL; Peláez, G; Pizarro, MA; Romero-Gómez, M; Rosemary-Gómez, M; Sánchez Martínez, H; Suárez, F, 2001) |
| " This paper demonstrated that flutamide combined with leuprorelin acetate produced a significant reduction in the growth rate of Dunning R3327-H prostatic adenocarcinoma." | 3.70 | [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats]. ( Abe, F; Kuroiwa, S; Okada, M; Tomura, A, 1998) |
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 3.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "Twelve consecutive men with disseminated prostate carcinoma were evaluated at 0, 6, and 12 months after treatment with a long acting gonadotropin-releasing hormone agonist (goserelin acetate) and an androgen antagonist (flutamide)." | 3.70 | The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. ( Bryant, C; Campbell, J; Diamond, T; Lynch, W, 1998) |
| "To assess the effectiveness of palladium-103 brachytherapy in stage T1 and T2 adenocarcinoma of the prostate." | 3.70 | Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. ( Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C, 2000) |
| " A pilot study was undertaken to test the efficacy of flutamide (an antiandrogen) in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer." | 3.70 | Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. ( Greenberg, N; Kuliyev, E; Raghow, S; Steakley, M; Steiner, MS, 2000) |
| "Patients with bulky clinical Stage C adenocarcinoma of the prostate were given 3 months of hormone treatment consisting of oral Flutamide and monthly Zoladex injections prior to irradiation." | 3.69 | The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. ( Abellera, M; Chen, GT; Chiru, P; Hamilton, RJ; Ray, P; Spelbring, D; Vaida, F; Vijayakumar, S; Yang, FE, 1995) |
| "To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma." | 3.69 | Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. ( Fabris, G; Magi-Galluzzi, C; Montironi, R; Muzzonigro, G; Polito, M; Prete, E, 1994) |
| "We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate." | 3.69 | Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. ( Braslis, KG; Civantos, F; Davi, RC; Nelson, E; Soloway, MS, 1995) |
| "Three of 34 patients treated with a TAS regimen incorporating flutamide developed significant hepatic abnormalities: elevated transaminases [2] and fatal hepatic necrosis [1]." | 3.69 | Flutamide-induced liver toxicity including fatal hepatic necrosis. ( Chen, A; Crownover, RL; Fu, KK; Holland, J; Krieg, R; Roach, M; Young, BK, 1996) |
| "We describe a 76-year-old male patient who developed a life-threatening acute hepatotoxicity possibly caused by flutamide, an antiandrogen drug given during the previous 10 months, in the scenario of a brief moderate hypotension secondary to atrial flutter." | 3.69 | [Hepatoxicity caused by flutamide increased by hypotensive situation?]. ( Fedriani Gorria, J; García López, F; Serrano Hernández, N, 1996) |
| "Six men being treated for advanced prostate carcinoma with flutamide/finasteride combination therapy developed painful gynecomastia, which was treated with tamoxifen 10 to 30 mg/day for 1 month." | 3.69 | Tamoxifen for flutamide/finasteride-induced gynecomastia. ( Lowe, FC; Staiman, VR, 1997) |
| "A series of 115 previously untreated patients displaying clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide; the average follow-up was 3." | 3.68 | Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. ( Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R, 1993) |
| "The authors report a case of clinical methemoglobinemia occurring one year after a patient began receiving flutamide 750 mg/d for prostate cancer with bone metastasis." | 3.68 | Flutamide-induced methemoglobinemia. ( Chareyre, S; Delmas, PD; Gozzo, I; Schott, AM; Vial, T, 1991) |
| "The histopathology of 23 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for 3-6 months with combination therapy including a luteinizing hormone-releasing hormone agonist and the antiandrogen drug flutamide was reviewed and compared with the pretreatment biopsies or transurethral resection material." | 3.68 | Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. ( Boivin, JC; Dupont, A; Labrie, F; Monfette, G; Pinault, S; Srigley, JR; Têtu, B, 1991) |
| "Twenty-one patients with advanced prostatic adenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide." | 3.66 | Experience with flutamide in previously untreated patients with advanced prostatic cancer. ( Sogani, PC; Whitmore, WF, 1979) |
| "5) conducted by the Scandinavian Prostate Cancer Group comparing parenteral estrogen with total androgen blockade." | 2.82 | Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. ( Berglund, A; Hedlund, PO; Klaff, R; Sandblom, G; Varenhorst, E, 2016) |
| "In high-risk prostate cancer (PCa), no study with observation times beyond 10 yr has demonstrated survival improvement after addition of prostatic radiotherapy (RAD) to endocrine treatment (ET) alone." | 2.82 | Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian ( Angelsen, A; Damber, JE; Fosså, SD; Hoyer, M; Klepp, O; Solberg, A; Widmark, A; Wiklund, F, 2016) |
| "Men with nonmetastatic prostate cancer were treated with 9 months of leuprolide and flutamide followed by a variable off-treatment interval; AD was resumed when prostate specific antigen (PSA) reached a prespecified value (1 ng/mL, radical prostatectomy; 4 ng/mL, intact prostate)." | 2.80 | Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. ( Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Hunter-Merrill, R; Kuo, KF; Yu, EY, 2015) |
| "Treatment of localized prostate cancer (PC) is controversial." | 2.80 | Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. ( Albertsson, P; Brandberg, Y; Damber, JE; Damm, O; Holmberg, E; Isacsson, U; Lennernäs, B; Ljung, G; Majumder, K; Nilsson, S, 2015) |
| "A lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival." | 2.80 | Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. ( Amin, MB; Balogh, AG; Bauman, GS; Chinn, DM; Dignam, JJ; Duclos, M; Gomella, LG; Gore, EM; Hunt, D; Lukka, HR; Pisansky, TM; Rosenthal, SA; Rotman, MZ; Sandler, HM; Seider, MJ; Shipley, WU, 2015) |
| " Although additional study is considered necessary to determine the daily dosage of flutamide, the anti-tumor effects obtained from this study indicated that 375 mg/day is appropriate as a daily dosage, and 250 mg/day can also be considered when concern exists regarding the occurrence of complications or the development of ADRs, including liver function disorders." | 2.79 | Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial. ( Akaza, H; Ijima, T; Kanetake, H; Ohashi, Y; Usami, M, 2014) |
| "The flutamide treated CaP cases had increased discriminant function scores in 19 out of 24 cases (79%) and an increase of the mean score by 43%; the 5 cases with lower scores involved only minor reductions." | 2.78 | A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. ( Alberts, DS; Bartels, HG; Bartels, PH; Carmignani, G; DeCensi, A; Decobelli, O; Hurle, R; Maffezzini, M; Mazzucchelli, R; Montironi, R; Puntoni, M, 2013) |
| "Phase II cohort study of 72 prostate cancer patients without metastatic bone disease." | 2.78 | Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study. ( Baker, MK; England, PJ; Galvão, DA; Judge, JS; Newton, RU; Peddle-McIntyre, C; Spry, NA; Stephens, DA; Taaffe, DR, 2013) |
| "The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial." | 2.77 | Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. ( Ahles, T; Gu, L; Halabi, S; Hussain, A; Kaplan, E; Kelly, WK; Monk, JP; Philips, G; Picus, J; Small, EJ; Vogelzang, N, 2012) |
| "In all, 38 patients have had disease progression (30/55, 55%) or died without progression (8/55, 15%) for a 10-year progression-free survival (PFS) estimate of 40% (95% CI 27-53)." | 2.77 | Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. ( Berglund, RK; Canby-Hagino, ED; Carroll, PR; Crawford, ED; deVere White, R; Haas, GP; Hemstreet, GP; Klein, EA; Lowe, BA; Powell, IJ; Tangen, CM; Thompson, IM, 2012) |
| "Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD." | 2.77 | Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. ( Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY, 2012) |
| "Flutamide (750 g/d) was administered for 1 mo." | 2.77 | Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. ( Mazeron, JJ; Molinie, V; Mottet, N; Peneau, M; Richaud, P, 2012) |
| "Patients with high risk prostate cancer with pT3 tumor and positive surgical margins have a high risk of biochemical failure after radical prostatectomy and adjuvant androgen deprivation therapy." | 2.77 | Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. ( Bader, P; Briganti, A; Capitanio, U; Gontero, P; Joniau, S; Karnes, JR; Kneitz, B; Montorsi, F; Scholz, CJ; Schubert, M; Spahn, M; van Poppel, H, 2012) |
| "The vast majority of residual tumors were poorly differentiated (Gleason score ≥ 8)." | 2.76 | Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. ( Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A, 2011) |
| "Post-treatment prostate biopsy side-effects were evaluated in patients with locally advanced prostate cancer on endocrine therapy alone or combined with radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial." | 2.76 | Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial. ( Ahlgren, G; Angelsen, A; Solberg, A; Tasdemir, I; Widmark, A, 2011) |
| "Seventy-one patients with localized prostate cancer, who received ADT, were prospectively studied based on their bone mineral density (BMD) and blood and urine samples at the baseline and after ADT for 6 months." | 2.75 | Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. ( Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I, 2010) |
| "Men with BR of prostate cancer after radical prostatectomy (RP) or radiation (RT) were treated with androgen deprivation therapy (ADT) comprised of leuprolide and flutamide." | 2.75 | Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. ( Etzioni, RD; Gulati, R; Higano, CS; Jiang, P; Nelson, PS; Russell, KJ; Tam, S; Telesca, D; Yu, EY, 2010) |
| "Although prostate cancer-specific survival was not statistically significantly different between treatment arms at 5 years (P = ." | 2.74 | Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. ( Bae, K; Hanks, GE; Hussain, MH; Ray, ME; Sandler, HM; Shipley, WU, 2009) |
| "Androgen treatment for prostate cancer can adversely affect functional domains of quality of life." | 2.74 | Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. ( Damber, JE; Fosså, S; Fransson, P; Klepp, O; Lund, JA; Widmark, A; Wiklund, F, 2009) |
| "To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy (WPRT) for high-risk prostate cancer patients was associated with survival benefit over prostate radiotherapy (PORT) only." | 2.74 | Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. ( Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J, 2009) |
| "Men with localized but unfavorable-risk prostate cancer who were treated with RT and 6 months of planned combined AST appear to have an increased risk of recurrence when treated with less than as compared with 6 months of the antiandrogen." | 2.73 | Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. ( Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA, 2008) |
| "Among men with androgen independent prostate cancer, no clear association could be detected between body mass index and progression-free survival, overall survival or prostate specific antigen response." | 2.73 | Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. ( Crawford, ED; Goldman, B; Hussain, M; Klein, EA; Montgomery, RB; Page, S; Petrylak, DP; Tangen, CM, 2007) |
| "High-grade prostatic intraepithelial neoplasia (HGPIN) appears to represent an ideal target for chemoprevention of prostate cancer (PCa)." | 2.73 | Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. ( Wenlu, S; Zhigang, Z, 2008) |
| "For good prognosis metastatic prostate cancer patients under anti-androgen treatment, PSA response at 6 months with cut-off levels of < or = 1 ng/ml and < or = 10 ng/ml is prognostic for survival." | 2.71 | Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). ( Collette, L; de Reijke, TM; Schröder, FH, 2003) |
| "Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity." | 2.71 | Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. ( Allegro, R; Daricello, G; Dispensa, N; Pavone, C; Pavone-Macaluso, M; Serretta, V, 2003) |
| "A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis." | 2.71 | Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. ( Itoh, K; Noda, S; Noguchi, M; Shiraishi, T; Ueda, S; Yoshida, M, 2004) |
| "The number of patients who died of prostate cancer up to this time is insufficient for a definitive analysis of specific survival." | 2.71 | Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. ( Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P, 2004) |
| "We treated 5 patients diagnosed with prostate cancer between September and November 2002." | 2.71 | [Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients]. ( Fujisawa, Y; Harano, M; Hida, T; Kano, M, 2004) |
| "Forty men with prostate cancer were clinically treated with androgen blockade therapy (flutamide and leuprolide) for 36 weeks and subsequently followed up for another 18 weeks after treatment was discontinued." | 2.71 | One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. ( Almeida, OP; Flicker, L; Martins, RN; Spry, N; Waterreus, A, 2004) |
| "Forty-nine men with prostate cancer were treated with ADT before beginning radical therapy for 6 months." | 2.71 | The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. ( Anraku, T; Ishizaki, F; Nishiyama, T; Shimura, H; Takahashi, K, 2005) |
| "Men with histologically confirmed prostate cancer not amenable to curative surgery or radiation therapy were eligible for the study if they had radiographic or PSA progression on at least one antiandrogen (not nilutamide) despite continued androgen suppression and standard antiandrogen withdrawal periods." | 2.71 | A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. ( Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ, 2005) |
| "A total of 51 patients with metastatic prostate cancer underwent a 6-months period of continuous maximal androgen blockade (MAB) consisting of leuprorelin (3." | 2.71 | Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? ( Avances, C; Lucas, C; Maubach, L; Mottet, N; Sene, E; Wolff, JM, 2005) |
| "818 men with locally advanced prostate cancer were randomly assigned to: no androgen deprivation (ie, radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6." | 2.71 | Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. ( Atkinson, C; Christie, D; D'Este, C; Denham, JW; Duchesne, G; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C, 2005) |
| "Patients with hormone relapsed prostate cancer (HRPC) are often treated with flutamide or diethylstilboestrol." | 2.70 | Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. ( Basketter, V; Burns-Cox, N; Higgins, B; Holmes, S, 2002) |
| "After disease progression, patients treated with B were assigned to castration." | 2.70 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E, 2002) |
| "Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups." | 2.70 | Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. ( Kumon, H; Maki, Y; Nasu, Y; Noda, M; Saika, T; Suyama, B; Tsushima, T; Yamato, T, 2001) |
| "Men with clinically confined prostate cancer were randomized to receive 7." | 2.70 | Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. ( Chetner, M; Chin, JL; Dupont, C; Gleave, ME; Goldenberg, SL; Jewett, M; Kassabian, V; Klotz, LH; Saad, F; Van Rensselaer, S; Warner, J, 2001) |
| "Treatment with pamidronate resulted in a 7." | 2.70 | The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. ( Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J, 2001) |
| "Twenty patients with Stage B2/T2 prostate cancer who were treated for a median duration of 7." | 2.70 | Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? ( Candas, B; Cusan, L; Gomez, JL; Labrie, F, 2002) |
| "In the past 20 years, 3,500 prostate cancer patients have been recruited in 16 phase III trials in untreated and advanced disease and in seven phase II trials in hormone-refractory, metastatic disease." | 2.69 | European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. ( Denis, L, 1998) |
| "Since prostate cancer is hormone dependent, tumor androgen deprivation may enhance tumor eradication." | 2.69 | Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. ( Bolla, M, 1999) |
| "The primary clinical events were disease progression and survival." | 2.69 | Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. ( Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1999) |
| "To evaluate the efficacy of chemoendocrine therapy for the initial treatment of stage D2 prostate cancer, we conducted a prospective randomized study which compared combined androgen blockade alone to that combined with UFT." | 2.69 | [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. ( Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A, 1999) |
| "Patient data related to prostatic intraepithelial neoplasia were analyzed." | 2.69 | Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. ( Balaji, KC; Bastar, A; Fair, WR; Rabbani, F; Tsai, H, 1999) |
| "After disease progression, patients treated with bicalutamide were assigned to castration." | 2.69 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G, 1999) |
| " Hepatic toxicity may limit the long-term use of both drugs." | 2.69 | Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. ( Collette, L; de Reijke, TM; Schröder, FH; Whelan, P, 2000) |
| "589 patients with advanced prostate cancer (55% with metastatic [M1] and 45% with locally advanced [M0] disease) were randomized to receive goserelin acetate 3." | 2.69 | Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. ( Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Jurincic-Winkler, C; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E, 2000) |
| "Patients with Stage D2 prostate cancer were treated with surgical or medical (LHRH analog) castration combined with either estrogen, chlormadinone acetate or flutamide as initial therapy." | 2.69 | [Endocrine therapy of stage D2 prostate cancer--comparison of drugs used for total androgen blockade]. ( Hamano, S; Kinsui, H; Murakami, S; Oikawa, T; Shimazaki, J; Suzuki, N; Tanaka, M, 2000) |
| "Regarding local disease progression, the advantage for the use of NHT approached but did not reach statistical significance:18 of 189 patients (10%) in the NHT group and 33 of 209 patients (16%) in the RP group (P = 0." | 2.69 | Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. ( Debruyne, FM; Witjes, WP, 2000) |
| "Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0." | 2.69 | Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000) |
| "To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer." | 2.68 | A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1995) |
| "This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity." | 2.68 | Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ( Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995) |
| "flutamide 3 times daily was evaluated prospectively before cessation of the flutamide." | 2.68 | Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. ( Dieringer, P; Herrada, J; Logothetis, CJ, 1996) |
| "To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer." | 2.68 | Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1996) |
| " We have conducted a randomized prospective clinical trial, investigating the efficacy and toxicity of MAB (orchiectomy followed by flutamide therapy) alone as compared to MAB combined with methotrexate (MTX, 50 mg/m2/week) in 53 patients with newly diagnosed stage IV(M1) prostatic cancer (UICC TNM Classification 1987)." | 2.68 | Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. ( Donner, G; Flamm, J; Fritz, E; Ludwig, H; Micksche, M; Sagaster, P, 1996) |
| "Suramin was given as intermittent infusions at fixed doses on days 1-5 and thereafter dosing was guided by adaptive control with feedback to maintain plasma suramin concentrations between 300-175 micrograms/ml." | 2.68 | Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Headlee, DJ; Myers, CE; Sartor, O; Sausville, EA; Steinberg, SM; Thibault, A, 1995) |
| "Of 102 patients with metastatic prostate cancer, 52 were treated with orchidectomy and 50 with CHB; 22 of these received a LHRH analog + Flutamide and 28 orchidectomy + Flutamide." | 2.68 | [Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications]. ( de Torres, JA; Encabo, G; López Pacios, MA; Lorente, JA; Morote, J; Soler Roselló, A; Vallejo, C, 1995) |
| "There is interest in treating prostate cancer with induction androgen deprivation prior to radical prostatectomy." | 2.68 | Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. ( Corn, BW; Gomella, LG; Hyslop, T; Liberman, SN; Mulholland, SG; Petersen, RO, 1996) |
| "Flutamide is a novel antiandrogen with fewer side effects." | 2.68 | Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. ( Blum, R; Chang, A; Davis, T; Fisher, H; Hahn, R; Khanna, O; Rosenthal, J; Schinella, R; Trump, D; Witte, R; Yeap, B, 1996) |
| "Leuprolide and flutamide were administered for 9 to 12 months and then discontinued until prostate-specific antigen (PSA) levels reached a threshold value determined by the baseline PSA value." | 2.68 | Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. ( Ellis, W; Higano, CS; Lange, PH; Russell, K, 1996) |
| "A randomized, multicenter trial, double-blind for antiandrogen therapy, compared the antiandrogens bicalutamide and flutamide, each combined with luteinizing hormone-releasing hormone analogue therapy (LHRH-A) in 813 patients with Stage D2 prostate carcinoma." | 2.68 | A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. ( Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1996) |
| "Flutamide was administered in monotherapy (75 patients (8%)) or as part of total androgen blockade (TAB groups): the latter group had orchiectomy (196 patients (22%)) or an LHRH (634 patients (70%))." | 2.68 | Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients. ( Casselman, J; Kurjatkin, O; Mattelaer, J; Oosterlinck, W; Schulman, C; Van Velthoven, R, 1996) |
| "Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis, but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent." | 2.68 | A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. ( Bitton, RJ; Bowden, CJ; Cooper, MR; Dawson, NA; Figg, WD; Headlee, D; Myers, CE; Reed, E; Sartor, O; Weinberger, MS, 1996) |
| "To assess the pathological staging and biochemical progression-free survival (assessed using serum prostate-specific antigen level) of patients with clinically localized prostate cancer using neoadjuvant androgen deprivation therapy (ADT) in combination with radical retropubic prostatectomy (RRP)." | 2.68 | Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. ( Begg, CB; Cookson, MS; Dalbagni, G; Fair, WR; Herr, H; Reuter, VE; Russo, P; Sheinfeld, J; Sogani, PC, 1997) |
| "Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL." | 2.68 | Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. ( Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B, 1997) |
| "In patients with > 5 sites of bone metastasis (D2max), the corresponding periods were 9 and 14 months (p = 0." | 2.68 | Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. ( Hubmer, G; Lehnert, M; Pummer, K; Stettner, H, 1997) |
| "Treatment with bicalutamide plus LHRH-A resulted in longer median survival than treatment with flutamide plus LHRH-A." | 2.68 | Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. ( Block, NL; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1997) |
| ") monotherapy at a daily dose of 100 mg, which is the most commonly used dosage in Japan for patients with prostatic cancer." | 2.67 | A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. ( Akaza, H; Aso, Y; Koiso, K; Kotake, T; Usami, M, 1993) |
| "The optimal treatment of prostate cancer in clinical stage C is controversial." | 2.67 | [Treatment of prostatic carcinoma in clinical stage C. Comparison between radiotherapy plus hormonal therapy after progression and immediate hormonal therapy]. ( Bottero, G; Buffa, G; Ferraris, V; Novella, V; Pacilli, N; Pisano, PF, 1994) |
| "Although the only opportunity to cure prostate cancer is treatment at an early stage, radical prostatectomy has remained relatively unpopular because 40-50% of prostate cancers estimated at diagnosis as confined to the prostate are found to be at a more advanced stage following histopathological analysis of the surgical specimen." | 2.67 | Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. ( Cusan, L; Diamond, P; Dupont, A; Fradet, Y; Gomez, J; Koutsilieris, M; Labrie, F; Lemay, M; Suburu, R; Têtu, B, 1993) |
| "Twenty-two patients with bulky prostatic cancers were treated with a 3 month course of neoadjuvant leuprolide acetate and eulexin prior to three-dimensional (3-D) conformal radiotherapy." | 2.67 | Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. ( Burman, CM; Fuks, Z; Happersett, L; Harrison, A; Kutcher, GJ; Leibel, SA; Zelefsky, MJ, 1994) |
| "A total of 327 patients with metastatic prostate cancer were randomized to receive bilateral orchiectomy or treatment with Zoladex and flutamide." | 2.67 | Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group. ( Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Sylvester, R; Whelan, P, 1993) |
| "The treatment of advanced prostate cancer is based on hormone manipulation to eliminate the trophic effect of testosterone on sensitive androgen tissue of the tumor." | 2.67 | Combination treatment in M1 prostate cancer. ( Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P; Pollastri, CA; Tavoni, F, 1993) |
| "Flutamide was found to be absorbed rapidly and to exist as a hydroxylated form (hydroxy-flutamide) in the plasma." | 2.67 | [Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer]. ( Akaza, H; Aso, Y; Fuse, H; Hosaka, M; Kawai, T; Koiso, K; Kumamoto, Y; Origasa, S; Shimazaki, J; Yamanaka, H, 1993) |
| "Prostate cancer is the most common cancer in American men today." | 2.67 | Controversies in the treatment of metastatic prostate cancer. ( Blumenstein, BA; Crawford, ED; Dorr, FA; Eisenberger, MA; McLeod, DG, 1992) |
| " All patients received hormonal therapy with surgical castration and long-term administration of flutamide." | 2.67 | Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. ( Pummer, K, 1991) |
| "A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid." | 2.67 | Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. ( Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K, 1990) |
| "A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3." | 2.67 | Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. ( Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R, 1990) |
| "Flutamide was given by mouth in a dose of 250 mg t." | 2.67 | Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. ( Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV, 1990) |
| "A total of 327 patients with metastatic prostate cancer have been randomized to either orchidectomy or treatment with goserelin (Zoladez) 3." | 2.67 | Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853). ( Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R, 1990) |
| " In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist." | 2.66 | The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. ( Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988) |
| "Only one patient has died from prostate cancer while 3 have died from other causes." | 2.66 | Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. ( Belanger, A; Bergeron, V; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacoursiere, Y; Monfette, G, 1985) |
| "Flutamide was given as additional medication to those already receiving an LHRH agonist alone." | 2.66 | Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. ( Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G, 1986) |
| "All estramustine-treated patients lost their libido, whereas only 20 per cent of the patients treated with flutamide did so." | 2.66 | Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. ( Andersson, SO; Beckman, KW; Johansson, JE; Lingårdh, G; Zador, G, 1987) |
| "Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy." | 2.65 | Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. ( Sogani, PC; Vagaiwala, MR; Whitmore, WF, 1984) |
| "Flutamide monotherapy is an alternative for some patients." | 2.49 | First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease. ( , 2013) |
| "The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part." | 2.49 | [Hormonal treatment in prostate cancer]. ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013) |
| "Prostate cancer is the most common nonskin cancer in the United States, with more than 2 million men currently living with the disease (Prostate Cancer Foundation, 2005)." | 2.44 | Hormone ablation therapy: lightening the load for today's prostate cancer patient. ( Matthews, PA, 2007) |
| "Prostate cancer is a relatively slow-growing disease compared to other cancers, and the patients tend to be older." | 2.43 | [Usefulness and positioning of MAB therapy for prostate cancer]. ( Akaza, H; Chodak, GW; Hirao, Y, 2005) |
| "Bicalutamide has a more favourable side-effect profile than the other antiandrogens and is more likely to promote compliance." | 2.42 | The role of antiandrogen monotherapy in the treatment of prostate cancer. ( Anderson, J, 2003) |
| " This technique has been used most commonly to treat prostate cancers in combination with hormonal therapy." | 2.42 | Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "In locally advanced M0 prostate cancer bicalutamide 150 mg monotherapy seems equivalent to castration in terms of overall survival and time to progression." | 2.42 | Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. ( Cardi, A; Di Silverio, F; Sciarra, A, 2004) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 2.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men, following lung cancer." | 2.42 | Clinical strategies in the management of biochemical recurrence after radical prostatectomy. ( Culkin, DJ; Zimmerman, RA, 2003) |
| "Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life." | 2.42 | Monotherapy in advanced prostate cancer: an overview. ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004) |
| "Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options." | 2.41 | Antiandrogen monotherapy: indications and results. ( Iversen, P, 2002) |
| "Prostate cancer is dependent on androgen stimulation mediated by the androgen receptor (AR), a member of the steroid hormone receptor family of ligand-dependent nuclear receptors." | 2.41 | Androgen receptor as a target in androgen-independent prostate cancer. ( Balk, SP, 2002) |
| "Under the diagnosis of prostatic cancer with multiple pulmonary metastasis, we performed total androgen blockade (TAB) consisting of luteinizing hormone releasing hormone agonist and flutamide following dietylstilbestrol (DES) intravenous injection therapy." | 2.41 | [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report]. ( Fukuda, M; Fuse, H; Hirano, S; Takashima, H, 2002) |
| "In advanced prostate cancer, androgen suppression (AS) by surgery or drugs controls testicular hormone secretion, and the further addition of an antiandrogen such as nilutamide, flutamide, or cyproterone acetate is referred to as maximum androgen blockade (MAB)." | 2.41 | Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. ( , 2000) |
| "Ten cases of SIADH caused by prostatic cancer have been reported including the present case." | 2.41 | Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report. ( Abe, H; Ito, H; Miura, T; Nishimura, T; Oaki, Y; Oka, F; Uchikoba, T, 2000) |
| "We report a case of prostatic cancer in a 73-year-old man detected by abnormalities in chest X-ray and serum prostate specific antigen (PSA) level." | 2.41 | [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]. ( Hashimoto, H; Inada, F; Ishida, H; Kawakami, N; Kitahara, K; Masui, N; Saga, Y; Tokumitsu, M; Yachiku, S, 2001) |
| "Appropriate patients with metastatic prostate cancer should be informed of the potential benefits, toxicities, and out-of-pocket expenditures." | 2.41 | Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. ( Bennett, CL; Crawford, ED; DeMasi, V; Sartor, O; Schellhammer, PF; Schmitt, B; Wilt, TJ, 2001) |
| "For metastatic prostatic cancer presenting with an emergency oncologic condition, the treatment of choice is surgical orchiectomy, but surgery may not be possible in the presence of severe DIC." | 2.41 | Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review. ( Amornpichetkul, K; Chakrapee-Sirisuk, S; Sangruchi, T; Sinlarat, P; Srimuninnimit, V; Visudhiphan, S, 2001) |
| "Nilutamide has been less extensively investigated, but the clinical utility of this agent, except for use in combined therapy, would appear to be somewhat limited by a high incidence of drug-related side effects." | 2.40 | Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? ( Boccon-Gibod, L, 1998) |
| "Prostatic cancer is the second most common cause of cancer death in males." | 2.40 | Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. ( Denis, L; Mahler, C; Verhelst, J, 1998) |
| " Assuming that each modality is equally effective, emphasis should be placed on increasing patient tolerance and compliance by the use of long-acting, nontoxic treatments with simple dosing regimens and minimal side effects." | 2.40 | Androgen deprivation for prostatic carcinoma: a rationale for choosing components. ( Chatelain, C; Fourcade, RO, 1998) |
| "For the endocrine therapy of prostate cancer, chlormadinone acetate, flutamide and bicalutamide are or will be available in Japan." | 2.40 | [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications]. ( Akakura, K; Furuya, Y; Ito, H, 1998) |
| "Recognition of this syndrome has introduced a non-toxic therapy for advanced prostate cancer patients and has had a dramatic impact on the interpretation and design of clinical trials in patients with 'hormone refractory disease'." | 2.40 | Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. ( Kelly, WK, 1998) |
| " Therefore, as yet there is no justification for long-term use of CAB." | 2.40 | Arguments against the long-term use of combined androgen blockade. ( Mills, RD; Studer, UE, 1998) |
| " Bicalutamide is available in a convenient one tablet, once-a-day dosing regimen, is at least as effective as flutamide and is better tolerated in terms of diarrhea." | 2.40 | Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen. ( Sarosdy, MF, 1999) |
| "Flutamide is an approved anti-androgen that has been incorporated in many of the combined androgen blockade studies." | 2.40 | Anti-androgens and other hormonal therapies for prostate cancer. ( Richie, JP, 1999) |
| "This article provides a summary of the pharmacodynamic properties of major antiandrogens as well as an extensive review of their tolerability." | 2.40 | Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. ( De Angelis, M; De Benedetto, G; Migliari, R; Murru, M; Muscas, G; Verdacchi, T, 1999) |
| "Suramin has been reintroduced in trials of chemohormonal intervention." | 2.39 | [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. ( Crawford, ED; DeAntoni, E, 1995) |
| "Antiandrogen therapy for benign prostatic hyperplasia (BPH) and prostatic carcinoma has been introduced in clinical practice." | 2.39 | [Application of antiandrogens on prostatic diseases]. ( Hasegawa, F; Isurugi, K; Takahashi, S, 1994) |
| "The critical volume of prostate cancer is estimated at 0." | 2.39 | Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. ( Candas, B; Cusan, L; Diamond, P; Gomez, JL; Labrie, F, 1995) |
| "Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which during long term administration reduces circulating levels of gonadotrophins (luteinising hormone and follicle stimulating hormone) and sex hormones." | 2.39 | Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. ( Brogden, RN; Faulds, D, 1995) |
| "Flutamide was inactive by itself and reversed the stimulatory effect of all other compounds, thus indicating its pure antiandrogenic activity." | 2.38 | Mechanism of action and pure antiandrogenic properties of flutamide. ( Labrie, F, 1993) |
| "Prostate cancer is the most frequent cancer diagnosed in American men today." | 2.38 | Antiandrogenic drugs. ( McLeod, DG, 1993) |
| "Flutamide is a non-steroidal anti-androgen which has been used to treat prostate cancer." | 2.38 | A rationale for the use of non-steroidal anti-androgens in the management of prostate cancer. ( Benson, RC, 1992) |
| "Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen action." | 2.38 | Flutamide: an antiandrogen for advanced prostate cancer. ( Goldspiel, BR; Kohler, DR, 1990) |
| "Flutamide is a non-steroidal antiandrogenic drug devoid of hormonal agonist activity." | 2.38 | Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. ( Brogden, RN; Clissold, SP, 1989) |
| "Development of androgen-independent prostatic cancer cells from androgen-responsive cells can occur by a variety of mechanisms (e." | 2.37 | Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. ( Isaacs, JT; Kyprianou, N, 1987) |
| "We gathered cases diagnosed with prostate cancer based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2004 to 2020." | 1.91 | Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. ( Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L, 2023) |
| "Flutamide is known to cause severe adverse events, which includes idiosyncratic liver injury." | 1.91 | Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes. ( Ijiri, Y; Kato, R; Kohda, Y; Noda, T; Tanaka, S; Yamada, T, 2023) |
| "We utilized prostate cancer LNCaP cells and subjected them to a stepwise increase in the antiandrogen 2-hydroxy-flutamide (FLU) concentration to generate a FLU-resistant cell line (LN-FLU)." | 1.91 | Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications. ( Bort, A; Díaz-Laviada, I; Díaz-Yuste, A; Mora-Rodríguez, JM; Palacín, AM; Sánchez, BG; Sánchez-Chapado, M; Sánchez-Rodríguez, C; Sebastián-Martín, A, 2023) |
| "When flutamide was replaced with temporary adrenocortical hormone treatment and blood transfusion, the blood indices and liver function of the patient improved gradually." | 1.91 | Haemolytic anaemia induced by flutamide: a case report. ( Hu, Q; Sun, Y; Xu, P; Zhu, S, 2023) |
| "Flutamide was used to bioconjugate with PGNPs to improve its efficacy against prostate cancer." | 1.62 | Papain Mediated Synthesized Gold Nanoparticles Encore the Potency of Bioconjugated Flutamide. ( Man, L; Xu, X, 2021) |
| "Flutamide, a chemotherapeutic agent for prostate cancer, is known to enhance warfarin anticoagulation." | 1.51 | Extreme Elevation of the Prothrombin Time-International Normalized Ratio due to a Probable Interaction between Warfarin and Flutamide. ( Araki, Y; Kawaguchi, O; Konishi, Y; Terada, T, 2019) |
| "Nine men with prostate cancer and a rising PSA (biochemical recurrence) without evidence of metastases were treated with intermittent ADT consisting of 9 months of complete androgen blockade achieved with combined leuprolide acetate and flutamide." | 1.48 | Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. ( Cherrier, MM; Cross, DJ; Higano, CS; Minoshima, S, 2018) |
| " The use of HIFU in combination with androgen deprivation was associated with a decrease in numerical density of microvessels in zones of tumor and non-tumor parenchyma in patients with relapses." | 1.48 | Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation. ( Abdullaev, NA; Bakarev, MA; Kachesov, IV; Levin, VP; Neimark, AI, 2018) |
| "Flutamide is an outstanding anticancer drug with poor oral bioavailability." | 1.48 | Elaboration of polymersomes versus conventional liposomes for improving oral bioavailability of the anticancer flutamide. ( Abdallah, OY; Elnaggar, YS; Youssef, SF, 2018) |
| "Elevated risks of arrhythmia (adjusted HR=1." | 1.46 | Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. ( Cassidy-Bushrow, AE; Haque, R; Keating, NL; Potosky, AL; Tsai, HT; UlcickasYood, M; Van Den Eeden, SK; Xu, X, 2017) |
| " In dose-response F2H experiments, we compared the potencies of abiraterone, bicalutamide, enzalutamide, flutamide, and galeterone/TOK-001 to prevent the dihydrotestosterone-induced N/C interaction in wt AR." | 1.46 | The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators. ( Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K, 2017) |
| "Flutamide (FLT) is a non steroidal antiandrogenic drug used to treat prostate cancer." | 1.46 | Assessment of Poly (vinyl alcohol) Coated Flutamide Nanoparticulates and their Efficacy on Prostate Cancer Cells. ( Lakshmanan, VK; Nair, SV; Sreenivasan, SK; Suseelan, SR, 2017) |
| "We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs, respectively, to clarify the significance of NCOAs in the effect of antiandrogens." | 1.43 | Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. ( Hara, N; Ishizaki, F; Nishiyama, T; Takeda, K; Tasaki, M; Tomita, Y, 2016) |
| "In contrast, in androgen-independent prostate cancer cell lines, TROP2high cells did not exhibit a differential treatment response but were characterized by their high self-renewal ability." | 1.43 | High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. ( Butler, L; Hollande, F; Mølck, C; Paquet-Fifield, S; Sloan, E; Ventura, S; Xie, J, 2016) |
| "This investigation explores the use of methoxy polyethylene glycol (mPEG) functionalised poly(D,L-lactide-co-glycolide) (PLGA) nanocrystals of flutamide (FLT) with enhanced solubility, bioavailability and blood circulation time for targeting prostate cancer." | 1.42 | Preparation and in vitro-in vivo evaluation of surface-modified poly(lactide-co-glycolide) nanoparticles as controlled release carriers for flutamide delivery. ( Dipsingh, SN; Ige, PP, 2015) |
| "The anti-prostate cancer drug flutamide occasionally causes hepatotoxicity, and predictive biomarkers of flutamide-induced liver injury (FILI) are needed to improve safety of this drug." | 1.42 | Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. ( Ando, H; Fujimura, A; Hosohata, K; Inui, K; Kurokawa, S; Masuda, S; Matsubara, K; Morita, T; Nakano, K; Takada, M; Tateishi, M; Ushijima, K; Yonezawa, A, 2015) |
| "In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide)." | 1.40 | [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)]. ( Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A, 2014) |
| "After intravenous administration into prostate cancer bearing rats for 28 days, FLT-loaded CAS micelles showed a higher antitumor efficacy as revealed by significantly higher reduction in PSA serum level (65." | 1.39 | Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. ( Elgindy, NA; Elzoghby, AO; Helmy, MW; Samy, WM, 2013) |
| "After intravenous administration into prostate cancer-bearing rats for 28 days, FLT-loaded CAS nanoparticles showed a higher anti-tumor efficacy as revealed by a significantly higher % reduction in PSA serum level (75%) compared to free FLT (55%)." | 1.39 | Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats. ( Elgindy, NA; Elzoghby, AO; Helmy, MW; Saad, NI; Samy, WM, 2013) |
| "We analysed the expression patterns of prostate cancer susceptibility candidate (PRAC) in prostate cancer." | 1.39 | Aberrant expression of the PRAC gene in prostate cancer. ( Chuang, CK; Lenka, G; Ng, KF; Pang, ST; Weng, WH, 2013) |
| "Seventy-one patients with localized prostate cancer, who received ADT with GnRHa, were prospectively studied based on their blood samples before treatment and after ADT for 6 months." | 1.38 | Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer. ( Hara, N; Hoshii, T; Isahaya, E; Ishizaki, F; Nishiyama, T; Takahashi, K; Takizawa, I, 2012) |
| " Pharmacokinetic study with compound 10 at an oral dose of 10." | 1.37 | Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. ( Dalela, D; Gupta, G; Jain, A; Kumar, L; Kumar, R; Lal, J; Lal, N; Maikhuri, JP; Pandey, SK; Prabhakar, YS; Sarswat, A; Sharma, S; Sharma, VL; Verma, V, 2011) |
| "Prostate cancer is the most common cancer diagnosed in men." | 1.37 | The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. ( Dotan, N; Mahajna, J; Wasser, SP, 2011) |
| "Flutamide (FLT) is a poorly soluble anticancer drug." | 1.37 | Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. ( Elgindy, N; Elkhodairy, K; Elzoghby, A; Molokhia, A, 2011) |
| "Oxidative stress plays a role in prostate cancer (PrCa) initiation and development." | 1.37 | Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. ( Boque, N; Calvo, A; Campion, J; Catena, R; Endermann, T; Gonzalez-Moreno, O; Milagro, F; Redrado, M; Saito, Y; Schomburg, L; Takahashi, K, 2011) |
| "Prostate cancer is one of the most common malignancies in men." | 1.37 | Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. ( Bo, JJ; Huang, YR; Li, Z; Liu, DM; Liu, P; Lv, JW; Sha, JJ; Zhang, C; Zhang, LH, 2011) |
| "In (early) prostate cancer (PCa) androgens also regulate tumor growth, which is exploited by hormonal therapies in metastatic disease." | 1.37 | Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. ( Dits, NF; Erkens-Schulze, S; Jenster, G; Marques, RB; van Ijcken, WF; van Weerden, WM, 2011) |
| "We collected the data of 45 advanced prostate cancer patients complicated with lower urinary tract symptoms who were treated by MAB." | 1.37 | [Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade]. ( Gui, M; He, L; Li, W; Long, Z; Zhong, K, 2011) |
| "In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited." | 1.36 | 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth. ( Bailis, N; Baniahmad, A; Fousteris, MA; Giannis, A; Nikolaropoulos, SS; Roediger, J; Roell, D; Schubert, U, 2010) |
| "The progression of prostate cancer from an organ-confined, androgen-sensitive disease to a metastatic one is associated with dysregulation of androgen receptor (AR)-regulated target genes and with a decrease in insulin-like growth factor-I receptor (IGF1R) expression." | 1.36 | Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. ( Bentov, I; Plymate, SR; Schayek, H; Sun, S; Werner, H, 2010) |
| "For patients with nonmetastatic prostate cancer, castration alone might be adequately practical and efficient." | 1.36 | Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. ( Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC, 2010) |
| "A total of 72 patients with localized prostate cancer were prospectively studied based on blood samples before and after androgen deprivation therapy for 6 months." | 1.36 | Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer. ( Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I, 2010) |
| "The present data suggest that those prostate cancer patients who have even marginally elevated adrenal androgens may especially benefit from combined androgen blockade." | 1.35 | Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. ( Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM, 2009) |
| "To evaluate the severity of genitourinary (GU) toxicity in high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy (EBRT) for prostate cancer and to explore factors that might affect the severity of GU toxicity." | 1.35 | Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy ( Baba, S; Hayakawa, K; Ishiyama, H; Kitano, M; Kotani, S; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K; Uemae, M, 2009) |
| "Patients with locally advanced prostate cancer have a high risk of progression after RP as single therapy." | 1.35 | Long-term follow-up after triple treatment of prostate cancer stage pT3. ( Aus, G; Klintenberg, C; Madsen, M; Mäkelä, E; Palmqvist, E; Schelin, S, 2009) |
| "Androgen-independent human prostate cancer cell line PC3 was transfected with plasmids expressing wild-type, W741C mutant, T877A mutant or W741C+T877A mutant androgen receptors." | 1.35 | Suppression of mutant androgen receptors by flutamide. ( Hara, S; Isaacs, JT; Ishioka, J; Kageyama, Y; Nishikawa, K; Tomura, A, 2009) |
| "Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life." | 1.35 | Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008) |
| "Flutamide pre-treatment completely prevented this increase." | 1.35 | Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. ( Farmer, PB; Gescher, AJ; Greaves, P; Mellon, JK; Pathak, S; Sharma, RA; Singh, R; Steward, WP; Verschoyle, RD, 2008) |
| "This suggests that HF promoted prostate cancer cell growth is COX-2 dependent and this HF-COX-2 activation pathway can account for one reason of CAB therapy failure." | 1.35 | A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. ( Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S, 2008) |
| "Lethal prostate cancers often become androgen-independent due to androgen receptor (AR) overexpression." | 1.34 | Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells. ( Benbrahim-Tallaa, L; Liu, J; Waalkes, MP; Webber, MM, 2007) |
| "For advanced prostate cancer patients who progressed on first-line MAB with bicalutamide, flutamide administration as a second-line antiandrogen was found to be relatively effective, especially for those who showed a longer duration of response to the first-line MAB." | 1.34 | Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. ( Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I, 2007) |
| "Flutamide (FLU) is an antiandrogen primarily used in the treatment of metastatic prostate cancer." | 1.34 | Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. ( Bammler, TK; Beyer, RP; Coe, KJ; Farin, FM; Fausto, N; Ho, HK; Jia, Y; Nelson, SD; Plymate, SR; Rademacher, P; Woodke, L, 2007) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "More than 85% of men with prostate cancer die of other causes." | 1.34 | Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. ( Jennrich, R; Johnson, H; Lam, R; Scholz, M; Strum, S; Trilling, T, 2007) |
| "This therapy's purpose is downstaging prostate cancer at radical prostatectomy and thereby improving the prognosis of prostate cancer." | 1.33 | [Neoadjuvant hormonal therapy for prostate cancer]. ( Miyakita, H, 2005) |
| "Hormone resistance of prostate cancer develops, in part, from upregulation of antiapoptotic genes after androgen deprivation." | 1.33 | Survivin mediates resistance to antiandrogen therapy in prostate cancer. ( Chakravarti, A; Delaney, MA; Latham, DE; Zhang, M, 2005) |
| "To evaluate the clinical efficacy of high intensity focused ultrasound (HIFU) combined with endocrine therapy in the treatment of patients with prostate cancer." | 1.33 | [High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer]. ( Hua, LX; Qian, LX; Song, NH; Sui, YG; Wu, HF; Zhang, JX; Zhang, W, 2005) |
| "The toxicity rates of 480 consecutive prostate cancer patients were reviewed and compared using the chi2 test." | 1.33 | Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer. ( Gratzle, J; Jani, AB; Myers, M, 2005) |
| "Approximately 80-90% of prostate cancers are androgen dependent at initial diagnosis." | 1.33 | Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. ( Bechor, Y; Birman, A; Chisin, R; Even-Sapir, E; Fadeeva, L; Golan, E; Gozin, M; Gutman, M; Icar, A; Jacobson, O; Leibovitch, I; Marom, H; Mishani, E; Novak, N, 2005) |
| "Lethal phenotypes of human prostate cancer are characterized by progression to androgen independence, although the mechanisms behind this progression remain unclear." | 1.33 | Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. ( Benbrahim-Tallaa, L; Waalkes, MP; Webber, MM, 2005) |
| "The incidence and discovery rate of prostate cancer is increased in recent years; with advanced age and multiple organs dysfunction, the advanced prostate cancer patients have poor quality of life." | 1.33 | [Experience in treating advanced prostate cancer with bladder outlet obstruction]. ( Chen, JH; Kong, L; Sheng, XJ; Ye, M; Zhang, L; Zhu, YJ, 2005) |
| "Imaging of tumors with a cooled charge-coupled device camera revealed that the response of AdTSTA to flutamide is more sensitive and robust than serum PSA measurements." | 1.33 | Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. ( Carey, M; Gambhir, SS; Ilagan, R; Iyer, M; Le, K; Pottratz, J; Salas, S; Wu, L; Zhang, LJ, 2005) |
| "The flutamide treated cells were set as the experimental group and the LNCaP cells as the control." | 1.33 | Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. ( Liu, F; Qin, WJ; Shao, C; Shao, GX; Shi, CH; Wang, H; Wang, PF; Wang, Y; Yang, B; Yue, HH; Zhang, L; Zhang, YT, 2005) |
| "Of the 59 patients with advanced prostate cancer, 3-year, 5-year and 7-year overall survival rates were 79." | 1.33 | [Long term survival results in advanced prostate cancer treated with combined androgen blockade]. ( Ding, Y; Wang, YH; Wu, Y; Zhang, SG, 2005) |
| "The androgen dependent prostate cancer cell line LNCaP was cultured in RPMI 1640 medium and treated with different concentrations of DHT(2, 10, 50 nmol/L) and flutamide (100 nmol/L)." | 1.33 | [Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line]. ( Gu, RG; Ma, QZ; Zhou, CW, 2006) |
| "Flutamide treatment exhibited agonist activities in HPE cells derived from tumor and non-tumor specimens which contained wild-type AR." | 1.33 | Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. ( Coetzee, GA; Cookson, MS; Gu, G; Kasper, S; Pitkänen-Arsiola, T; Roberts, RL; Tillman, JE; Wantroba, M; Yuan, J, 2006) |
| "In this series high-risk prostate cancer was defined as clinical stage T2c or T3, pretreatment serum prostate-specific antigen (PSA) >20 ng/ml and/or a biopsy Gleason score of 8-10." | 1.33 | The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men. ( Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I, 2006) |
| "Most prostate cancers are androgen dependent upon initial diagnosis." | 1.33 | Chiral dimethylamine flutamide derivatives--modeling, synthesis, androgen receptor affinities and carbon-11 labeling. ( Carlson, KE; Chisin, R; Elgavish, S; Even-Sapir, E; Gozin, M; Gutman, M; Jacobson, O; Katzenellenbogen, JA; Laky, D; Leibovitc, I; Mishani, E, 2006) |
| " The radiation therapy was carried out with 6 or 18 MV LINAC photons, with a dose fractioning scheme of 5 x 180-200 cGy, a total dosage of 66-72 Gy to prostate, 56 Gy to seminal vesicles and, in the high-risk cases, 46 Gy to pelvic lymph nodes." | 1.33 | Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy. ( López Carrizosa, MC; Melchor Iñiguez, M; Pérez Casas, A; Pérez Vara, C; Rubio Rodríguez, MC; Samper, PM; Vallejo, C, 2006) |
| "We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer." | 1.33 | Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. ( Hiraoka, M; Kamoto, T; Kinoshita, H; Mitsumori, M; Mizowaki, T; Nagata, Y; Negoro, Y; Ogawa, O; Sasai, K; Sasaki, Y; Takayama, K, 2006) |
| "The histological diagnosis of prostate cancer treated with hormonal agents is often difficult because of various morphological changes induced by androgen ablation." | 1.33 | [Histological investigation of prostate cancer treated with hormonal agents]. ( Azumi, M; Hashimoto, H; Kakizaki, H; Saga, Y, 2006) |
| "Flutamide was stopped and patient made slow recovery." | 1.32 | Flutamide-induced hepatotoxicity with possible potentiation by simvastatin. ( Ashar, U; Bhaduri, A; Desai, D, 2003) |
| " We hypothesize that GI side effects of flutamide are not a direct local toxic effect resulting in a similar side effect profile for irradiated and nonirradiated cases." | 1.32 | Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. ( Langenstroer, P; McLeod, DG; Porter, HJ; Thrasher, JB, 2004) |
| "During the diagnostic work-up, prostate cancer was diagnosed." | 1.32 | Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. ( Grigoriadis, N; Kallinikidis, T; Kalpidis, P; Karakolios, A; Kasapis, C, 2003) |
| "Once metastatic, prostate cancer was regarded as a systemic disease that is not amenable to surgical therapy." | 1.32 | Biochemical remission after resection of prostate cancer lung metastasis. ( Brooks, JD; Chao, DH; Higgins, JP, 2004) |
| "Thirty patients with prostate cancer arising and localizing in the peripheral zone were enrolled in this study." | 1.32 | Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging. ( Nishiyama, T; Takahashi, K; Tomita, Y, 2004) |
| "PC3 and LNCaP human prostate cancer cell lines were exposed for 72 hours to rapamycin (mTOR inhibition), LY294002 (PI3K/AKT inhibition) and TGF-beta1 in a proliferation (WST-1) assay." | 1.32 | Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. ( van der Poel, HG, 2004) |
| "A 88-year-old man with prostate cancer was receiving non-steroidal anti-androgen therapy (flutamide, 375 mg/day)." | 1.32 | Interstitial pneumonitis related to flutamide monotherapy for prostate cancer. ( Fujimoto, N; Matsumoto, T; Nomura, M; Sato, H, 2004) |
| "Flutamide is a nonsteroidal antiandrogen that is frequently used for total androgen blockage in the treatment of advanced prostate cancer." | 1.32 | Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. ( Bolaños, O; Carmena, MJ; Montalvo, L; Prieto, JC; Rodríguez-Henche, N; Sánchez-Chapado, M, 2004) |
| "Flutamide is a non-steroidal antiandrogen drug that is frequently used for total androgen blockage." | 1.31 | Flutamide-induced acute renal failure in a patient with metastatic prostate cancer. ( Altiparmak, MR; Bilici, A; Kisacik, B; Ozguroglu, M, 2002) |
| "Twenty selected patients with prostate cancer, who were treated with hormonal therapy and demonstrated biochemical downstaging by reduction of PSA prior to RP and bilateral pelvic node dissection at the Tohsei National Hospital between January 1997 and August 2001, are reported on." | 1.31 | Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse. ( Kiriyama, I; Nishimura, T; Ogaki, K; Ohba, S, 2002) |
| "124 patients with prostate cancer were diagnosed and followed at Kobe City General Hospital between 1995 and 1997." | 1.31 | Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. ( Fujikawa, K; Fukuzawa, S; Matsui, Y; Takeuchi, H, 2000) |
| "The numb chin syndrome is characterized by facial numbness along the distribution of the mental branch of the trigeminal nerve." | 1.31 | Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma. ( Halachmi, S; Madeb, R; Madjar, S; Nativ, O; River, Y; Wald, M, 2000) |
| "Four patients suffered bone fractures, none pathological." | 1.31 | A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. ( Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R, 2000) |
| "Overall PSA recurrence rate was 12." | 1.31 | Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. ( Bruchovsky, N; Gleave, ME; Goldenberg, SL; Jones, EC; La Bianca, SE; Sullivan, LD, 2000) |
| "Ninety-five patients with prostate cancer were divided into one of three groups: 26 patients with bone metastasis (BM(+)), 35 patients without bone metastasis on nonhormonal therapy (BM(-)HT(-)) and 34 patients without bone metastasis on hormonal therapy (BM(-)HT(+))." | 1.31 | Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. ( Fukunaga, M; Jo, Y; Sone, T; Tamada, T; Tanaka, H; Tomomitsu, T, 2001) |
| "African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study." | 1.31 | Association of African-American ethnic background with survival in men with metastatic prostate cancer. ( Crawford, E; Eisenberger, M; Moinpour, C; Tangen, C; Thompson, I; Tolcher, A, 2001) |
| "In hemodialysis patients, few cases of prostate cancer have been reported until recently." | 1.31 | Prostate cancer with multiple lung metastases in a hemodialysis patient. ( Aoyagi, T; Hata, M; Hayakawa, K; Matsumoto, M; Miyaji, K, 2000) |
| "Eighteen patients with prostate cancer and 17 healthy subjects matched for age and body mass index were included." | 1.31 | Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. ( Bryc, W; Kokot, F; Nowicki, M, 2001) |
| "High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma." | 1.31 | Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. ( Alberts, SR; Blute, ML, 2001) |
| "47 patients with clinical localised prostate cancer were given LH-RH analogs plus flutamide for complete androgenic blockade (CAB) for at least 3 months prior to radical prostatectomy." | 1.31 | [Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate]. ( Arango Toro, O; Bielsa Gali, O; Gelabert Mas, A; Griño Garreta, J; Lorente Garín, JA, 2001) |
| "Four of the patients died of prostate cancer." | 1.31 | M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. ( Aizawa, T; Akiyama, A; Ito, T; Miki, M; Tachibana, M; Yamamoto, S, 2001) |
| "The flutamide therapy was immediately discontinued and this resulted in spontaneous remission (clinical and liver function test results returned to normal) during the next 8 weeks." | 1.31 | Flutamide-induced acute hepatitis in advanced prostate cancer patients. ( Kraus, I; Oguic, R; Vitezic, D, 2001) |
| "The accuracy of T staging for prostate cancer after NAH in MRI was 71%." | 1.31 | [Local staging with magnetic resonance imaging after neoadjuvant hormonal therapy for prostate cancer]. ( Ichijo, K; Mugiya, S; Nagae, H; Nagata, M; Sato, T; Un-no, T, 2001) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later." | 1.31 | Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. ( Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T, 2002) |
| "Treatment decisions for metastatic prostate cancer require the consideration of factors such as survival, quality of life, costs of care, and toxicities." | 1.30 | Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. ( Bennett, CL; Matchar, DB; McCrory, DC, 1997) |
| "Turosteride (FCE 26073) is a new, potent, and selective 5 alpha-reductase inhibitor." | 1.30 | Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. ( di Salle, E; Giudici, D; Zaccheo, T, 1997) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | 1.30 | Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. ( Lubos, W; Schmeller, N, 1997) |
| "For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response." | 1.30 | Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. ( Chen, Y; Furr, B; Haas, GP; Klein, E; Kolvenbag, GJ; Nieh, PT; Patterson, AL; Schellhammer, PF; Seabaugh, DR; Small, EJ; Venner, P; Wajsman, Z, 1997) |
| "Patients with prostate cancer were evaluated prospectively by physical examination and laboratory tests at baseline and at routine intervals while receiving CHB." | 1.30 | Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. ( Johnson, H; McDermed, JE; Scholz, MC; Strum, SB; Tisman, G, 1997) |
| "Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy." | 1.30 | Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. ( Colecchia, M; Colloi, D; Del Boca, C; Frigo, B; Guardamagna, A; Leopardi, O; Zucchi, A, 1997) |
| "Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily." | 1.30 | Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. ( Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L, 1997) |
| "Suramin has demonstrated modest activity against prostate cancer and is being investigated in clinical trials." | 1.30 | Acute renal failure in a patient receiving treatment with suramin. ( Harbour, D; Liebmann, J; Smith, A, 1997) |
| "a day for androgen independent prostate cancer was performed." | 1.30 | High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. ( Balk, S; Bubley, GJ; Constantine, M; DeWolf, W; Fenton, MA; Gaynes, L; Joyce, R; Kolvenbag, G; Rode, P; Taplin, ME, 1998) |
| "Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer." | 1.30 | Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. ( del Valle, M; Escaf, S; Guate, JL; Menendez, CL; Vega, JA, 1997) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed." | 1.30 | Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. ( Akakura, K; Akimoto, S; Furuya, Y; Igarashi, T; Ito, H; Murakami, S; Shimazaki, J, 1998) |
| "A total of 66 stage D2 prostate cancer patients were enrolled from Nov." | 1.30 | [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer]. ( Aizawa, T; Ito, T; Miki, M; Ohkubo, Y; Tsujino, S; Yamamoto, S, 1998) |
| "Flutamide is a nonsteroidal antiandrogen drug used in the treatment of prostatic cancer." | 1.30 | Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms. ( Albano, E; Boldorini, R; Morelli, S; Pittau, S; Pontiroli, L; Sartori, M, 1998) |
| "Flutamide is known to inhibit cytochrome P450-mediated testosterone synthesis and metabolism." | 1.30 | Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement. ( Brandes, LJ; LaBella, FS; Queen, GM, 1997) |
| " Dose-response curves were analyzed for 5alpha-dihydrotestosterone, the most active androgen in normal prostate, and androstenedione, a major androgen derived from the adrenals." | 1.30 | Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. ( Balk, SP; Bubley, GJ; Fenton, MA; Fertig, AM; Kolvenbag, G; Shuster, TD; Taplin, ME, 1997) |
| "Flutamide is a nonsteroidal antiandrogen agent." | 1.30 | Flutamide-induced liver injury: a case report. ( Chang, FY; Chu, CW; Huang, YS; Hwang, SJ; Lee, SD; Li, CP; Luo, JC; Tsay, SH, 1998) |
| "After diagnosis and staging of prostate cancer, baseline results were obtained for a set of five liver function tests (LF Ts)." | 1.30 | Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. ( Altinbaş, M; Cetin, M; Demirci, D; Güven, M; Unal, A; Unlühizarci, K, 1999) |
| "Here we demonstrate that the growth of prostate cancer LNCaP cells can also be increased by the stable transfection of HER2/Neu." | 1.30 | From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. ( Chang, C; Kang, HY; Lin, HK; Lin, MF; Thin, TH; Yeh, S, 1999) |
| "Flutamide is an antiandrogen used for the treatment of prostatic carcinoma." | 1.30 | [Flutamide-induced late cutaneous pseudoporphyria]. ( Bahadoran, P; Bermon, C; Lacour, JP; Mantoux, F; Ortonne, JP; Perrin, C, 1999) |
| "A seventy-three year-old patient with prostate cancer underwent radical prostatectomy, followed by total androgen brocking therapy using flutamide and LH-RH agonist." | 1.30 | [Fatal hepatic failure following hepatitis caused by flutamide: a case report]. ( Kinebuchi, Y; Murata, Y; Okaneya, T, 1999) |
| "Low levels of p27Kip1 in primary prostate cancer specimens have been shown to be associated with higher rates of disease recurrence and poor rates of disease-free survival in patients with localized disease." | 1.30 | Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. ( Fan, Z; Mendelsohn, J; Ye, D, 1999) |
| "We retrospectively reviewed 121 prostate cancer patients who received long-term antiandrogen, either flutamide (n = 56) or cyproterone acetate (n = 65), and had normal pretreatment serum alanine aminotransferase (ALT) levels." | 1.30 | Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. ( Chen, J; Kao, JH; Lai, MK; Liu, CM; Pu, YS, 1999) |
| "Accordingly, the final diagnosis was prostate cancer (cT3N4M1, stage D2)." | 1.30 | [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report]. ( Higashi, T; Maruyama, Y; Nagayoshi, J, 1999) |
| "A given prostate cancer patient's response to therapy may be predicted by following apoptotic and mitotic activity, as well as Ki-67 and p53 expression in repeated biopsies." | 1.30 | Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. ( Bély, M; Lovász, S; Romics, I; Szegedi, Z; Szende, B; Torda, I, 1999) |
| "Severe hepatotoxicity occurred in a prostate cancer patient treated with 375 mg of flutamide per day, 125 mg three times a day, for 11 weeks." | 1.30 | [Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer]. ( Koyama, M; Matsumoto, M; Nakagawa, Y, 1999) |
| "However, the drugs can not eradicate prostate cancer completely." | 1.30 | [The effect of combined endocrine therapy on prostate and testis]. ( Gu, F; Guo, Y; Hao, J; Kong, X; Mi, P; Na, Y; Pan, B; Wang, J; Xia, T; Xue, Z; Zeng, L, 1999) |
| "Flutamide is a potent hepatotoxin in certain patients." | 1.29 | Flutamide hepatotoxicity. ( Fourcroy, JL; Wysowski, DK, 1996) |
| "Flutamide withdrawal, when combined with the simultaneous administration of aminoglutethimide, is a therapeutically active approach in patients with "hormone-refractory" prostate cancer." | 1.29 | Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994) |
| "The treatment of locally advanced prostatic cancer is controversial, as there are several possible treatment options." | 1.29 | Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. ( Schulman, CC, 1994) |
| "Patients with node-positive prostate cancer that is regionally localized (T1-4, N1-3, M0) have a relatively poor prognosis when a single-treatment modality such as radical surgery, definitive radiotherapy, or androgen ablation is used." | 1.29 | Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. ( Pollack, A; Sands, ME; Zagars, GK, 1995) |
| "We report that growth of LNCaP human prostate cancer cells is significantly stimulated (up to 120% above control) by physiological estradiol (E2) concentrations." | 1.29 | Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. ( Calabrò, M; Carruba, G; Castagnetta, LA; Farruggio, R; Miceli, MD; Oliveri, G; Pfeffer, U; Sorci, CM, 1995) |
| "These data show that PSA synthesis by prostate cancer is reduced after androgen deprivation but that the PSA nadir and PSA doubling time following treatment provide important prognostic information." | 1.29 | Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. ( Braswell, NT; Feliz, TP; Fowler, JE; Pandey, P; Seaver, LE, 1995) |
| "Flutamide appears to cause hepatotoxic effects in certain patients." | 1.29 | Fatal and nonfatal hepatotoxicity associated with flutamide. ( Freiman, JP; Horton, ML; Tourtelot, JB; Wysowski, DK, 1993) |
| "Flutamide has an incremental cost effectiveness more favorable than most accepted therapies." | 1.29 | Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. ( Bennett, CL; Crawford, ED; Hillner, BE; McLeod, DG, 1995) |
| "Secondary testicular tumors are very rare." | 1.29 | [Bilateral testicular metastasis of an adenocarcinoma of the prostate]. ( Agnanti, N; Bai, M; Giannakopoulos, X; Grammeniatis, E; Stefanou, D, 1994) |
| "In a group of 42 patients with prostatic cancer (PC), in 29 cases (69." | 1.29 | [Attempt at using chemoluminescence in modern diagnosis and monitoring of therapy in prostatic cancer]. ( Dutkiewicz, S; Owczarczyk, B; Tałałaj, M; Witeska, A, 1993) |
| "His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10." | 1.29 | Acute renal toxicity associated with suramin in the treatment of prostate cancer. ( Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A, 1994) |
| "Metastases to the meninges from prostatic cancer are rare, accounting for less than 0." | 1.29 | Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. ( DeAngelis, LM; Mencel, PJ; Motzer, RJ, 1994) |
| "Transfection studies in the human prostate cancer cell line LNCaP examine the ability of dihydrotestosterone (DHT), hydroxyflutamide (HO-FLU), cyproterone acetate (Cypro." | 1.29 | Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. ( Govindan, MV; Koutsilieris, M; Pagé, N; Warriar, N, 1994) |
| "Flutamide-treated tumors histologically consisted of small or dilated glandular structure with an increase in stromal area, but androgen receptors were preserved." | 1.29 | Effect of early exposure of flutamide on subsequent growth of transplantable rat prostatic tumor (dunning R-3327). ( Lee, SZ; Masai, M; Sato, N; Shimazaki, J; Suzuki, H; Watabe, Y, 1994) |
| "Flutamide was administered to a patient in conjunction with orchiectomy for stage D2 prostate cancer." | 1.29 | Severe reversible neutropenia following treatment of prostate cancer with flutamide. ( Livingston, RB; McDonnell, ND, 1994) |
| "Fourty-eight patients with stage D2 prostate cancer, initially treated with endocrine therapy at the University of Tokyo between 1981 and 1990, were followed up and analysed." | 1.29 | [Objective and subjective response in stage D2 prostate cancer patients with cancer pain]. ( Aso, Y; Higashihara, E; Hirasawa, K; Homma, Y; Kasuya, Y; Kawabe, K; Tanaka, Y; Yoshida, M, 1994) |
| "A 75-year-old patient presented with a superior vena cava syndrome (SVCS) lasting 3 years." | 1.29 | Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome. ( Bellas, C; Hernanz, I; Molina, JP; Montalbán, C; Moreno, MA, 1993) |
| "We describe a florid xanthomatous histiocytic reaction in the pelvic lymph nodes of a patient treated with androgen deprivation therapy prior to radical prostatectomy." | 1.29 | Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. ( Gormley, EA; Schned, AR, 1996) |
| "Flutamide withdrawal was undertaken at the time of disease progression." | 1.29 | The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. ( Small, EJ; Srinivas, S, 1995) |
| "Flutamide toxicity was common." | 1.29 | Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. ( Andras, EJ; Brooks, CP; Chang, GC; Gilbert, RM; Leibenhaut, MH; Linstadt, DE; Rosenthal, SA; Stickney, DR; Wolkov, HB, 1996) |
| "Cancer of the prostate is the most frequent cancer and the second leading cause of cancer death in men in North America." | 1.29 | Large Shionogi tumors lose their responsiveness to flutamide treatment. ( Chen, C; Labrie, F; Poulin, R, 1996) |
| "Flutamide is a nonsteroidal antiandrogen commonly used in the treatment of prostate cancer." | 1.29 | Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. ( Barbara, L; Cicognani, C; Malavolti, M; Morselli-Labate, AM; Sama, C, 1996) |
| "Seventeen men with various stages of prostate cancer, all of whom were candidates for androgen deprivation therapy, were treated with finasteride plus flutamide and were followed for a mean of 13." | 1.29 | Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. ( Fair, WR; Fleshner, NE, 1996) |
| "Flutamide is a non-steroid antiandrogen used in advanced prostate cancer." | 1.29 | Flutamide photosensitivity. ( Dompmartin, A; Leroy, D; Szczurko, C, 1996) |
| "Flutamide was discontinued and 8 weeks later liver enzymes had returned to normal." | 1.28 | Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer. ( Dankoff, JS, 1992) |
| "Human prostatic cancer cell lines LNCaP and DU 145 were studied to examine the effects of heat shock treatment (HST), androgen (5 alpha-dihydrotestosterone: 5 alpha DHT) and antiandrogen (hydroxyflutamide: OH-Flut) on cell growth and survival." | 1.28 | Local hyperthermia for prostatic disease: in vitro studies on human prostatic cancer cell lines. ( Chalmers, D; Kirk, D; Leake, RE; Lloyd, SN, 1992) |
| " using therapy with leuprolide acetate in monthly dosage of 7." | 1.28 | [Complete androgenic blockade: myth or reality. Study and follow-up of 35 patients with advanced carcinoma of the prostate]. ( Amrani Akdi, Y; Leva Vallejo, M; Molina Sánchez, J; Prieto Castro, R; Regueiro López, JC; Requena Tapia, MJ; Saceda López, JL, 1992) |
| "Lymphangitic carcinomatosis of the lung is a late and often fatal manifestation of cancer." | 1.28 | Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report. ( Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D, 1991) |
| " In the last experiment, at equivalent total daily dosages of either 150 or 300 mg/kg/day Win 49,596, twice a day (BID) dosing was more effective than once a day (SID) dosing in inhibiting tumor growth." | 1.28 | Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer. ( Fetrow, N; Isaacs, JT; Juniewicz, PE; Lamb, J; Marinelli, J; Wolf, M; Young, E, 1991) |
| "Treatment of advanced prostate cancer with a combination of luteinising hormone-releasing hormone analogues and anti-androgens is advisable for the initial 2 weeks, in patients with newly diagnosed, extensive disease." | 1.28 | LHRH analogues in combination with an anti-androgen in the treatment of advanced disease. ( Denis, L, 1989) |
| "In men with severely painful bony metastasis, an inexpensive drug used in Paget's disease, etidronate disodium, may be palliative." | 1.27 | Advances in the treatment of metastatic prostatic cancer. ( Elder, JS; Gibbons, RP, 1985) |
| "Flutamide was administered (250 mg three times daily) for 10 days; before and after treatment, a synthetic ACTH1-24 stimulation test (250 micrograms im, with blood sampling immediately before and 60 min after the stimulus) was performed." | 1.27 | The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. ( Balzano, S; Campus, G; Cappa, M; Danielli, E; Martino, E; Migliari, R; Pintus, C; Scarpa, RM; Sica, V; Usai, E, 1988) |
| "in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy." | 1.27 | [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986) |
| "Patients (154) with clinical stage D2 prostate cancer with no previous endocrine therapy or chemotherapy received the combination therapy with the pure antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average of 22 months (3-49 months)." | 1.27 | Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. ( Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lachance, R; Lacourciere, Y; Monfette, G, 1987) |
| "Ten castrated patients with prostatic cancer received flutamide (FLU) alone for 2 months and, afterwards, the combined therapy of FLU and AG for 2 months." | 1.27 | Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. ( Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F, 1987) |
| "Flutamide was administered SC at a daily dose of 25 mg/kg." | 1.27 | Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. ( Redding, TW; Schally, AV, 1985) |
| "Flutamide is a nonsteroidal antiandrogen used in the treatment of prostatic carcinoma." | 1.27 | The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. ( Becker, H; Donn, F; Schmoldt, A; Schulz, M, 1988) |
| "Three patients have died from prostate cancer while three have died from other causes, 93." | 1.27 | Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. ( Belanger, A; Bergeron, N; Borsanyi, JP; Cusan, L; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y, 1988) |
| "Ten men with prostatic cancer, stage T3M0 Nx or more, who were anxious to maintain sexual potency, were treated with flutamide." | 1.27 | Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency. ( Johansson, JE; Schnürer, LB; Stegmayr, B, 1988) |
| "An androgen-responsive prostate cancer cell line in monolayer culture provides a means to study the biochemical mechanisms mediating hormonal stimulation of cell proliferation." | 1.27 | Androgen dependence of the Dunning R3327G cell line in monolayer culture. ( Mauvais-Jarvis, P; Mowszowicz, I; Portois, MC; Santen, RJ, 1987) |
| " Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment." | 1.27 | Ocular toxicity of Anandron in patients treated for prostatic cancer. ( Dupont, A; Harnois, C; Labrie, F; Malenfant, M, 1986) |
| "Hormonal therapy for metastatic prostate cancer blocks the androgen-mediated action that stimulates the hormone-dependent clone of tumor cells." | 1.27 | Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. ( Geller, J, 1985) |
| " The dosage of the drug was 750 mg." | 1.25 | Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis. ( Daly, JJ; Griffin, PP; Irwin, RJ; Kliman, B; MacLaughlin, RA; Prout, GR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 113 (11.54) | 18.7374 |
| 1990's | 434 (44.33) | 18.2507 |
| 2000's | 300 (30.64) | 29.6817 |
| 2010's | 120 (12.26) | 24.3611 |
| 2020's | 12 (1.23) | 2.80 |
| Authors | Studies |
|---|---|
| Cogan, PS | 1 |
| Koch, TH | 1 |
| Handratta, VD | 1 |
| Vasaitis, TS | 1 |
| Njar, VC | 1 |
| Gediya, LK | 1 |
| Kataria, R | 1 |
| Chopra, P | 1 |
| Newman, D | 1 |
| Farquhar, R | 1 |
| Guo, Z | 1 |
| Qiu, Y | 1 |
| Brodie, AM | 1 |
| Wakabayashi, K | 1 |
| Imai, K | 1 |
| Miyachi, H | 1 |
| Hashimoto, Y | 2 |
| Tanatani, A | 2 |
| Schlienger, N | 1 |
| Lund, BW | 1 |
| Pawlas, J | 1 |
| Badalassi, F | 1 |
| Bertozzi, F | 1 |
| Lewinsky, R | 1 |
| Fejzic, A | 1 |
| Thygesen, MB | 1 |
| Tabatabaei, A | 1 |
| Bradley, SR | 1 |
| Gardell, LR | 1 |
| Piu, F | 1 |
| Olsson, R | 1 |
| Goto, T | 2 |
| Ohta, K | 1 |
| Fujii, S | 2 |
| Ohta, S | 1 |
| Endo, Y | 1 |
| Fousteris, MA | 1 |
| Schubert, U | 1 |
| Roell, D | 2 |
| Roediger, J | 1 |
| Bailis, N | 1 |
| Nikolaropoulos, SS | 1 |
| Baniahmad, A | 2 |
| Giannis, A | 1 |
| Sarswat, A | 1 |
| Kumar, R | 1 |
| Kumar, L | 1 |
| Lal, N | 1 |
| Sharma, S | 1 |
| Prabhakar, YS | 1 |
| Pandey, SK | 1 |
| Lal, J | 1 |
| Verma, V | 1 |
| Jain, A | 1 |
| Maikhuri, JP | 1 |
| Dalela, D | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| Khatik, GL | 1 |
| Kaur, J | 1 |
| Kumar, V | 1 |
| Tikoo, K | 1 |
| Venugopalan, P | 1 |
| Nair, VA | 1 |
| Shi, Q | 1 |
| Wada, K | 1 |
| Ohkoshi, E | 1 |
| Lin, L | 1 |
| Huang, R | 2 |
| Morris-Natschke, SL | 1 |
| Goto, M | 1 |
| Lee, KH | 1 |
| Cortés-Benítez, F | 1 |
| Cabeza, M | 1 |
| Ramírez-Apan, MT | 1 |
| Alvarez-Manrique, B | 1 |
| Bratoeff, E | 1 |
| Wu, B | 1 |
| Shen, P | 1 |
| Yin, X | 1 |
| Yu, L | 1 |
| Wu, F | 1 |
| Chen, C | 2 |
| Li, J | 2 |
| Xu, T | 1 |
| Marcoccia, D | 1 |
| Smeriglio, A | 1 |
| Mantovani, A | 1 |
| Trombetta, D | 1 |
| Lorenzetti, S | 1 |
| Madan, RA | 1 |
| Bilusic, M | 1 |
| Stein, MN | 1 |
| Donahue, RN | 1 |
| Arlen, PM | 1 |
| Karzai, F | 1 |
| Plimack, E | 1 |
| Wong, YN | 1 |
| Geynisman, DM | 1 |
| Zibelman, M | 1 |
| Mayer, T | 1 |
| Strauss, J | 1 |
| Chen, G | 1 |
| Rauckhorst, M | 1 |
| McMahon, S | 1 |
| Couvillon, A | 1 |
| Steinberg, S | 2 |
| Figg, WD | 10 |
| Dahut, WL | 1 |
| Schlom, J | 1 |
| Gulley, JL | 1 |
| Kato, R | 1 |
| Yamada, T | 1 |
| Noda, T | 1 |
| Tanaka, S | 2 |
| Kohda, Y | 1 |
| Ijiri, Y | 1 |
| Tan, X | 1 |
| Namadchian, M | 1 |
| Baghayeri, M | 1 |
| Rahimnia, R | 1 |
| Akbari, MR | 1 |
| Yasseri, AF | 1 |
| Taheri, D | 1 |
| Mirzaei, A | 1 |
| Ghajar, HA | 1 |
| Farashah, PD | 1 |
| Baghdadabad, LZ | 1 |
| Aghamir, SMK | 1 |
| Mora-Rodríguez, JM | 1 |
| Sánchez, BG | 1 |
| Sebastián-Martín, A | 1 |
| Díaz-Yuste, A | 1 |
| Sánchez-Chapado, M | 2 |
| Palacín, AM | 1 |
| Sánchez-Rodríguez, C | 1 |
| Bort, A | 1 |
| Díaz-Laviada, I | 1 |
| Muramatsu, T | 1 |
| Funahashi, Y | 1 |
| Yamamoto, A | 3 |
| Sassa, N | 1 |
| Matsukawa, Y | 1 |
| Gotoh, M | 1 |
| Xu, X | 2 |
| Man, L | 1 |
| Mirsafaei, R | 2 |
| Varshosaz, J | 2 |
| Mirsattari, SN | 1 |
| Koga, H | 1 |
| Negishi, M | 1 |
| Kinoshita, M | 1 |
| Mori, S | 1 |
| Ishigami-Yuasa, M | 1 |
| Kawachi, E | 1 |
| Kagechika, H | 1 |
| Sun, Y | 1 |
| Zhu, S | 1 |
| Hu, Q | 1 |
| Xu, P | 1 |
| Zhang, T | 1 |
| Wu, H | 1 |
| Liu, S | 2 |
| He, W | 1 |
| Ding, K | 1 |
| Lawton, CAF | 2 |
| Lin, X | 1 |
| Hanks, GE | 4 |
| Lepor, H | 1 |
| Grignon, DJ | 3 |
| Brereton, HD | 2 |
| Bedi, M | 1 |
| Rosenthal, SA | 3 |
| Zeitzer, KL | 4 |
| Venkatesan, VM | 1 |
| Horwitz, EM | 2 |
| Pisansky, TM | 3 |
| Kim, H | 1 |
| Parliament, MB | 1 |
| Rabinovitch, R | 2 |
| Roach, M | 8 |
| Kwok, Y | 2 |
| Dignam, JJ | 2 |
| Sandler, HM | 7 |
| Licciardello, MP | 1 |
| Ringler, A | 1 |
| Markt, P | 1 |
| Klepsch, F | 1 |
| Lardeau, CH | 1 |
| Sdelci, S | 1 |
| Schirghuber, E | 1 |
| Müller, AC | 1 |
| Caldera, M | 1 |
| Wagner, A | 1 |
| Herzog, R | 1 |
| Penz, T | 1 |
| Schuster, M | 1 |
| Boidol, B | 1 |
| Dürnberger, G | 1 |
| Folkvaljon, Y | 1 |
| Stattin, P | 2 |
| Ivanov, V | 1 |
| Colinge, J | 1 |
| Bock, C | 1 |
| Kratochwill, K | 1 |
| Menche, J | 1 |
| Bennett, KL | 1 |
| Kubicek, S | 1 |
| Rodda, S | 1 |
| Morris, WJ | 1 |
| Hamm, J | 1 |
| Duncan, G | 1 |
| Tammela, TL | 2 |
| Häggman, M | 1 |
| Ladjevardi, S | 1 |
| Taari, K | 2 |
| Isotalo, T | 2 |
| Lennernäs, H | 3 |
| Weis, J | 1 |
| von Below, C | 1 |
| Wassberg, C | 1 |
| Lennernäs, B | 4 |
| Tolf, A | 1 |
| Axén, N | 2 |
| Gölander, CG | 1 |
| Ahlström, H | 1 |
| Haque, R | 1 |
| UlcickasYood, M | 1 |
| Cassidy-Bushrow, AE | 1 |
| Tsai, HT | 1 |
| Keating, NL | 1 |
| Van Den Eeden, SK | 1 |
| Potosky, AL | 1 |
| Reis, LO | 1 |
| Zani, EL | 1 |
| García-Perdomo, HA | 1 |
| Cherrier, MM | 2 |
| Cross, DJ | 1 |
| Higano, CS | 5 |
| Minoshima, S | 1 |
| Bakarev, MA | 1 |
| Levin, VP | 1 |
| Kachesov, IV | 1 |
| Abdullaev, NA | 1 |
| Neimark, AI | 1 |
| Moughan, J | 1 |
| Dicker, AP | 1 |
| Gore, EM | 3 |
| Seider, MJ | 2 |
| Hsu, IC | 1 |
| Hartford, AC | 1 |
| Yamoah, K | 1 |
| Jones, CU | 4 |
| Michalski, JM | 1 |
| Lee, WR | 1 |
| Rotman, M | 6 |
| Pryzant, RM | 1 |
| Kim, HE | 1 |
| Thomas, CR | 1 |
| Shipley, WU | 12 |
| Youssef, SF | 1 |
| Elnaggar, YS | 1 |
| Abdallah, OY | 1 |
| Deka, R | 1 |
| Rose, BS | 1 |
| Bryant, AK | 1 |
| Sarkar, RR | 1 |
| Nalawade, V | 1 |
| McKay, R | 1 |
| Murphy, JD | 1 |
| Simpson, DR | 1 |
| Konishi, Y | 1 |
| Terada, T | 1 |
| Araki, Y | 1 |
| Kawaguchi, O | 1 |
| Verhoven, B | 1 |
| Yan, Y | 1 |
| Ritter, M | 1 |
| Khor, LY | 1 |
| Hammond, E | 1 |
| Jones, C | 1 |
| Amin, M | 1 |
| Bahary, JP | 3 |
| Zeitzer, K | 1 |
| Pollack, A | 4 |
| Anitha, A | 1 |
| Uthaman, S | 1 |
| Nair, SV | 2 |
| Jayakumar, R | 1 |
| Lakshmanan, VK | 2 |
| Elzoghby, AO | 2 |
| Helmy, MW | 2 |
| Samy, WM | 2 |
| Elgindy, NA | 2 |
| Saad, NI | 1 |
| Lenka, G | 1 |
| Weng, WH | 1 |
| Chuang, CK | 1 |
| Ng, KF | 1 |
| Pang, ST | 1 |
| Bastide, C | 1 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 1 |
| Rozet, F | 1 |
| Kitamura, Y | 1 |
| Okuno, H | 1 |
| Sakura, Y | 1 |
| Manabe, Y | 1 |
| Masuda, N | 1 |
| Ito, H | 6 |
| Mishina, M | 1 |
| Taoka, R | 1 |
| Terai, A | 1 |
| Sugimoto, M | 1 |
| Kakehi, Y | 1 |
| Thomas, LN | 1 |
| Merrimen, J | 1 |
| Bell, DG | 1 |
| Rendon, R | 1 |
| Goffin, V | 1 |
| Too, CK | 1 |
| Hirano, D | 2 |
| Hasegawa, R | 1 |
| Satoh, K | 1 |
| Mochida, J | 1 |
| Yamanaka, Y | 1 |
| Hirakata, H | 1 |
| Yamaguchi, K | 1 |
| Sugimoto, S | 1 |
| Kawata, N | 1 |
| Takahashi, S | 3 |
| Culig, Z | 4 |
| Kunath, F | 1 |
| Grobe, HR | 1 |
| Rücker, G | 1 |
| Motschall, E | 1 |
| Antes, G | 1 |
| Dahm, P | 1 |
| Wullich, B | 2 |
| Meerpohl, JJ | 1 |
| Sjögren, E | 1 |
| Malmsten, LÅ | 1 |
| Kuo, KF | 2 |
| Hunter-Merrill, R | 1 |
| Gulati, R | 3 |
| Hall, SP | 2 |
| Gambol, TE | 2 |
| Yu, EY | 3 |
| Majumder, K | 1 |
| Damber, JE | 7 |
| Albertsson, P | 1 |
| Holmberg, E | 1 |
| Brandberg, Y | 1 |
| Isacsson, U | 1 |
| Ljung, G | 1 |
| Damm, O | 1 |
| Nilsson, S | 1 |
| Liu, JB | 1 |
| Dai, CM | 1 |
| Su, XY | 1 |
| Cao, L | 1 |
| Qin, R | 1 |
| Kong, QB | 1 |
| Hunt, D | 2 |
| Gomella, LG | 2 |
| Amin, MB | 2 |
| Balogh, AG | 1 |
| Chinn, DM | 1 |
| Duclos, M | 1 |
| Bauman, GS | 1 |
| Rotman, MZ | 1 |
| Lukka, HR | 1 |
| Chernichenko, OA | 1 |
| Sakalo, VS | 1 |
| Yakovlev, PG | 1 |
| Sakalo, AV | 1 |
| Zhylchuk, YV | 1 |
| Zsolt, A | 1 |
| Ige, PP | 1 |
| Dipsingh, SN | 1 |
| Kanetake, H | 4 |
| Usami, M | 4 |
| Ohashi, Y | 1 |
| Ijima, T | 1 |
| Akaza, H | 7 |
| Zapatero, A | 1 |
| Guerrero, A | 1 |
| Maldonado, X | 1 |
| Alvarez, A | 1 |
| Gonzalez San Segundo, C | 1 |
| Cabeza Rodríguez, MA | 1 |
| Macias, V | 1 |
| Pedro Olive, A | 1 |
| Casas, F | 1 |
| Boladeras, A | 1 |
| de Vidales, CM | 1 |
| Vazquez de la Torre, ML | 1 |
| Villà, S | 1 |
| Perez de la Haza, A | 1 |
| Calvo, FA | 1 |
| Locke, JA | 1 |
| Dal Pra, A | 1 |
| Supiot, S | 1 |
| Warde, P | 1 |
| Bristow, RG | 1 |
| Nakano, K | 1 |
| Ando, H | 1 |
| Kurokawa, S | 2 |
| Hosohata, K | 1 |
| Ushijima, K | 1 |
| Takada, M | 1 |
| Tateishi, M | 1 |
| Yonezawa, A | 1 |
| Masuda, S | 1 |
| Matsubara, K | 1 |
| Inui, K | 1 |
| Morita, T | 2 |
| Fujimura, A | 1 |
| Nakai, Y | 1 |
| Tanaka, N | 1 |
| Anai, S | 1 |
| Miyake, M | 1 |
| Tatsumi, Y | 1 |
| Fujimoto, K | 2 |
| Krauss, DJ | 1 |
| Hu, C | 1 |
| Souhami, L | 3 |
| Chafe, SM | 1 |
| Leibenhaut, MH | 4 |
| Narayan, S | 1 |
| Torres-Roca, J | 1 |
| Michalski, J | 1 |
| Donavanik, V | 1 |
| Sandler, H | 2 |
| McGowan, DG | 3 |
| Suh, JH | 1 |
| Chattopadhyay, A | 1 |
| Sieglaff, DH | 1 |
| Storer Samaniego, C | 1 |
| Cox, MB | 1 |
| Webb, P | 1 |
| Voog, JC | 1 |
| Paulus, R | 1 |
| Smith, MR | 4 |
| Husain, SM | 2 |
| Gore, E | 1 |
| Raben, A | 1 |
| Chafe, S | 1 |
| Efstathiou, JA | 2 |
| Varenhorst, E | 9 |
| Klaff, R | 1 |
| Berglund, A | 1 |
| Hedlund, PO | 6 |
| Sandblom, G | 2 |
| Morote, J | 3 |
| Regis, L | 1 |
| Celma, A | 1 |
| Planas, J | 1 |
| Higashiyama, A | 1 |
| Yokoyama, T | 1 |
| Omoto, Y | 1 |
| Habe, K | 1 |
| Yamanaka, K | 1 |
| Mizutani, H | 1 |
| Fosså, SD | 7 |
| Wiklund, F | 3 |
| Klepp, O | 3 |
| Angelsen, A | 4 |
| Solberg, A | 4 |
| Hoyer, M | 2 |
| Widmark, A | 5 |
| Chakraborty, S | 1 |
| Kumar, A | 1 |
| Butt, NA | 1 |
| Zhang, L | 4 |
| Williams, R | 1 |
| Rimando, AM | 1 |
| Biswas, PK | 1 |
| Levenson, AS | 2 |
| Bogner, J | 1 |
| Zolghadr, K | 1 |
| Hickson, I | 1 |
| Romer, T | 1 |
| Yurlova, L | 1 |
| Takeda, K | 1 |
| Hara, N | 5 |
| Nishiyama, T | 8 |
| Tasaki, M | 1 |
| Ishizaki, F | 3 |
| Tomita, Y | 2 |
| Strum, SB | 2 |
| Scholz, MC | 2 |
| Xie, J | 1 |
| Mølck, C | 1 |
| Paquet-Fifield, S | 1 |
| Butler, L | 1 |
| Sloan, E | 1 |
| Ventura, S | 1 |
| Hollande, F | 1 |
| Yokomizo, Y | 1 |
| Kawahara, T | 1 |
| Miyoshi, Y | 1 |
| Otani, M | 1 |
| Yamanaka, S | 1 |
| Teranishi, J | 1 |
| Noguchi, K | 2 |
| Yao, M | 1 |
| Uemura, H | 2 |
| Suseelan, SR | 1 |
| Sreenivasan, SK | 1 |
| Górowska-Wójtowicz, E | 1 |
| Hejmej, A | 1 |
| Kamińska, A | 1 |
| Pardyak, L | 1 |
| Kotula-Balak, M | 1 |
| Dulińska-Litewka, J | 1 |
| Laidler, P | 1 |
| Bilińska, B | 1 |
| D'Amico, AV | 9 |
| Chen, MH | 7 |
| Renshaw, AA | 6 |
| Loffredo, B | 1 |
| Kantoff, PW | 9 |
| Spitz, IM | 3 |
| Chertin, B | 3 |
| Fridmans, A | 2 |
| Farkas, A | 3 |
| Belanger, A | 23 |
| Hartman, H | 1 |
| Labrie, F | 59 |
| Suzuki, H | 4 |
| Okihara, K | 1 |
| Miyake, H | 3 |
| Fujisawa, M | 2 |
| Miyoshi, S | 1 |
| Matsumoto, T | 2 |
| Fujii, M | 1 |
| Takihana, Y | 1 |
| Usui, T | 1 |
| Matsuda, T | 3 |
| Ozono, S | 5 |
| Kumon, H | 3 |
| Ichikawa, T | 2 |
| Miki, T | 2 |
| Robinson, D | 1 |
| Johansson, R | 3 |
| Garmo, H | 1 |
| Aus, G | 2 |
| Crook, J | 3 |
| Ludgate, C | 4 |
| Malone, S | 4 |
| Perry, G | 3 |
| Eapen, L | 3 |
| Bowen, J | 3 |
| Robertson, S | 3 |
| Lockwood, G | 3 |
| Söderholm, AA | 1 |
| Viiliäinen, J | 1 |
| Lehtovuori, PT | 1 |
| Eskelinen, H | 1 |
| Nyrönen, TH | 1 |
| Köllermann, J | 4 |
| Weikert, S | 1 |
| Schostak, M | 1 |
| Kempkensteffen, C | 1 |
| Kleinschmidt, K | 1 |
| Rau, T | 1 |
| Pantel, K | 2 |
| Brower, V | 1 |
| Gao, X | 1 |
| Zhou, T | 1 |
| Tang, YJ | 1 |
| Lu, X | 1 |
| Sun, YH | 1 |
| Fransson, P | 2 |
| Lund, JA | 2 |
| Tasdemir, I | 3 |
| Crook, JM | 1 |
| Owen, J | 1 |
| Fung, S | 1 |
| He, H | 1 |
| Morely, JE | 1 |
| Silva-Lopez, E | 1 |
| Bottenus, B | 1 |
| Montajano, M | 1 |
| Fugate, GA | 1 |
| Twamley, B | 1 |
| Benny, PD | 2 |
| Ray, ME | 1 |
| Bae, K | 4 |
| Hussain, MH | 2 |
| Bañez, LL | 1 |
| Blake, GW | 1 |
| McLeod, DG | 18 |
| Crawford, ED | 27 |
| Moul, JW | 3 |
| Ishiyama, H | 1 |
| Kitano, M | 1 |
| Satoh, T | 3 |
| Kotani, S | 1 |
| Uemae, M | 1 |
| Matsumoto, K | 2 |
| Okusa, H | 1 |
| Tabata, K | 1 |
| Baba, S | 2 |
| Hayakawa, K | 2 |
| Spry, NA | 6 |
| Galvão, DA | 2 |
| Davies, R | 1 |
| La Bianca, S | 1 |
| Joseph, D | 5 |
| Davidson, A | 1 |
| Prince, R | 1 |
| Fosså, S | 1 |
| Ho, AY | 1 |
| Burri, RJ | 1 |
| Cesaretti, JA | 2 |
| Stone, NN | 4 |
| Stock, RG | 4 |
| Schelin, S | 1 |
| Madsen, M | 1 |
| Palmqvist, E | 1 |
| Mäkelä, E | 1 |
| Klintenberg, C | 1 |
| Steinkamp, MP | 1 |
| O'Mahony, OA | 1 |
| Brogley, M | 1 |
| Rehman, H | 1 |
| Lapensee, EW | 1 |
| Dhanasekaran, S | 1 |
| Hofer, MD | 1 |
| Kuefer, R | 2 |
| Chinnaiyan, A | 1 |
| Rubin, MA | 2 |
| Pienta, KJ | 2 |
| Robins, DM | 1 |
| Ishioka, J | 2 |
| Hara, S | 2 |
| Isaacs, JT | 5 |
| Tomura, A | 3 |
| Nishikawa, K | 3 |
| Kageyama, Y | 2 |
| Loffredo, M | 5 |
| Alexander, A | 1 |
| Jones, S | 1 |
| Truong, P | 1 |
| Pai, H | 1 |
| Bolla, M | 3 |
| de Reijke, TM | 4 |
| Van Tienhoven, G | 1 |
| Van den Bergh, AC | 1 |
| Oddens, J | 1 |
| Poortmans, PM | 1 |
| Gez, E | 1 |
| Kil, P | 1 |
| Akdas, A | 1 |
| Soete, G | 1 |
| Kariakine, O | 1 |
| van der Steen-Banasik, EM | 1 |
| Musat, E | 1 |
| Piérart, M | 1 |
| Mauer, ME | 1 |
| Collette, L | 6 |
| Gannon, PO | 1 |
| Poisson, AO | 1 |
| Delvoye, N | 1 |
| Lapointe, R | 1 |
| Mes-Masson, AM | 1 |
| Saad, F | 2 |
| Yee, DS | 1 |
| Lowrance, WT | 1 |
| Eastham, JA | 2 |
| Maschino, AC | 1 |
| Cronin, AM | 1 |
| Rabbani, F | 2 |
| Knudsen, KE | 1 |
| Scher, HI | 10 |
| Pflueger, D | 1 |
| Rickman, DS | 1 |
| Sboner, A | 1 |
| Perner, S | 1 |
| LaFargue, CJ | 1 |
| Svensson, MA | 1 |
| Moss, BJ | 1 |
| Kitabayashi, N | 1 |
| Pan, Y | 1 |
| de la Taille, A | 1 |
| Tewari, AK | 1 |
| Demichelis, F | 1 |
| Chee, MS | 1 |
| Gerstein, MB | 1 |
| Isahaya, E | 4 |
| Hoshii, T | 4 |
| Takizawa, I | 4 |
| Takahashi, K | 8 |
| Terada, N | 1 |
| Shimizu, Y | 1 |
| Yoshida, T | 1 |
| Maeno, A | 1 |
| Kamba, T | 1 |
| Inoue, T | 1 |
| Nakamura, E | 1 |
| Kamoto, T | 2 |
| Ogawa, O | 2 |
| O'Rourke, ME | 1 |
| Ruble, K | 1 |
| Milecki, P | 1 |
| Baczyk, M | 1 |
| Skowronek, J | 1 |
| Antczak, A | 1 |
| Kwias, Z | 1 |
| Martenka, P | 1 |
| Nguyen, PL | 2 |
| Beard, CJ | 2 |
| Suh, WW | 1 |
| McMahon, E | 2 |
| van de Wijngaart, DJ | 1 |
| Molier, M | 1 |
| Lusher, SJ | 1 |
| Hersmus, R | 2 |
| Jenster, G | 3 |
| Trapman, J | 3 |
| Dubbink, HJ | 1 |
| Moore, AL | 1 |
| Bucar, DK | 1 |
| Macgillivray, LR | 1 |
| Narimoto, K | 1 |
| Mizokami, A | 3 |
| Izumi, K | 1 |
| Mihara, S | 1 |
| Sawada, K | 1 |
| Sugata, T | 1 |
| Shimamura, M | 1 |
| Miyazaki, K | 1 |
| Nishino, A | 1 |
| Namiki, M | 2 |
| Schayek, H | 1 |
| Bentov, I | 1 |
| Sun, S | 1 |
| Plymate, SR | 2 |
| Werner, H | 1 |
| Telesca, D | 1 |
| Jiang, P | 1 |
| Tam, S | 1 |
| Russell, KJ | 1 |
| Nelson, PS | 1 |
| Etzioni, RD | 1 |
| Haugen, OA | 1 |
| Viset, T | 1 |
| Bergh, A | 2 |
| Ahlgren, G | 2 |
| Kumar, M | 1 |
| Denham, JW | 4 |
| Steigler, A | 4 |
| Dahlman, A | 1 |
| Edsjö, A | 1 |
| Halldén, C | 1 |
| Persson, JL | 1 |
| Fine, SW | 1 |
| Lilja, H | 1 |
| Gerald, W | 2 |
| Bjartell, A | 1 |
| Chen, XQ | 1 |
| Huang, Y | 1 |
| Li, X | 2 |
| Zhang, P | 1 |
| Xia, J | 1 |
| Chen, N | 1 |
| Wei, Q | 1 |
| Zhu, YC | 1 |
| Yang, YR | 1 |
| Zeng, H | 1 |
| Armstrong, JG | 1 |
| Gillham, CM | 1 |
| Dunne, MT | 1 |
| Fitzpatrick, DA | 1 |
| Finn, MA | 1 |
| Cannon, ME | 1 |
| Taylor, JC | 1 |
| O'Shea, CM | 1 |
| Buckney, SJ | 1 |
| Thirion, PG | 1 |
| Okegawa, T | 1 |
| Nutahara, K | 1 |
| Higashihara, E | 2 |
| Pérez-Montaña, A | 1 |
| Navarro, JT | 1 |
| Juncà, J | 1 |
| Ribera, JM | 1 |
| Dotan, N | 1 |
| Wasser, SP | 1 |
| Mahajna, J | 1 |
| Elgindy, N | 1 |
| Elkhodairy, K | 1 |
| Molokhia, A | 1 |
| Elzoghby, A | 1 |
| Kawabata, R | 1 |
| Oie, S | 1 |
| Oka, T | 1 |
| Takahashi, M | 1 |
| Kanayama, H | 1 |
| Itoh, K | 2 |
| Vainio, P | 1 |
| Gupta, S | 1 |
| Ketola, K | 1 |
| Mirtti, T | 1 |
| Mpindi, JP | 1 |
| Kohonen, P | 1 |
| Fey, V | 1 |
| Perälä, M | 1 |
| Smit, F | 1 |
| Verhaegh, G | 1 |
| Schalken, J | 1 |
| Alanen, KA | 1 |
| Kallioniemi, O | 1 |
| Iljin, K | 1 |
| Tong, da Y | 2 |
| Wen, XQ | 1 |
| Jin, Y | 2 |
| Liu, ZW | 2 |
| Sun, HY | 2 |
| Zhou, FJ | 2 |
| Wu, XY | 2 |
| Lamb, DS | 3 |
| Turner, S | 5 |
| Matthews, J | 4 |
| Atkinson, C | 3 |
| North, J | 4 |
| Christie, D | 3 |
| Tai, KH | 3 |
| Wynne, C | 3 |
| D'Este, C | 2 |
| Gonzalez-Moreno, O | 1 |
| Boque, N | 1 |
| Redrado, M | 1 |
| Milagro, F | 1 |
| Campion, J | 1 |
| Endermann, T | 1 |
| Saito, Y | 1 |
| Catena, R | 1 |
| Schomburg, L | 1 |
| Calvo, A | 1 |
| Kobayashi, M | 1 |
| Nukui, A | 1 |
| Suzuki, K | 4 |
| Mazeron, JJ | 3 |
| Hagerman, I | 3 |
| Henriksson, P | 4 |
| Iversen, P | 12 |
| Klarskov, P | 4 |
| Mogensen, P | 2 |
| Rasmussen, F | 5 |
| Wang, Y | 3 |
| Li, JQ | 1 |
| Shao, C | 2 |
| Shi, CH | 2 |
| Liu, F | 2 |
| Yang, ZY | 1 |
| Qiu, JX | 1 |
| Li, YM | 1 |
| Fu, Q | 1 |
| Zhang, W | 3 |
| Xue, W | 1 |
| Lei, YH | 1 |
| Gao, JY | 1 |
| Wang, JY | 1 |
| Gao, XP | 1 |
| Yuan, JL | 1 |
| Bao, TY | 1 |
| Zhang, YT | 2 |
| Chetner, MP | 1 |
| Bruner, DW | 1 |
| Montironi, R | 4 |
| Bartels, PH | 1 |
| DeCensi, A | 3 |
| Puntoni, M | 1 |
| Hurle, R | 1 |
| Decobelli, O | 1 |
| Carmignani, G | 3 |
| Mazzucchelli, R | 1 |
| Bartels, HG | 1 |
| Alberts, DS | 1 |
| Maffezzini, M | 1 |
| Bo, JJ | 1 |
| Zhang, C | 1 |
| Zhang, LH | 1 |
| Liu, P | 1 |
| Sha, JJ | 1 |
| Lv, JW | 1 |
| Liu, DM | 1 |
| Huang, YR | 1 |
| Li, Z | 1 |
| Takada, T | 1 |
| Ishizuya, Y | 1 |
| Okada, T | 1 |
| Ueda, T | 2 |
| Inoue, H | 1 |
| Hara, T | 1 |
| Marques, RB | 2 |
| Dits, NF | 1 |
| Erkens-Schulze, S | 2 |
| van Ijcken, WF | 1 |
| van Weerden, WM | 2 |
| Andrieu, T | 1 |
| Bertolini, R | 1 |
| Nichols, SE | 1 |
| Setoud, R | 1 |
| Frey, FJ | 1 |
| Baker, ME | 1 |
| Frey, BM | 1 |
| Zhong, K | 1 |
| Li, W | 1 |
| Gui, M | 1 |
| Long, Z | 1 |
| He, L | 1 |
| Kai, L | 1 |
| Jain, HV | 1 |
| Clinton, SK | 1 |
| Bhinder, A | 1 |
| Friedman, A | 1 |
| Reznikov, OH | 1 |
| Chaĭkovs'ka, LV | 1 |
| Poliakova, LI | 1 |
| Sachyns'ka, OV | 1 |
| Monk, JP | 1 |
| Halabi, S | 2 |
| Picus, J | 1 |
| Hussain, A | 1 |
| Philips, G | 1 |
| Kaplan, E | 1 |
| Ahles, T | 1 |
| Gu, L | 1 |
| Vogelzang, N | 4 |
| Kelly, WK | 8 |
| Small, EJ | 9 |
| Reznikov, AG | 1 |
| Chaykovskaya, LV | 1 |
| Polyakova, LI | 1 |
| Kornelyuk, AI | 1 |
| Grygorenko, VN | 1 |
| Berglund, RK | 1 |
| Tangen, CM | 6 |
| Powell, IJ | 2 |
| Lowe, BA | 4 |
| Haas, GP | 2 |
| Carroll, PR | 5 |
| Canby-Hagino, ED | 1 |
| deVere White, R | 2 |
| Hemstreet, GP | 1 |
| Thompson, IM | 7 |
| Klein, EA | 3 |
| Jang, JW | 1 |
| Hwang, WT | 1 |
| Guzzo, TJ | 1 |
| Wein, AJ | 2 |
| Haas, NB | 1 |
| Both, S | 1 |
| Vapiwala, N | 1 |
| Pašalić, D | 1 |
| Pauković, P | 1 |
| Cvijetić, S | 1 |
| Pizent, A | 1 |
| Jurasović, J | 1 |
| Milković-Kraus, S | 1 |
| Dodig, S | 1 |
| Mück-Šeler, D | 1 |
| Mustapić, M | 1 |
| Pivac, N | 1 |
| Pavlović, M | 1 |
| Chen, S | 1 |
| Jiang, PY | 1 |
| Pitzel, P | 1 |
| Mottet, N | 3 |
| Van Damme, J | 1 |
| Loulidi, S | 1 |
| Russel, C | 1 |
| Leitenberger, A | 1 |
| Wolff, JM | 2 |
| Peneau, M | 1 |
| Molinie, V | 1 |
| Richaud, P | 1 |
| Mearini, L | 1 |
| Ng, E | 1 |
| Woo, HH | 1 |
| Leong, E | 1 |
| Jackson, M | 1 |
| Spry, N | 4 |
| Ischia, J | 1 |
| Goldenberg, SL | 5 |
| Piccionello, AP | 1 |
| Pitarresi, G | 1 |
| Pace, A | 1 |
| Triolo, D | 1 |
| Picone, P | 1 |
| Buscemi, S | 1 |
| Giammona, G | 1 |
| Martin, NE | 1 |
| Loffredo, MJ | 1 |
| Spahn, M | 1 |
| Briganti, A | 1 |
| Capitanio, U | 1 |
| Kneitz, B | 1 |
| Gontero, P | 1 |
| Karnes, JR | 1 |
| Schubert, M | 1 |
| Montorsi, F | 1 |
| Scholz, CJ | 1 |
| Bader, P | 1 |
| van Poppel, H | 2 |
| Joniau, S | 1 |
| Taaffe, DR | 1 |
| England, PJ | 1 |
| Judge, JS | 1 |
| Stephens, DA | 1 |
| Peddle-McIntyre, C | 1 |
| Baker, MK | 1 |
| Newton, RU | 1 |
| Sanchez, C | 1 |
| Chan, R | 1 |
| Bajgain, P | 1 |
| Rambally, S | 1 |
| Palapattu, G | 1 |
| Mims, M | 1 |
| Rooney, CM | 1 |
| Leen, AM | 1 |
| Brenner, MK | 1 |
| Vera, JF | 1 |
| Godoy-Tundidor, S | 1 |
| Hobisch, A | 3 |
| Pfeil, K | 1 |
| Bartsch, G | 3 |
| Altiparmak, MR | 1 |
| Bilici, A | 1 |
| Kisacik, B | 1 |
| Ozguroglu, M | 1 |
| Sigala, S | 1 |
| Tognazzi, N | 1 |
| Rizzetti, MC | 1 |
| Faraoni, I | 1 |
| Missale, C | 1 |
| Bonmassar, E | 1 |
| Spano, P | 1 |
| Burns-Cox, N | 1 |
| Basketter, V | 1 |
| Higgins, B | 3 |
| Holmes, S | 1 |
| Balk, SP | 3 |
| Fukuda, M | 1 |
| Takashima, H | 1 |
| Fuse, H | 6 |
| Hirano, S | 1 |
| Bennett, CL | 5 |
| Raisch, DW | 1 |
| Sartor, O | 11 |
| Kiriyama, I | 1 |
| Ogaki, K | 1 |
| Ohba, S | 2 |
| Nishimura, T | 2 |
| Miller, GJ | 1 |
| Haas, G | 1 |
| Osswald, MB | 1 |
| Lee, YF | 2 |
| Lin, WJ | 1 |
| Huang, J | 3 |
| Messing, EM | 1 |
| Chan, FL | 1 |
| Wilding, G | 5 |
| Chang, C | 10 |
| Boccardo, F | 7 |
| Barichello, M | 2 |
| Battaglia, M | 3 |
| Comeri, G | 2 |
| Ferraris, V | 4 |
| Lilliu, S | 2 |
| Montefiore, F | 2 |
| Portoghese, F | 2 |
| Cortellini, P | 4 |
| Rigatti, P | 1 |
| Usai, E | 4 |
| Rubagotti, A | 4 |
| Lu, JD | 1 |
| Pilepich, MV | 9 |
| Heydon, K | 1 |
| Wolkov, HB | 4 |
| Sause, WT | 3 |
| Rubin, P | 5 |
| Lawton, CA | 6 |
| Machtay, M | 2 |
| Glass, TR | 1 |
| Thompson, I | 2 |
| Lu, J | 1 |
| Asbell, SO | 2 |
| Mohiuddin, M | 1 |
| Grignon, D | 4 |
| Yamaguchi, A | 2 |
| Mochizuki, H | 1 |
| Kawakami, T | 1 |
| Otani, T | 1 |
| Yoshida, K | 3 |
| Ichinei, M | 1 |
| Yamashita, T | 1 |
| Hirao, Y | 5 |
| Sakai, H | 1 |
| Zhang, Y | 1 |
| Chen, W | 1 |
| Hu, XK | 1 |
| Gui, ZN | 1 |
| Miller, NL | 1 |
| Bissonette, EA | 1 |
| Bahnson, R | 1 |
| Wilson, J | 1 |
| Theodorescu, D | 1 |
| Maeda, O | 1 |
| Anderson, J | 1 |
| Ala-Opas, M | 1 |
| Brekkan, E | 1 |
| Damber, L | 1 |
| Haukaas, S | 2 |
| Pousette, A | 2 |
| Salo, J | 1 |
| Vaage, S | 1 |
| Preston, DM | 1 |
| Torréns, JI | 1 |
| Harding, P | 1 |
| Howard, RS | 1 |
| Duncan, WE | 1 |
| Dockery, F | 1 |
| Bulpitt, CJ | 1 |
| Agarwal, S | 1 |
| Rajkumar, C | 1 |
| Sanguineti, G | 1 |
| Marcenaro, M | 1 |
| Franzone, P | 1 |
| Foppiano, F | 1 |
| Vitale, V | 1 |
| Kaur, C | 1 |
| Thami, GP | 1 |
| Yoshimura, K | 1 |
| Sumiyoshi, Y | 2 |
| Hashimura, T | 1 |
| Kamiryo, Y | 1 |
| Arai, Y | 1 |
| Furuya, Y | 4 |
| Nagakawa, O | 2 |
| Heydon, KH | 1 |
| Hammond, EH | 2 |
| Mesic, JB | 2 |
| Fu, KK | 3 |
| Porter, AT | 1 |
| Abrams, RA | 3 |
| Sciarra, A | 2 |
| Monti, S | 1 |
| Gentile, V | 1 |
| Mariotti, G | 1 |
| Cardi, A | 2 |
| Voria, G | 1 |
| Lucera, R | 1 |
| Di Silverio, F | 5 |
| Ashar, U | 1 |
| Desai, D | 1 |
| Bhaduri, A | 1 |
| Karasawa, K | 1 |
| Kaizu, T | 1 |
| Niibe, Y | 1 |
| Igaki, H | 1 |
| Shinohara, M | 1 |
| Tanaka, Y | 2 |
| Meineke, V | 1 |
| Köhn, FM | 1 |
| Pickl, U | 1 |
| Ring, J | 1 |
| Vogt, HJ | 1 |
| Kosugi, M | 1 |
| Hanawa, Y | 1 |
| Momma, T | 1 |
| Saito, S | 2 |
| Hirose, S | 1 |
| Qiao, S | 1 |
| Pennanen, P | 1 |
| Nazarova, N | 2 |
| Lou, YR | 2 |
| Tuohimaa, P | 2 |
| Oh, WK | 1 |
| Manola, J | 2 |
| Bittmann, L | 1 |
| Brufsky, A | 2 |
| Kaplan, ID | 1 |
| Kaufman, DS | 1 |
| Mabjeesh, NJ | 1 |
| Willard, MT | 1 |
| Frederickson, CE | 1 |
| Zhong, H | 1 |
| Simons, JW | 1 |
| Schröder, FH | 7 |
| Shao, TC | 1 |
| Li, H | 1 |
| Eid, W | 1 |
| Ittmann, M | 1 |
| Unni, E | 1 |
| Cunningham, GR | 1 |
| Jani, AB | 3 |
| Basu, A | 1 |
| Abdalla, I | 1 |
| Connell, PP | 1 |
| Krauz, L | 1 |
| Vijayakumar, S | 2 |
| Nishimura, K | 3 |
| Ting, HJ | 3 |
| Harada, Y | 1 |
| Tokizane, T | 1 |
| Nonomura, N | 1 |
| Kang, HY | 3 |
| Chang, HC | 2 |
| Yeh, S | 8 |
| Miyamoto, H | 5 |
| Shin, M | 1 |
| Aozasa, K | 1 |
| Okuyama, A | 1 |
| Mameghan, H | 3 |
| Franklin, I | 3 |
| Poulsen, M | 3 |
| Kovacev, O | 3 |
| Robertson, R | 1 |
| Francis, L | 1 |
| Duchesne, G | 2 |
| Serretta, V | 5 |
| Daricello, G | 5 |
| Dispensa, N | 1 |
| Allegro, R | 1 |
| Pavone, C | 5 |
| Pavone-Macaluso, M | 8 |
| Rose, AL | 1 |
| Higano, C | 2 |
| Sheski, FD | 1 |
| Henley, JD | 1 |
| Foster, RS | 1 |
| Einhorn, LH | 1 |
| Aizawa, Y | 4 |
| Ikemoto, I | 4 |
| Kishimoto, K | 1 |
| Wada, T | 3 |
| Yamazaki, H | 3 |
| Ohishi, Y | 3 |
| Kiyota, H | 1 |
| Furuta, N | 1 |
| Ueda, M | 2 |
| Barqawi, A | 1 |
| Akduman, B | 1 |
| Abouelfadel, Z | 1 |
| Robischon, M | 1 |
| Barqawi, AB | 1 |
| Ziada, A | 1 |
| Handel, L | 1 |
| Lorente, JA | 3 |
| Arango, O | 1 |
| Bielsa, O | 1 |
| Cortadellas, R | 1 |
| Cañis, D | 1 |
| Lloreta-Trull, J | 1 |
| Gelabert-Mas, A | 1 |
| Hopfenmüller, W | 1 |
| Caprano, J | 2 |
| Budde, A | 1 |
| Weidenfeld, H | 1 |
| Weidenfeld, M | 1 |
| Helpap, B | 2 |
| Holzbeierlein, J | 1 |
| Lal, P | 2 |
| LaTulippe, E | 1 |
| Smith, A | 4 |
| Satagopan, J | 2 |
| Ryan, C | 1 |
| Smith, S | 1 |
| Scher, H | 1 |
| Scardino, P | 2 |
| Reuter, V | 4 |
| Gerald, WL | 1 |
| Noguchi, M | 1 |
| Noda, S | 1 |
| Yoshida, M | 2 |
| Ueda, S | 1 |
| Shiraishi, T | 1 |
| Kojima, S | 1 |
| Akakura, K | 4 |
| Shimbo, M | 1 |
| Langenstroer, P | 1 |
| Porter, HJ | 1 |
| Thrasher, JB | 2 |
| Letsch, M | 1 |
| Schally, AV | 2 |
| Stangelberger, A | 1 |
| Groot, K | 1 |
| Varga, JL | 1 |
| Nabi, G | 1 |
| Seth, A | 2 |
| Dinda, AK | 1 |
| Gupta, NP | 2 |
| Lübbert, C | 1 |
| Wiese, M | 1 |
| Haupt, R | 1 |
| Ruf, BR | 1 |
| Lin, AD | 1 |
| Chen, KK | 1 |
| Lin, AT | 1 |
| Chang, YH | 1 |
| Wu, HH | 1 |
| Kuo, JY | 1 |
| Huang, WJ | 1 |
| Hsu, YS | 1 |
| Chung, HJ | 1 |
| Chang, LS | 1 |
| Tanvetyanon, T | 1 |
| Choudhury, AM | 1 |
| Karakolios, A | 1 |
| Kasapis, C | 1 |
| Kallinikidis, T | 1 |
| Kalpidis, P | 1 |
| Grigoriadis, N | 1 |
| Chao, DH | 1 |
| Higgins, JP | 1 |
| Brooks, JD | 1 |
| Wirth, MP | 1 |
| Weissbach, L | 1 |
| Marx, FJ | 1 |
| Heckl, W | 1 |
| Jellinghaus, W | 1 |
| Riedmiller, H | 1 |
| Noack, B | 1 |
| Hinke, A | 2 |
| Froehner, M | 2 |
| Zimmerman, RA | 1 |
| Culkin, DJ | 2 |
| Whelan, P | 8 |
| Kurth, KH | 1 |
| Mattelaer, J | 4 |
| van Velthoven, RF | 1 |
| Debois, M | 1 |
| Harano, M | 1 |
| Kano, M | 2 |
| Hida, T | 1 |
| Fujisawa, Y | 1 |
| Faulkner, JR | 1 |
| Eisenberger, M | 3 |
| Hussain, M | 2 |
| de Leval, J | 1 |
| Boca, P | 1 |
| Yousef, E | 1 |
| Nicolas, H | 1 |
| Jeukenne, M | 1 |
| Seidel, L | 1 |
| Bouffioux, C | 2 |
| Coppens, L | 1 |
| Bonnet, P | 2 |
| Andrianne, R | 1 |
| Wlatregny, D | 1 |
| Teh, BS | 2 |
| Ayala, G | 2 |
| Aguilar, L | 1 |
| Mai, WY | 2 |
| Timme, TL | 1 |
| Vlachaki, MT | 2 |
| Miles, B | 2 |
| Kadmon, D | 2 |
| Wheeler, T | 2 |
| Caillouet, J | 2 |
| Davis, M | 2 |
| Carpenter, LS | 2 |
| Lu, HH | 2 |
| Chiu, JK | 2 |
| Woo, SY | 2 |
| Thompson, T | 2 |
| Aguilar-Cordova, E | 2 |
| Butler, EB | 2 |
| Minamiguchi, K | 1 |
| Kawada, M | 1 |
| Takamoto, K | 1 |
| Ishizuka, M | 1 |
| Zwergel, T | 1 |
| Tahmatzopoulos, A | 1 |
| Zwergel, U | 1 |
| Stöckle, M | 3 |
| Unteregger, G | 1 |
| Pitts, WR | 1 |
| Hu, YC | 2 |
| Yeh, SD | 1 |
| Sampson, ER | 1 |
| Li, P | 1 |
| Hsu, CL | 2 |
| Lin, HK | 3 |
| Wang, L | 1 |
| Kim, E | 1 |
| Ni, J | 1 |
| Cohen, MR | 1 |
| Martín-Lázaro, J | 1 |
| Buján, JG | 1 |
| Arrondo, AP | 1 |
| Lozano, JR | 1 |
| Galindo, EC | 1 |
| Capdevila, EF | 1 |
| Almeida, OP | 2 |
| Waterreus, A | 1 |
| Flicker, L | 2 |
| Martins, RN | 2 |
| Rocco, B | 1 |
| Matei, DV | 1 |
| de Cobelli, O | 1 |
| Rocco, F | 1 |
| Diamond, TH | 2 |
| Bucci, J | 1 |
| Kersley, JH | 2 |
| Aslan, P | 1 |
| Lynch, WB | 1 |
| Bryant, C | 3 |
| Gardiner, RA | 1 |
| Nicol, DL | 2 |
| Green, HJ | 1 |
| Yaxley, J | 1 |
| Watson, R | 1 |
| Mactaggart, P | 1 |
| Headley, BC | 1 |
| Swanson, C | 1 |
| Pakenham, KI | 1 |
| Benaim, EA | 1 |
| Karam, JA | 1 |
| Soboorian, MH | 1 |
| Roehrborn, CG | 1 |
| McConnell, JD | 1 |
| Lin, V | 1 |
| Cahlon, O | 1 |
| Kollmeier, MA | 1 |
| Sgambato, A | 2 |
| Camerini, A | 1 |
| Faraglia, B | 2 |
| Ardito, R | 1 |
| Bianchino, G | 1 |
| Spada, D | 1 |
| Boninsegna, A | 2 |
| Valentini, V | 2 |
| Cittadini, A | 2 |
| Sato, N | 2 |
| Isaka, S | 3 |
| Nakatsu, H | 1 |
| Tanaka, M | 2 |
| Masai, M | 3 |
| DellaCroce, A | 1 |
| Lim, J | 1 |
| van der Poel, HG | 1 |
| Nomura, M | 1 |
| Sato, H | 1 |
| Fujimoto, N | 2 |
| Baltogiannis, D | 1 |
| Giannakopoulos, X | 2 |
| Charalabopoulos, K | 1 |
| Sofikitis, N | 1 |
| Montalvo, L | 1 |
| Carmena, MJ | 1 |
| Bolaños, O | 1 |
| Rodríguez-Henche, N | 1 |
| Prieto, JC | 1 |
| Whitaker, HC | 1 |
| Hanrahan, S | 1 |
| Totty, N | 1 |
| Gamble, SC | 1 |
| Waxman, J | 6 |
| Cato, AC | 2 |
| Hurst, HC | 1 |
| Bevan, CL | 1 |
| Talonpoika, R | 1 |
| Qian, LX | 2 |
| Hua, LX | 2 |
| Wu, HF | 2 |
| Sui, YG | 2 |
| Cheng, SG | 1 |
| Wang, XR | 1 |
| Anraku, T | 1 |
| Shimura, H | 1 |
| Shields, A | 1 |
| Wood, N | 1 |
| Brown, J | 1 |
| Tangen, C | 2 |
| Ansari, MS | 1 |
| Hemal, AK | 1 |
| Dogra, PN | 1 |
| Koulikov, D | 1 |
| Lindenberg, T | 2 |
| Gelber, H | 1 |
| Leiter, C | 1 |
| Miyakita, H | 2 |
| Gurina, LI | 1 |
| Iudin, SV | 1 |
| Zhang, M | 1 |
| Latham, DE | 1 |
| Delaney, MA | 1 |
| Chakravarti, A | 1 |
| Voegeli, TA | 1 |
| Kurtz, A | 1 |
| Grimm, MO | 1 |
| Effert, P | 1 |
| Eckardt, KU | 1 |
| Song, NH | 1 |
| Zhang, JX | 1 |
| Ajayi, AA | 1 |
| Halushka, PV | 1 |
| Muradian, AA | 1 |
| de Ridder, CM | 1 |
| Hermans, KG | 1 |
| Waltering, K | 1 |
| Visakorpi, T | 1 |
| Romijn, JC | 1 |
| Ma, G | 1 |
| Troxel, AB | 1 |
| Heitjan, DF | 1 |
| Gratzle, J | 2 |
| Myers, M | 1 |
| Bengoechea Gallastegui, L | 1 |
| Vita Garay, A | 1 |
| Castiella Eguzkiza, A | 1 |
| Egido Arroyo, JF | 1 |
| Bern, MM | 1 |
| Jacobson, O | 2 |
| Bechor, Y | 1 |
| Icar, A | 1 |
| Novak, N | 1 |
| Birman, A | 1 |
| Marom, H | 1 |
| Fadeeva, L | 1 |
| Golan, E | 1 |
| Leibovitch, I | 1 |
| Gutman, M | 2 |
| Even-Sapir, E | 2 |
| Chisin, R | 2 |
| Gozin, M | 2 |
| Mishani, E | 2 |
| Benbrahim-Tallaa, L | 2 |
| Webber, MM | 2 |
| Waalkes, MP | 2 |
| Farla, P | 1 |
| Houtsmuller, AB | 1 |
| Davis, NB | 1 |
| Ryan, CW | 1 |
| Stadler, WM | 1 |
| Vogelzang, NJ | 6 |
| Hara, I | 2 |
| Eto, H | 1 |
| Lucas, C | 1 |
| Sene, E | 1 |
| Avances, C | 1 |
| Maubach, L | 1 |
| Sheng, XJ | 1 |
| Zhu, YJ | 1 |
| Ye, M | 1 |
| Chen, JH | 1 |
| Kong, L | 1 |
| Chodak, GW | 2 |
| Ramsey, S | 1 |
| Veenstra, D | 1 |
| Clarke, L | 1 |
| Gandhi, S | 1 |
| Hirsch, M | 1 |
| Penson, D | 2 |
| Ilagan, R | 1 |
| Zhang, LJ | 1 |
| Pottratz, J | 1 |
| Le, K | 1 |
| Salas, S | 1 |
| Iyer, M | 1 |
| Wu, L | 1 |
| Gambhir, SS | 1 |
| Carey, M | 1 |
| Yue, HH | 1 |
| Wang, PF | 1 |
| Yang, B | 1 |
| Qin, WJ | 1 |
| Wang, H | 1 |
| Shao, GX | 1 |
| Zhang, SG | 1 |
| Wang, YH | 1 |
| Ding, Y | 1 |
| Wu, Y | 1 |
| Papaioannides, D | 1 |
| Korantzopoulos, P | 1 |
| Bouropoulos, C | 1 |
| Latsi, P | 1 |
| Fotinou, M | 1 |
| Orphanidou, D | 1 |
| Konski, A | 1 |
| Watkins-Bruner, D | 2 |
| Brereton, H | 1 |
| Feigenberg, S | 1 |
| Hanks, G | 3 |
| Ohlson, N | 1 |
| Nygren, K | 1 |
| Wikström, P | 1 |
| Desilvio, M | 1 |
| Monge, A | 1 |
| Jagla, M | 1 |
| Lapouge, G | 1 |
| Sasorith, S | 1 |
| Cruchant, M | 1 |
| Wurtz, JM | 1 |
| Jacqmin, D | 1 |
| Bergerat, JP | 1 |
| Céraline, J | 1 |
| Goda, R | 2 |
| Nagai, D | 2 |
| Akiyama, Y | 1 |
| Nagata, K | 1 |
| Yamazoe, Y | 1 |
| Tevell, A | 1 |
| Jönsson, M | 1 |
| Norlin, M | 1 |
| Bondesson, U | 1 |
| Hedeland, M | 1 |
| Gu, RG | 1 |
| Zhou, CW | 1 |
| Ma, QZ | 1 |
| Kristjanson, L | 1 |
| Hooton, B | 1 |
| Hayden, L | 1 |
| Neerhut, G | 1 |
| Gurney, H | 1 |
| Corica, T | 1 |
| Korbel, E | 1 |
| Weinstein, S | 1 |
| McCaul, K | 1 |
| Pitkänen-Arsiola, T | 1 |
| Tillman, JE | 1 |
| Gu, G | 1 |
| Yuan, J | 1 |
| Roberts, RL | 1 |
| Wantroba, M | 1 |
| Coetzee, GA | 1 |
| Cookson, MS | 3 |
| Kasper, S | 2 |
| Matsuzaki, Y | 1 |
| Ichimura, E | 1 |
| Doi, M | 1 |
| Sakai, I | 1 |
| Inoue, TA | 1 |
| Laky, D | 1 |
| Carlson, KE | 1 |
| Elgavish, S | 1 |
| Leibovitc, I | 1 |
| Katzenellenbogen, JA | 1 |
| Yamamoto, S | 3 |
| Yonese, J | 1 |
| Kawakami, S | 1 |
| Tsukamoto, T | 1 |
| Ohkubo, Y | 2 |
| Tatokoro, M | 1 |
| Fukui, I | 1 |
| Samper, PM | 1 |
| López Carrizosa, MC | 1 |
| Pérez Casas, A | 1 |
| Vallejo, C | 3 |
| Rubio Rodríguez, MC | 1 |
| Pérez Vara, C | 1 |
| Melchor Iñiguez, M | 1 |
| Tsai, HK | 1 |
| Richie, JP | 2 |
| Mitsumori, M | 1 |
| Sasaki, Y | 1 |
| Mizowaki, T | 1 |
| Takayama, K | 1 |
| Nagata, Y | 1 |
| Hiraoka, M | 1 |
| Negoro, Y | 1 |
| Sasai, K | 1 |
| Kinoshita, H | 1 |
| Ryan, CJ | 1 |
| Liu, J | 1 |
| Metzner, C | 1 |
| Nöldge, G | 1 |
| Delling, G | 1 |
| Oehler, U | 2 |
| Nawroth, P | 1 |
| Kasperk, C | 1 |
| Azumi, M | 1 |
| Saga, Y | 2 |
| Hashimoto, H | 2 |
| Kakizaki, H | 1 |
| Vandyke, K | 1 |
| Jackson, P | 1 |
| Rowe, A | 1 |
| Russell, PJ | 1 |
| Blair, JM | 1 |
| Heymann, JJ | 1 |
| Benson, MC | 1 |
| O'Toole, KM | 1 |
| Malyszko, B | 1 |
| Brody, R | 1 |
| Vecchio, D | 1 |
| Schiff, PB | 1 |
| Mansukhani, MM | 1 |
| Ennis, RD | 1 |
| Mercader, M | 2 |
| Sengupta, S | 1 |
| Bodner, BK | 2 |
| Manecke, RG | 2 |
| Cosar, EF | 1 |
| Moser, MT | 2 |
| Ballman, KV | 1 |
| Wojcik, EM | 2 |
| Kwon, ED | 2 |
| Raina, R | 1 |
| Pahalajani, G | 1 |
| Agarwal, A | 1 |
| Zippe, C | 1 |
| Korenaga, S | 1 |
| Sakari, M | 1 |
| Hiyama, T | 1 |
| Ito, T | 3 |
| Kimura, K | 1 |
| Kato, S | 1 |
| Urushibara, M | 1 |
| Hyochi, N | 1 |
| Kihara, K | 1 |
| Singh, P | 1 |
| Arichi, N | 1 |
| Tokugawa, S | 1 |
| Yoshioka, I | 1 |
| Kishikawa, H | 1 |
| Ichikawa, Y | 1 |
| Cho, YM | 1 |
| Asamoto, M | 1 |
| Suzuki, S | 1 |
| Tang, M | 1 |
| Shirai, T | 1 |
| Matthews, PA | 1 |
| De Silvio, M | 1 |
| Rebbick, T | 1 |
| Wolkov, H | 1 |
| Fisher, B | 1 |
| De Paola, B | 1 |
| Migaldi, M | 1 |
| Di Salvatore, M | 1 |
| Rettino, A | 1 |
| Rossi, G | 1 |
| Maiorana, A | 1 |
| Lu, S | 2 |
| Wang, A | 1 |
| Dong, Z | 1 |
| Lloyd, A | 1 |
| Dewilde, S | 1 |
| Kleinman, L | 1 |
| Ikarashi, T | 1 |
| Wako, K | 1 |
| Coe, KJ | 1 |
| Jia, Y | 1 |
| Ho, HK | 1 |
| Rademacher, P | 1 |
| Bammler, TK | 1 |
| Beyer, RP | 1 |
| Farin, FM | 1 |
| Woodke, L | 1 |
| Fausto, N | 1 |
| Nelson, SD | 1 |
| Slovin, SF | 1 |
| Miquel, M | 1 |
| Soler, A | 1 |
| Vaqué, A | 1 |
| Ojanguren, I | 1 |
| Costa, J | 1 |
| Planas, R | 1 |
| Montgomery, RB | 1 |
| Goldman, B | 1 |
| Petrylak, DP | 1 |
| Page, S | 1 |
| Pilepich, M | 1 |
| Shipley, W | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Lin, CJ | 1 |
| Hsieh, RK | 1 |
| Lim, KH | 1 |
| Chen, HH | 1 |
| Cheng, YC | 1 |
| Wu, CJ | 1 |
| Scholz, M | 1 |
| Lam, R | 1 |
| Strum, S | 1 |
| Jennrich, R | 1 |
| Johnson, H | 2 |
| Trilling, T | 1 |
| Zhigang, Z | 1 |
| Wenlu, S | 1 |
| Pathak, S | 1 |
| Singh, R | 1 |
| Verschoyle, RD | 1 |
| Greaves, P | 1 |
| Farmer, PB | 1 |
| Steward, WP | 1 |
| Mellon, JK | 1 |
| Gescher, AJ | 1 |
| Sharma, RA | 1 |
| Speight, J | 1 |
| Lee, RJ | 1 |
| Lawton, C | 2 |
| Valicenti, R | 1 |
| Ebara, S | 1 |
| Manabe, D | 1 |
| Kobayashi, Y | 1 |
| Tanimoto, R | 1 |
| Saika, T | 2 |
| Nasu, Y | 2 |
| Miki, K | 1 |
| Hashine, K | 2 |
| Vollmer, R | 1 |
| Sanford, B | 1 |
| Archer, L | 1 |
| Irani, J | 1 |
| Celhay, O | 1 |
| Hubert, J | 2 |
| Bladou, F | 1 |
| Ragni, E | 1 |
| Trape, G | 1 |
| Doré, B | 1 |
| Albrecht, W | 1 |
| Sartor, AO | 1 |
| Eisenberger, MA | 8 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Cai, Y | 1 |
| Li, G | 1 |
| Bao, BY | 1 |
| Lundbeck, F | 1 |
| Viitanen, J | 1 |
| Anose, BM | 1 |
| LaGoo, L | 1 |
| Schwendinger, J | 1 |
| Jacobi, GH | 1 |
| Wenderoth, UK | 1 |
| Sogani, PC | 6 |
| Vagaiwala, MR | 1 |
| Whitmore, WF | 7 |
| Soloway, MS | 18 |
| Sarfaty, GA | 1 |
| Alder, SJ | 1 |
| McLean, RG | 1 |
| Narayana, AS | 1 |
| Loening, SA | 1 |
| Culp, DA | 1 |
| Fukushima, DK | 3 |
| Smulowitz, M | 1 |
| Levin, J | 4 |
| Weissman, RM | 1 |
| Coffey, DS | 2 |
| Scott, WW | 1 |
| Pandha, H | 1 |
| Quartey, P | 1 |
| DeAntoni, E | 1 |
| Oosterlinck, W | 4 |
| Derde, MP | 2 |
| Kaufman, L | 2 |
| Wysowski, DK | 2 |
| Fourcroy, JL | 1 |
| Gleave, ME | 3 |
| Jones, EC | 2 |
| Bruchovsky, N | 3 |
| Sullivan, LD | 2 |
| deKernion, JB | 2 |
| Yang, FE | 1 |
| Chen, GT | 1 |
| Ray, P | 1 |
| Vaida, F | 1 |
| Chiru, P | 1 |
| Hamilton, RJ | 1 |
| Spelbring, D | 1 |
| Abellera, M | 1 |
| Randal, J | 1 |
| Keizur, JJ | 1 |
| Kane, CJ | 1 |
| North, R | 1 |
| Leidich, RB | 1 |
| Fleshner, NE | 3 |
| Trachtenberg, J | 2 |
| Sassine, AM | 3 |
| Schulman, CC | 7 |
| Cooper, M | 1 |
| Weinberger, M | 1 |
| Headlee, D | 3 |
| Thibault, A | 4 |
| Tompkins, A | 3 |
| Linehan, WM | 2 |
| Myers, CE | 5 |
| Hachiya, T | 4 |
| Ruiz, HE | 2 |
| Gomez, CC | 2 |
| Civantos, F | 5 |
| Rozanski, TA | 3 |
| Faerber, GJ | 1 |
| Murphy, WM | 4 |
| Hasegawa, F | 1 |
| Isurugi, K | 1 |
| Johnson, TL | 1 |
| Cusan, L | 26 |
| Gomez, JL | 11 |
| Dupont, A | 38 |
| Diamond, P | 9 |
| Lemay, M | 7 |
| Moore, S | 1 |
| Voges, GE | 2 |
| Mottrie, AM | 2 |
| Müller, SC | 1 |
| Andros, EA | 1 |
| Danesghari, F | 1 |
| Armas, OA | 1 |
| Aprikian, AG | 3 |
| Melamed, J | 1 |
| Cordon-Cardo, C | 1 |
| Cohen, DW | 1 |
| Erlandson, R | 1 |
| Fair, WR | 9 |
| Reuter, VE | 3 |
| Paus, E | 2 |
| Magi-Galluzzi, C | 1 |
| Muzzonigro, G | 3 |
| Prete, E | 1 |
| Polito, M | 3 |
| Fabris, G | 1 |
| Cooper, EH | 2 |
| Purves, D | 1 |
| Van de Voorde, WM | 1 |
| Elgamal, AA | 1 |
| Van Poppel, HP | 1 |
| Verbeken, EK | 1 |
| Baert, LV | 1 |
| Lauweryns, JM | 1 |
| Sands, ME | 1 |
| Zagars, GK | 1 |
| Cheson, BD | 1 |
| Kaplan, RS | 1 |
| Phillips, PH | 1 |
| Cooper, MR | 5 |
| Bergan, RC | 4 |
| Dawson, N | 2 |
| Reed, E | 6 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Garin-Chesa, P | 1 |
| Castagnetta, LA | 2 |
| Miceli, MD | 1 |
| Sorci, CM | 1 |
| Pfeffer, U | 1 |
| Farruggio, R | 2 |
| Oliveri, G | 1 |
| Calabrò, M | 1 |
| Carruba, G | 2 |
| Schellhammer, P | 3 |
| Sharifi, R | 9 |
| Block, N | 2 |
| Soloway, M | 3 |
| Venner, P | 4 |
| Patterson, AL | 8 |
| Sarosdy, M | 3 |
| Jones, J | 3 |
| Kolvenbag, G | 7 |
| Fowler, JE | 3 |
| Pandey, P | 2 |
| Seaver, LE | 2 |
| Feliz, TP | 2 |
| Braswell, NT | 1 |
| Gee, WF | 1 |
| Holtgrewe, HL | 1 |
| Albertsen, PC | 3 |
| Litwin, MS | 1 |
| Manyak, MJ | 1 |
| O'Leary, MP | 1 |
| Painter, MR | 1 |
| Candas, B | 9 |
| Wajsman, Z | 4 |
| McLeod, D | 2 |
| Wood, DP | 2 |
| Puras-Baez, A | 2 |
| Cher, ML | 1 |
| Shinohara, K | 1 |
| Breslin, S | 1 |
| Vapnek, J | 1 |
| Whittington, R | 1 |
| Malkowicz, B | 1 |
| Barnes, MM | 1 |
| Broderick, GA | 1 |
| Van Arsdalen, K | 1 |
| Dougherty, MJ | 1 |
| Srivastava, S | 1 |
| Peterziel, H | 1 |
| Stober, J | 1 |
| Radmayr, C | 2 |
| Klocker, H | 2 |
| Brogden, RN | 3 |
| Faulds, D | 1 |
| Suburu, R | 5 |
| Têtu, B | 10 |
| Fradet, Y | 5 |
| Kehinde, EO | 1 |
| Terry, TR | 1 |
| Mistry, N | 1 |
| Horsburgh, T | 1 |
| Sandhu, DP | 1 |
| Bell, PR | 1 |
| Rosen, P | 1 |
| Belldegrun, A | 2 |
| Furr, BJ | 3 |
| Miceli, D | 1 |
| D'Amico, D | 1 |
| Comito, L | 1 |
| Montesanti, A | 1 |
| Polito, L | 1 |
| Sinibaldi, VJ | 1 |
| Reyno, LM | 1 |
| Sridhara, R | 1 |
| Jodrell, DI | 1 |
| Zuhowski, EG | 1 |
| Tkaczuk, KH | 1 |
| Lowitt, MH | 1 |
| Hemady, RK | 1 |
| Jacobs, SC | 1 |
| Oesterling, JE | 1 |
| Andrews, PE | 1 |
| Suman, VJ | 1 |
| Zincke, H | 2 |
| Myers, RP | 1 |
| Mazumdar, M | 2 |
| Vlamis, V | 1 |
| Schwartz, M | 2 |
| Freiman, JP | 1 |
| Tourtelot, JB | 1 |
| Horton, ML | 1 |
| Marshall, S | 1 |
| Narayan, P | 2 |
| Macfarlane, MT | 1 |
| Abi-Aad, A | 1 |
| Stein, A | 1 |
| Danella, J | 1 |
| Strohmaier, WL | 1 |
| Flüchter, SH | 1 |
| Wilbert, DM | 1 |
| Bichler, KH | 1 |
| Koutsilieris, M | 4 |
| Kotake, T | 2 |
| Koiso, K | 4 |
| Aso, Y | 5 |
| Krall, JM | 2 |
| al-Sarraf, M | 1 |
| John, MJ | 3 |
| Doggett, RL | 1 |
| Hillner, BE | 3 |
| Jackson, SH | 1 |
| Barker, SJ | 1 |
| Debruyne, FM | 4 |
| Witjes, WP | 4 |
| van Cangh, PJ | 2 |
| Oosterhof, GO | 1 |
| Ravenna, L | 1 |
| Lubrano, C | 1 |
| Vacca, A | 1 |
| Felli, MP | 1 |
| Maroder, M | 1 |
| D'Eramo, G | 2 |
| Sciarra, F | 3 |
| Frati, L | 1 |
| Gulino, A | 1 |
| Bai, M | 1 |
| Grammeniatis, E | 1 |
| Stefanou, D | 1 |
| Agnanti, N | 1 |
| Bologna, M | 1 |
| Muzi, P | 1 |
| Biordi, L | 1 |
| Festuccia, C | 1 |
| Vicentini, C | 1 |
| Braslis, KG | 1 |
| Davi, RC | 1 |
| Nelson, E | 1 |
| Atkins, CD | 1 |
| Magi Galluzzi, C | 1 |
| Giannulis, I | 1 |
| Diamanti, L | 1 |
| Scarpelli, M | 1 |
| Stevens, MJ | 1 |
| Bell, DR | 1 |
| Blome, SA | 1 |
| Begbie, SD | 1 |
| Pacilli, N | 2 |
| Bottero, G | 1 |
| Novella, V | 1 |
| Pisano, PF | 2 |
| Buffa, G | 2 |
| Collinson, MP | 2 |
| Tyrrell, CJ | 5 |
| Gomez, J | 5 |
| Cohen, D | 2 |
| Sogani, P | 2 |
| Solomon, MH | 1 |
| McHugh, TA | 1 |
| Dorr, RP | 1 |
| Lee, F | 1 |
| Siders, DB | 1 |
| Dourakis, SP | 1 |
| Alexopoulou, AA | 1 |
| Hadziyannis, SJ | 1 |
| Jindal, PK | 1 |
| Hota, D | 1 |
| Prasad, KV | 1 |
| Nijhawan, R | 1 |
| Vaidyanathan, S | 1 |
| Witeska, A | 1 |
| Owczarczyk, B | 1 |
| Dutkiewicz, S | 1 |
| Tałałaj, M | 1 |
| Zelefsky, MJ | 3 |
| Leibel, SA | 2 |
| Burman, CM | 1 |
| Kutcher, GJ | 1 |
| Harrison, A | 2 |
| Happersett, L | 1 |
| Fuks, Z | 2 |
| Ferguson, J | 1 |
| Ellison, E | 1 |
| Bergstrahl, E | 1 |
| Bostwick, DG | 1 |
| Humphrey, J | 1 |
| Sica, G | 1 |
| Dell'Acqua, G | 1 |
| Iacopino, F | 1 |
| Fattorossi, A | 1 |
| Marchetti, P | 1 |
| van der Kwast, TH | 7 |
| Smith, DM | 1 |
| Roessler, W | 1 |
| Wieland, WF | 1 |
| Martínez Bruna, MS | 1 |
| Velila Alcubilla, JP | 1 |
| Abinzano, M | 1 |
| Martínez Velasco, C | 1 |
| García Mauriz, ME | 1 |
| Urbieta Echezareta, M | 1 |
| Mencel, PJ | 1 |
| DeAngelis, LM | 1 |
| Motzer, RJ | 1 |
| Warriar, N | 1 |
| Pagé, N | 1 |
| Govindan, MV | 1 |
| Lee, SZ | 1 |
| Watabe, Y | 1 |
| Shimazaki, J | 5 |
| McDonnell, ND | 1 |
| Livingston, RB | 1 |
| Prattichizzo, FA | 1 |
| Hirasawa, K | 1 |
| Kasuya, Y | 1 |
| Homma, Y | 1 |
| Kawabe, K | 2 |
| Denis, L | 22 |
| Carrascosa, M | 1 |
| Perez-Castrillon, JL | 1 |
| Mendez, MA | 1 |
| Cillero, L | 1 |
| Valle, R | 1 |
| Caballería, E | 1 |
| Aragó, JV | 1 |
| Sanchís, A | 1 |
| Mast, P | 1 |
| Bilgrami, S | 1 |
| Greenberg, B | 1 |
| Newling, DW | 6 |
| Vermeylen, K | 2 |
| Christensen, IJ | 1 |
| Keuppens, F | 7 |
| Carneiro de Moura, JL | 2 |
| Newling, D | 8 |
| Bono, A | 9 |
| Robinson, M | 5 |
| Mahler, C | 7 |
| Sylvester, R | 14 |
| De Pauw, M | 8 |
| Benson, RC | 4 |
| Blumenstein, BA | 7 |
| Spicer, D | 1 |
| Spaulding, JT | 4 |
| Altwein, JE | 3 |
| Klippel, F | 3 |
| Lunglmayr, G | 5 |
| Holdaway, IM | 3 |
| Haefliger, JM | 4 |
| Jordaan, JP | 3 |
| Sotarauta, M | 1 |
| Ferrari, P | 3 |
| Castagnetti, G | 2 |
| Ferrari, G | 2 |
| Pollastri, CA | 1 |
| Tavoni, F | 1 |
| Dotti, A | 2 |
| Anson, KM | 1 |
| Barnes, DG | 1 |
| Briggs, TP | 1 |
| Watson, GM | 1 |
| Miller, RA | 1 |
| da Silva, FC | 3 |
| Simard, J | 4 |
| Luu-The, V | 1 |
| Berrevoets, CA | 1 |
| Veldscholte, J | 1 |
| Mulder, E | 1 |
| Heathcote, PS | 1 |
| Kateley, GD | 1 |
| Lloyd, S | 1 |
| Maucher, A | 1 |
| von Angerer, E | 1 |
| Rosman, AS | 1 |
| Frissora-Rodeo, C | 1 |
| Marshall, AT | 1 |
| Reiter, BP | 1 |
| Paronetto, F | 1 |
| Denis, LJ | 5 |
| Carnelro de Moura, JL | 1 |
| Depauw, M | 1 |
| Montalbán, C | 1 |
| Moreno, MA | 1 |
| Molina, JP | 1 |
| Hernanz, I | 1 |
| Bellas, C | 1 |
| Matzkin, H | 1 |
| Kameyama, S | 1 |
| Koyanagi, T | 1 |
| Kawai, T | 2 |
| Kumamoto, Y | 2 |
| Tazaki, H | 1 |
| Funyu, T | 1 |
| Oshima, H | 1 |
| Origasa, S | 1 |
| Hosaka, M | 2 |
| Yamanaka, H | 4 |
| Pace, M | 1 |
| Guarneri, D | 2 |
| Oneto, F | 2 |
| Martorana, G | 2 |
| Giuliani, L | 2 |
| Selvaggi, F | 1 |
| Fichtner, J | 1 |
| Mappes, C | 1 |
| Störkel, S | 1 |
| Hohenfellner, R | 1 |
| Vailancourt, L | 1 |
| Ttu, B | 1 |
| Suburu, ER | 3 |
| Schned, AR | 1 |
| Gormley, EA | 1 |
| Herrada, J | 1 |
| Dieringer, P | 1 |
| Logothetis, CJ | 1 |
| Zhang, ZF | 1 |
| Nanus, D | 1 |
| Crownover, RL | 1 |
| Holland, J | 1 |
| Chen, A | 1 |
| Krieg, R | 1 |
| Young, BK | 1 |
| Sagaster, P | 1 |
| Flamm, J | 3 |
| Micksche, M | 1 |
| Fritz, E | 1 |
| Donner, G | 1 |
| Ludwig, H | 1 |
| Yachia, D | 1 |
| Aridogan, IA | 1 |
| Srinivas, S | 1 |
| Vollmer, G | 1 |
| Michna, H | 1 |
| Schneider, MR | 1 |
| Dawson, NA | 4 |
| Headlee, DJ | 1 |
| Steinberg, SM | 2 |
| Sausville, EA | 2 |
| Walsh, PC | 1 |
| Anand, N | 1 |
| Anand, A | 1 |
| Matchar, D | 1 |
| McCrory, D | 1 |
| Noldus, J | 1 |
| Ferrari, M | 1 |
| Prestigiacomo, A | 1 |
| Stamey, TA | 2 |
| Regueiro López, JC | 2 |
| Ruiz Alvarez Cienfuegos, F | 1 |
| Leva Vallejo, M | 2 |
| Requena Tapia, MJ | 2 |
| Merchan García, JA | 1 |
| Prieto Castro, R | 2 |
| Alvarez Kindelan, J | 1 |
| Hermans, BP | 1 |
| Lorge, F | 1 |
| Wese, FX | 1 |
| Opsomer, RJ | 1 |
| Linstadt, DE | 1 |
| Andras, EJ | 1 |
| Brooks, CP | 1 |
| Stickney, DR | 1 |
| Chang, GC | 1 |
| Gilbert, RM | 1 |
| Encabo, G | 2 |
| López Pacios, MA | 2 |
| de Torres, JA | 1 |
| Soler Roselló, A | 2 |
| Liberman, SN | 1 |
| Mulholland, SG | 2 |
| Petersen, RO | 1 |
| Hyslop, T | 2 |
| Corn, BW | 2 |
| Aaronson, NK | 2 |
| Serbouti, S | 1 |
| Casselman, J | 3 |
| Hetherington, J | 1 |
| Fava, C | 1 |
| Richards, B | 1 |
| Robinson, MR | 3 |
| Denti, L | 2 |
| Pasolini, G | 1 |
| Ferretti, S | 1 |
| Sanfelici, L | 1 |
| Ablondi, F | 1 |
| Valenti, G | 2 |
| Scalliet, P | 1 |
| Verhelst, J | 2 |
| Zalcberg, JR | 1 |
| Raghaven, D | 1 |
| Marshall, V | 1 |
| Thompson, PJ | 1 |
| Chang, A | 1 |
| Yeap, B | 1 |
| Davis, T | 1 |
| Blum, R | 1 |
| Hahn, R | 1 |
| Khanna, O | 1 |
| Fisher, H | 1 |
| Rosenthal, J | 1 |
| Witte, R | 1 |
| Schinella, R | 1 |
| Trump, D | 1 |
| Kruithof-Dekker, IG | 1 |
| Janssen, PJ | 1 |
| Pinto, JE | 1 |
| Andréjak, M | 1 |
| Nguyen-Khac, E | 1 |
| Decocq, G | 1 |
| Capron, JP | 1 |
| Blackledge, G | 1 |
| Nash, A | 1 |
| Tunn, UW | 1 |
| Acar, O | 1 |
| Goldschmidt, AJ | 1 |
| Baisi, B | 1 |
| Abbas, F | 1 |
| Kaplan, M | 1 |
| Marcial, MA | 1 |
| Banks, ER | 1 |
| Ho, CK | 1 |
| Speights, VO | 1 |
| Drew, PA | 1 |
| Wheeler, TM | 1 |
| Leon, SA | 1 |
| Tester, WJ | 1 |
| Ago, CT | 1 |
| Zerbib, M | 1 |
| Payan, C | 1 |
| Ellis, W | 1 |
| Russell, K | 1 |
| Lange, PH | 1 |
| Schellhammer, PF | 7 |
| Block, NL | 4 |
| Venner, PM | 4 |
| Sarosdy, MF | 6 |
| Chen, Y | 2 |
| Kolvenbag, GJ | 9 |
| Poulin, R | 1 |
| Middleman, MN | 1 |
| Brawley, O | 1 |
| Lush, RM | 1 |
| Senderowicz, A | 1 |
| Steinberg, SH | 1 |
| Cicognani, C | 1 |
| Malavolti, M | 1 |
| Morselli-Labate, AM | 1 |
| Sama, C | 1 |
| Barbara, L | 1 |
| Ornstein, DK | 3 |
| Rao, GS | 1 |
| Johnson, B | 1 |
| Charlton, ET | 1 |
| Andriole, GL | 4 |
| Van Velthoven, R | 2 |
| Kurjatkin, O | 1 |
| Schulman, C | 1 |
| Grant, ES | 1 |
| Batchelor, KW | 1 |
| Habib, FK | 1 |
| Minardi, D | 1 |
| Bowden, CJ | 1 |
| Bitton, RJ | 1 |
| Weinberger, MS | 1 |
| Dole, EJ | 1 |
| Holdsworth, MT | 1 |
| Caplan, R | 1 |
| Sarkar, FH | 1 |
| Forman, JD | 1 |
| Mesic, J | 1 |
| Pajak, TF | 1 |
| Cox, JD | 1 |
| Sumi, S | 1 |
| Umeda, H | 1 |
| Yano, M | 1 |
| Koga, F | 1 |
| Arai, K | 1 |
| Imai, T | 1 |
| Hosoya, Y | 1 |
| Maeda, S | 1 |
| Honda, M | 1 |
| Suzuki, T | 2 |
| Serrano Hernández, N | 1 |
| García López, F | 1 |
| Fedriani Gorria, J | 1 |
| Muller, MJ | 1 |
| Keller, SD | 1 |
| Ware, JE | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Zaccheo, T | 2 |
| Giudici, D | 2 |
| di Salle, E | 2 |
| Schmeller, N | 2 |
| Lubos, W | 1 |
| Villavicencio Mavrich, H | 1 |
| Chéchile Toniolo, G | 1 |
| Salinas Duffo, D | 1 |
| Muñoz Plaza, J | 1 |
| Sorraca Ibáñez, YJ | 1 |
| López López, C | 1 |
| Quilez Fenoll, JM | 1 |
| Gómez Ruiz, JJ | 1 |
| López López, AF | 1 |
| Romero Maroto, YJ | 1 |
| Laverdière, J | 1 |
| Fortin, A | 1 |
| Kaisary, AV | 2 |
| Patel, H | 1 |
| Rhee, E | 1 |
| Zimmern, PE | 1 |
| Tan, J | 1 |
| Sharief, Y | 1 |
| Hamil, KG | 1 |
| Gregory, CW | 1 |
| Zang, DY | 1 |
| Sar, M | 1 |
| Gumerlock, PH | 1 |
| deVere White, RW | 1 |
| Pretlow, TG | 1 |
| Harris, SE | 1 |
| Wilson, EM | 1 |
| Mohler, JL | 1 |
| French, FS | 1 |
| Fernández Peña, CM | 1 |
| Morano Amado, LE | 1 |
| Montes Santiago, J | 1 |
| Fachal, C | 1 |
| Leroy, D | 1 |
| Dompmartin, A | 1 |
| Szczurko, C | 1 |
| Nieh, PT | 1 |
| Seabaugh, DR | 1 |
| Klein, E | 2 |
| Furr, B | 1 |
| Russo, P | 2 |
| Sheinfeld, J | 2 |
| Herr, H | 2 |
| Dalbagni, G | 1 |
| Begg, CB | 2 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Stroumbakis, N | 1 |
| Soloway, SM | 1 |
| Dalgabni, G | 1 |
| Heston, WD | 1 |
| Johnson, CF | 1 |
| Peabody, JO | 1 |
| Coffield, S | 1 |
| Slovin, S | 1 |
| Kagebayashi, Y | 1 |
| Takashima, K | 1 |
| Yoshikawa, M | 2 |
| Hayashi, Y | 1 |
| Kaneko, Y | 1 |
| Maruyama, Y | 3 |
| Okajima, E | 2 |
| Kroog, G | 1 |
| Duray, P | 1 |
| Walther, MM | 1 |
| Patronas, N | 1 |
| Palmberg, C | 1 |
| Kylmala, T | 1 |
| Tammela, T | 1 |
| Enzmann, T | 1 |
| Riethmüller, G | 1 |
| Köllermann, MW | 2 |
| Bigler, SA | 1 |
| Renfroe, DL | 1 |
| Dabagia, MD | 1 |
| Krijnen, JL | 1 |
| Bogdanowicz, JF | 2 |
| Seldenrijk, CA | 1 |
| Mulder, PG | 1 |
| Datta, SN | 1 |
| Thomas, K | 1 |
| Matthews, PN | 1 |
| Fontaine-Rothe, P | 1 |
| Berlane, K | 1 |
| Rieker, P | 1 |
| Jiroutek, M | 1 |
| Kaplan, I | 1 |
| Kaufman, D | 1 |
| Kantoff, P | 1 |
| Senderowicz, AM | 1 |
| Weinberger, B | 1 |
| Teruel, JL | 1 |
| Cano, T | 1 |
| Marcén, R | 1 |
| Villafruela, JJ | 1 |
| Rivera, M | 1 |
| Fernández-Juarez, G | 1 |
| Ortuño, J | 1 |
| McDermed, JE | 1 |
| Tisman, G | 1 |
| Colecchia, M | 1 |
| Frigo, B | 1 |
| Del Boca, C | 1 |
| Guardamagna, A | 1 |
| Zucchi, A | 1 |
| Colloi, D | 1 |
| Leopardi, O | 1 |
| Hittmair, A | 1 |
| Cronauer, MV | 1 |
| Zhang, J | 1 |
| Cellini, N | 1 |
| Luzi, S | 1 |
| Morganti, AG | 1 |
| Balducci, M | 1 |
| Caiazza, A | 1 |
| Salvi, G | 1 |
| Trodella, L | 1 |
| Singh, SM | 1 |
| Liebertz, C | 1 |
| Brett, C | 1 |
| Schwartz, L | 1 |
| Shapiro, L | 1 |
| Harbour, D | 1 |
| Liebmann, J | 1 |
| Egawa, S | 2 |
| Katsuta, M | 1 |
| Iwamura, M | 1 |
| Uchida, T | 1 |
| Koshiba, K | 1 |
| Pummer, K | 2 |
| Lehnert, M | 1 |
| Stettner, H | 1 |
| Hubmer, G | 1 |
| Sandhu, SS | 1 |
| Matveev, VB | 1 |
| Losa, M | 1 |
| Grasso, M | 1 |
| Giugni, E | 1 |
| Mortini, P | 1 |
| Acerno, S | 1 |
| Giovanelli, M | 1 |
| Schellenger, JJ | 2 |
| Gómez Veiga, F | 1 |
| Lorenzo Patiño, MJ | 1 |
| Díaz Bermúdez, J | 1 |
| Duarte Novo, J | 1 |
| Alvarez Castelo, L | 1 |
| Chantada Abal, V | 1 |
| Sánchez Rodríguez, J | 1 |
| González Martín, M | 1 |
| Noordzij, MA | 1 |
| van Krimpen, C | 1 |
| van Steenbrugge, GJ | 1 |
| Baron, A | 1 |
| Bok, R | 1 |
| Okada, K | 2 |
| Wietzke, P | 1 |
| Münke, H | 1 |
| Hartmann, H | 1 |
| Ramadori, G | 1 |
| Anderson, PR | 1 |
| Hanlon, AL | 1 |
| Movsas, B | 1 |
| Joyce, R | 1 |
| Fenton, MA | 2 |
| Rode, P | 1 |
| Constantine, M | 1 |
| Gaynes, L | 1 |
| DeWolf, W | 1 |
| Balk, S | 1 |
| Taplin, ME | 3 |
| Bubley, GJ | 3 |
| Boccon-Gibod, L | 2 |
| Fournier, G | 1 |
| Bottet, P | 1 |
| Marechal, JM | 1 |
| Guiter, J | 1 |
| Rischman, P | 1 |
| Soret, JY | 2 |
| Mangin, P | 2 |
| Mallo, C | 1 |
| Fraysse, CE | 1 |
| Staiman, VR | 1 |
| Lowe, FC | 1 |
| Guate, JL | 1 |
| Escaf, S | 1 |
| Menendez, CL | 1 |
| del Valle, M | 1 |
| Vega, JA | 1 |
| Unger, PD | 1 |
| Wang, Q | 1 |
| Gordon, RE | 1 |
| Stock, R | 1 |
| Stone, N | 1 |
| Hornák, M | 1 |
| Bárdos, A | 1 |
| Goncalves, F | 1 |
| Lansiaux, P | 1 |
| García-Gascó, P | 1 |
| Morata Aldea, C | 1 |
| Segura Huertas, A | 1 |
| Aparicio Urtasun, J | 1 |
| Tran, TA | 1 |
| Jennings, TA | 1 |
| Ross, JS | 1 |
| Nazeer, T | 1 |
| Vilaplana, J | 1 |
| Romaguera, C | 1 |
| Azón, A | 1 |
| Lecha, M | 1 |
| Sylvester, RJ | 2 |
| de Voogt, H | 1 |
| Smith, PH | 4 |
| de Moura, JL | 4 |
| Akimoto, S | 2 |
| Igarashi, T | 1 |
| Murakami, S | 2 |
| Kuroiwa, S | 1 |
| Okada, M | 1 |
| Abe, F | 1 |
| Breul, J | 1 |
| Paul, R | 1 |
| Bono, AV | 1 |
| DiSilverio, F | 1 |
| Robustelli della Cuna, G | 1 |
| Benvenuti, C | 1 |
| Brausi, M | 2 |
| Gibba, A | 1 |
| Galli, L | 1 |
| Newton, M | 1 |
| Kosier, JH | 1 |
| Reid, MB | 1 |
| Glode, LM | 1 |
| Valicenti, RK | 1 |
| Gomella, L | 1 |
| Sharkey, J | 2 |
| Chovnick, SD | 2 |
| Behar, RJ | 2 |
| Perez, R | 2 |
| Otheguy, J | 2 |
| Solc, Z | 2 |
| Huff, W | 2 |
| Cantor, A | 2 |
| Longmore, L | 1 |
| Foley, JP | 1 |
| Eulau, SM | 1 |
| Tate, DJ | 1 |
| Bagshaw, MA | 1 |
| Hancock, SL | 1 |
| Fourcade, RO | 2 |
| Chatelain, C | 1 |
| Yokote, R | 1 |
| Tokura, Y | 1 |
| Igarashi, N | 1 |
| Ishikawa, O | 1 |
| Miyachi, Y | 1 |
| Lardy, H | 1 |
| Messing, E | 1 |
| Pogromov, AP | 1 |
| Popova, AM | 1 |
| Schow, DA | 1 |
| Renfer, LG | 1 |
| Aizawa, T | 2 |
| Tsujino, S | 1 |
| Miki, M | 2 |
| Pontiroli, L | 1 |
| Sartori, M | 1 |
| Pittau, S | 1 |
| Morelli, S | 1 |
| Boldorini, R | 1 |
| Albano, E | 1 |
| Miller, G | 1 |
| Loehrer, PJ | 1 |
| Sears, K | 1 |
| Bueschen, AJ | 1 |
| Lyass, O | 1 |
| Wolfe, T | 1 |
| Burman, C | 1 |
| Ling, CC | 1 |
| Diamond, T | 1 |
| Campbell, J | 1 |
| Lynch, W | 1 |
| Moinpour, CM | 2 |
| Savage, MJ | 1 |
| Troxel, A | 1 |
| Lovato, LC | 1 |
| Veith, RW | 1 |
| Skeel, R | 1 |
| Yee, M | 1 |
| Meyskens, FL | 1 |
| Brandes, LJ | 1 |
| Queen, GM | 1 |
| LaBella, FS | 1 |
| Shuster, TD | 1 |
| Fertig, AM | 1 |
| Morote Robles, J | 2 |
| Lorente Garín, JA | 2 |
| Smith, DS | 1 |
| Studer, UE | 2 |
| Mills, RD | 1 |
| Chu, CW | 1 |
| Hwang, SJ | 1 |
| Luo, JC | 1 |
| Tsay, SH | 1 |
| Li, CP | 1 |
| Huang, YS | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Rosendahl, I | 1 |
| Kiebert, GM | 1 |
| Curran, D | 1 |
| Cole, BF | 1 |
| Weeks, JC | 1 |
| Hall, RR | 2 |
| Berruti, A | 2 |
| Dogliotti, L | 2 |
| Fasolis, G | 2 |
| Mosca, A | 1 |
| Tarabuzzi, R | 2 |
| Torta, M | 1 |
| Mari, M | 2 |
| Fontana, D | 2 |
| Angeli, A | 2 |
| Azuma, T | 1 |
| Kurimoto, S | 1 |
| Mikami, K | 2 |
| Oshi, M | 1 |
| Caubet, JF | 1 |
| Tsukamoto, S | 1 |
| Burch, PA | 1 |
| Loprinzi, CL | 1 |
| Emond, J | 16 |
| Daniel, F | 1 |
| Teasdale, C | 1 |
| Rothman, KJ | 1 |
| Johnson, ES | 1 |
| Sugano, DS | 1 |
| Cetin, M | 1 |
| Demirci, D | 1 |
| Unal, A | 1 |
| Altinbaş, M | 1 |
| Güven, M | 1 |
| Unlühizarci, K | 1 |
| Matsushima, H | 1 |
| Hosaka, Y | 1 |
| Kitamura, T | 1 |
| Beiser, JA | 1 |
| Thin, TH | 1 |
| Lin, MF | 1 |
| Wang, LG | 1 |
| Liu, XM | 1 |
| Kreis, W | 1 |
| Budman, DR | 1 |
| Mantoux, F | 1 |
| Bahadoran, P | 1 |
| Perrin, C | 1 |
| Bermon, C | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
| Ko, YJ | 1 |
| Upton, M | 1 |
| Rajeshkumar, B | 1 |
| Okaneya, T | 1 |
| Murata, Y | 1 |
| Kinebuchi, Y | 1 |
| Kirby, R | 1 |
| Robertson, C | 1 |
| Turkes, A | 1 |
| Griffiths, K | 1 |
| Boyle, P | 1 |
| Altwein, J | 1 |
| Schröder, F | 1 |
| Kelley, RP | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Tréchot, P | 1 |
| Kuwahara, M | 1 |
| Aki, M | 1 |
| Akazawa, S | 1 |
| Takenaka, A | 1 |
| Balaji, KC | 1 |
| Tsai, H | 1 |
| Bastar, A | 1 |
| Bhayani, SB | 1 |
| Ye, D | 1 |
| Mendelsohn, J | 1 |
| Fan, Z | 1 |
| Pu, YS | 1 |
| Liu, CM | 1 |
| Kao, JH | 1 |
| Chen, J | 1 |
| Lai, MK | 1 |
| Abe, K | 1 |
| Kobari, T | 1 |
| Nakata, J | 1 |
| Nagayoshi, J | 1 |
| Higashi, T | 1 |
| Wirth, M | 1 |
| Conti, G | 1 |
| Cruciani, G | 1 |
| Dammino, S | 1 |
| Delliponti, U | 1 |
| Ditonno, P | 1 |
| Spano, G | 1 |
| Ortiz Rey, JA | 1 |
| Da Silva, EA | 1 |
| Antón Badiola, I | 1 |
| Alvarez Alvarez, C | 1 |
| Zungri Telo, E | 1 |
| de la Fuente Buceta, A | 1 |
| Szende, B | 1 |
| Romics, I | 1 |
| Torda, I | 1 |
| Bély, M | 1 |
| Szegedi, Z | 1 |
| Lovász, S | 1 |
| Wu, JT | 1 |
| Wu, TL | 1 |
| Chang, CP | 1 |
| Tsao, KC | 1 |
| Sun, CF | 1 |
| Nakagawa, Y | 1 |
| Koyama, M | 1 |
| Matsumoto, M | 2 |
| Migliari, R | 4 |
| Muscas, G | 1 |
| Murru, M | 1 |
| Verdacchi, T | 1 |
| De Benedetto, G | 1 |
| De Angelis, M | 1 |
| Schrader, TJ | 1 |
| Cooke, GM | 1 |
| Johnson, R | 1 |
| Carroll, K | 1 |
| Kurita, M | 1 |
| Kato, Y | 1 |
| Tamura, Y | 1 |
| Jurincic-Winkler, C | 1 |
| Fujikawa, K | 1 |
| Matsui, Y | 1 |
| Fukuzawa, S | 1 |
| Takeuchi, H | 1 |
| Rahman, M | 1 |
| Huang, KE | 1 |
| Suzuki, N | 1 |
| Hamano, S | 1 |
| Kinsui, H | 1 |
| Oikawa, T | 1 |
| Halachmi, S | 1 |
| Madeb, R | 1 |
| Madjar, S | 1 |
| Wald, M | 1 |
| River, Y | 1 |
| Nativ, O | 1 |
| Lamb, D | 1 |
| Denham, J | 1 |
| Takashima, R | 1 |
| Mizoguchi, H | 1 |
| Kuwao, S | 1 |
| Herr, HW | 1 |
| O'Sullivan, M | 1 |
| Rabinowitz, R | 1 |
| Steele, J | 1 |
| Webster, C | 1 |
| Donohue, M | 1 |
| La Bianca, SE | 1 |
| Raghow, S | 1 |
| Kuliyev, E | 1 |
| Steakley, M | 1 |
| Greenberg, N | 1 |
| Steiner, MS | 1 |
| Granter, SR | 1 |
| Lyng, FM | 1 |
| Jones, GR | 1 |
| Rommerts, FF | 1 |
| del Vecchio, MT | 1 |
| Tripodi, SA | 1 |
| Arcuri, F | 1 |
| Pergola, L | 1 |
| Hako, L | 1 |
| Vatti, R | 1 |
| Cintorino, M | 1 |
| Abe, H | 1 |
| Oka, F | 1 |
| Miura, T | 2 |
| Uchikoba, T | 1 |
| Oaki, Y | 1 |
| Rodríguez Gómez, SJ | 1 |
| Martínez Moreno, J | 1 |
| Martín Arribas, MI | 1 |
| Pérez Villoria, A | 1 |
| De la Serna Higuera, C | 1 |
| Betancourt González, A | 1 |
| Nakazato, H | 2 |
| Kurokawa, K | 2 |
| Unger, P | 1 |
| Klotz, L | 1 |
| Gleave, M | 1 |
| Betancourt, JE | 1 |
| Deeths, J | 1 |
| Bennett, C | 1 |
| Iyer, P | 1 |
| Dineen, MK | 1 |
| Zhai, S | 1 |
| Wang, J | 2 |
| Halford, S | 1 |
| Rigg, A | 1 |
| Roylance, R | 1 |
| Lynch, M | 1 |
| Cecchi, M | 1 |
| Sepich, CA | 1 |
| Bertolini, L | 1 |
| Catastini, M | 1 |
| Di Benedetto, A | 1 |
| Ippolito, C | 1 |
| Pazzagli, I | 1 |
| Summonti, D | 1 |
| Bonadio, AG | 1 |
| Fiorentini, L | 1 |
| Iwai, A | 1 |
| Moriya, A | 1 |
| Samma, S | 1 |
| Yamabe, Y | 1 |
| Hoshino, A | 1 |
| Imura, N | 1 |
| Himeno, S | 1 |
| Forster, G | 1 |
| Selvaggi, FP | 1 |
| Zlotta, AR | 1 |
| Feek, U | 1 |
| Müller, H | 1 |
| Kaulfuss, U | 1 |
| Wilson, KS | 1 |
| Ludgate, CM | 1 |
| Wilson, AG | 1 |
| Alexander, AS | 1 |
| Melezinek, I | 1 |
| Schmidt, A | 1 |
| Slee, PH | 1 |
| Horenblas, S | 1 |
| Hetherington, JW | 1 |
| Aaronson, N | 2 |
| Minei, S | 1 |
| Kobayashi, K | 1 |
| Ishida, H | 3 |
| Buchanan, G | 1 |
| Yang, M | 1 |
| Harris, JM | 1 |
| Nahm, HS | 1 |
| Han, G | 1 |
| Moore, N | 1 |
| Bentel, JM | 1 |
| Matusik, RJ | 2 |
| Horsfall, DJ | 1 |
| Marshall, VR | 1 |
| Greenberg, NM | 1 |
| Tilley, WD | 1 |
| Tamada, T | 1 |
| Sone, T | 1 |
| Tomomitsu, T | 1 |
| Jo, Y | 1 |
| Tanaka, H | 1 |
| Fukunaga, M | 1 |
| Tolcher, A | 1 |
| Crawford, E | 1 |
| Moinpour, C | 1 |
| Aoyagi, T | 1 |
| Miyaji, K | 1 |
| Hata, M | 1 |
| Chakarov, S | 1 |
| Bechev, R | 1 |
| Lazarov, Z | 1 |
| Fachikov, Ts | 1 |
| Rangelov, S | 1 |
| Schulz, M | 2 |
| Schmoldt, A | 2 |
| Donn, F | 2 |
| Becker, H | 2 |
| Nowicki, M | 1 |
| Bryc, W | 1 |
| Kokot, F | 1 |
| Ito, K | 1 |
| Fukabori, Y | 1 |
| Tokumitsu, M | 1 |
| Inada, F | 1 |
| Kitahara, K | 1 |
| Kawakami, N | 1 |
| Masui, N | 1 |
| Yachiku, S | 1 |
| Alberts, SR | 1 |
| Blute, ML | 1 |
| Schmitt, B | 1 |
| Wilt, TJ | 1 |
| DeMasi, V | 1 |
| Leibowitz, RL | 1 |
| Tucker, SJ | 1 |
| Tsushima, T | 1 |
| Maki, Y | 1 |
| Noda, M | 1 |
| Suyama, B | 1 |
| Yamato, T | 1 |
| Junicho, A | 1 |
| Yamamoto, T | 1 |
| Kishi, H | 1 |
| Korkmaz, K | 1 |
| Saatcioglu, F | 1 |
| Muraguchi, A | 1 |
| Gandy, S | 1 |
| Fonte, J | 1 |
| Lim, D | 1 |
| Waterrus, A | 1 |
| Rapoport, J | 1 |
| Arango Toro, O | 1 |
| Bielsa Gali, O | 1 |
| Griño Garreta, J | 1 |
| Gelabert Mas, A | 1 |
| Noël, G | 1 |
| Shimizu, K | 1 |
| Kiyohara, H | 1 |
| Nakayama, J | 1 |
| Fujii, T | 1 |
| Hosomi, M | 1 |
| Akiyama, A | 1 |
| Tachibana, M | 1 |
| Chin, JL | 1 |
| Warner, J | 1 |
| Klotz, LH | 1 |
| Jewett, M | 1 |
| Kassabian, V | 1 |
| Chetner, M | 1 |
| Dupont, C | 1 |
| Van Rensselaer, S | 1 |
| Spetz, AC | 1 |
| Hammar, M | 1 |
| Lindberg, B | 1 |
| Spångberg, A | 1 |
| Winter, K | 1 |
| Sause, W | 1 |
| D'Amico, A | 1 |
| Andriani, F | 1 |
| Nan, B | 1 |
| Yu, J | 1 |
| Weigel, NL | 1 |
| McPhaul, MJ | 1 |
| Kagawa, S | 1 |
| Fang, B | 1 |
| Denner, L | 1 |
| Marcelli, M | 1 |
| Kraus, I | 1 |
| Vitezic, D | 1 |
| Oguic, R | 1 |
| Kernen, K | 1 |
| Chou, CC | 1 |
| Shalev, M | 1 |
| Brady, J | 1 |
| García Cortés, M | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Sánchez Martínez, H | 1 |
| Fernández, MC | 1 |
| Ferrer, T | 1 |
| Martín-Vivaldi, R | 1 |
| Peláez, G | 1 |
| Suárez, F | 1 |
| Romero-Gómez, M | 1 |
| Montero, JL | 1 |
| Fraga, E | 1 |
| Camargo, R | 1 |
| Alcántara, R | 1 |
| Pizarro, MA | 1 |
| García-Ruiz, E | 1 |
| Rosemary-Gómez, M | 1 |
| Nagae, H | 1 |
| Sato, T | 1 |
| Nagata, M | 1 |
| Un-no, T | 1 |
| Mugiya, S | 1 |
| Ichijo, K | 1 |
| Sun, XY | 1 |
| Donald, SP | 1 |
| Phang, JM | 1 |
| Harada, M | 1 |
| Moriyama, M | 1 |
| Fukuoka, H | 1 |
| Kitami, K | 1 |
| Kwon, PS | 1 |
| Park, ES | 1 |
| Ellis, TM | 1 |
| Yang, D | 1 |
| Flanigan, RC | 1 |
| Waters, WB | 1 |
| Kast, WM | 1 |
| Pareek, K | 1 |
| Winters, J | 1 |
| De Souza, P | 1 |
| Lynch, WJ | 1 |
| Evans, CP | 1 |
| Stapp, EC | 1 |
| Dall'Era, MA | 1 |
| Juarez, J | 1 |
| Yang, JC | 1 |
| Ruiz, R | 1 |
| Casañ, R | 1 |
| Juan, O | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Amornpichetkul, K | 1 |
| Visudhiphan, S | 1 |
| Sangruchi, T | 1 |
| Srimuninnimit, V | 1 |
| Sinlarat, P | 1 |
| Kong, X | 1 |
| Zeng, L | 1 |
| Xia, T | 1 |
| Mi, P | 1 |
| Na, Y | 1 |
| Xue, Z | 1 |
| Pan, B | 1 |
| Hao, J | 1 |
| Gu, F | 1 |
| Guo, Y | 1 |
| Kojima, M | 1 |
| Kamoi, K | 1 |
| Ukimura, O | 1 |
| Fujito, A | 1 |
| Nakao, M | 1 |
| Miyashita, H | 1 |
| Iwamoto, N | 1 |
| Ohe, H | 1 |
| Kitamori, T | 1 |
| Date, S | 1 |
| Kitamura, K | 1 |
| Araki, H | 1 |
| Aoki, T | 1 |
| Imada, N | 1 |
| Takada, H | 1 |
| Imaide, Y | 1 |
| Uchida, M | 1 |
| Saitoh, M | 1 |
| Terrone, C | 1 |
| Cerutti, S | 1 |
| Isaia, G | 1 |
| Reimondo, G | 1 |
| Ardissone, P | 1 |
| De Luca, S | 1 |
| Rossetti, SR | 1 |
| Nozaki, T | 1 |
| Sprangers, MA | 1 |
| Moynihan, TJ | 1 |
| Patrick, DL | 1 |
| Revicki, DA | 1 |
| Prout, GR | 5 |
| Kliman, B | 2 |
| Daly, JJ | 2 |
| Maclaughlin, RA | 2 |
| Griffin, PP | 3 |
| Neri, RO | 1 |
| Airhart, RA | 1 |
| Barnett, TF | 1 |
| Sullivan, JW | 1 |
| Levine, RL | 1 |
| Schlegel, JU | 1 |
| Lakey, WH | 1 |
| Callaway, T | 1 |
| Comeau, T | 1 |
| Lieskovsky, G | 1 |
| Rennie, P | 1 |
| Shnitka, T | 1 |
| Wilkin, P | 1 |
| Murphy, GP | 4 |
| Merrin, CE | 1 |
| Kream, J | 1 |
| Freed, SZ | 1 |
| Hellman, L | 3 |
| Zumoff, B | 3 |
| Sanford, EJ | 1 |
| Bowditch, RR | 1 |
| Rohner, TJ | 1 |
| Bardin, CW | 1 |
| Fishman, J | 1 |
| Freed, S | 2 |
| Bradlow, HL | 1 |
| Rosenfeld, RS | 1 |
| Jacobo, E | 1 |
| Schmidt, JD | 2 |
| Weinstein, SH | 1 |
| Flocks, RH | 1 |
| Müntzing, J | 2 |
| Varkarakis, MJ | 1 |
| Saroff, J | 2 |
| Sandberg, AA | 2 |
| Myhrberg, H | 1 |
| Mittelman, A | 1 |
| Seligman, AM | 1 |
| Ray, B | 1 |
| Irwin, RJ | 2 |
| Jorion, JL | 1 |
| Higa, T | 1 |
| Tremblay, M | 2 |
| Dreicer, R | 1 |
| Seidman, AD | 1 |
| Petrylak, D | 1 |
| Dershaw, DD | 1 |
| Curley, T | 1 |
| Kastelan, M | 1 |
| Kraljić, I | 1 |
| Tarle, M | 2 |
| Kaskas, M | 1 |
| Sauvage, L | 1 |
| Hattab, B | 1 |
| Dankoff, JS | 1 |
| Zaragoza, MR | 1 |
| Grossman, HB | 1 |
| Lloyd, SN | 1 |
| Chalmers, D | 1 |
| Leake, RE | 1 |
| Kirk, D | 1 |
| Long, JP | 1 |
| Huben, RP | 1 |
| Ameye, F | 1 |
| Oyen, R | 1 |
| Van De Voorde, W | 1 |
| Baert, L | 1 |
| Vila Barja, J | 1 |
| de Torres Mateos, JA | 1 |
| Pinault, S | 3 |
| Gagnon, J | 1 |
| Monfette, G | 16 |
| Dorr, FA | 4 |
| Lacourcière, Y | 13 |
| Saceda López, JL | 1 |
| Amrani Akdi, Y | 1 |
| Molina Sánchez, J | 1 |
| Armitage, TG | 2 |
| Richards, BR | 1 |
| Hosbach, G | 1 |
| Baum, N | 1 |
| Brown, P | 1 |
| Radoś, N | 1 |
| Weiss, RB | 1 |
| Frank, JA | 1 |
| Jacob, JL | 1 |
| Gelmann, EP | 1 |
| Chime-Udeh, E | 1 |
| Chrisp, P | 1 |
| Smith, P | 5 |
| Miseria, S | 1 |
| Torresi, U | 1 |
| Menichetti, ET | 1 |
| Tummarello, D | 1 |
| Baldelli, S | 1 |
| Murer, B | 1 |
| Cellerino, R | 1 |
| Fischer, M | 2 |
| Höltl, W | 1 |
| Pflüger, H | 1 |
| Tomschi, W | 1 |
| Jurincic, CD | 1 |
| Horlbeck, R | 1 |
| Klippel, KF | 1 |
| Oliveira, PD | 1 |
| Oliveira, MG | 1 |
| Pina, F | 1 |
| Andrade, JA | 1 |
| Pina-Cabral, JM | 1 |
| Berná, L | 1 |
| Germá, JR | 1 |
| Estorch, M | 1 |
| Torres, G | 1 |
| Blanco, R | 1 |
| Carrió, I | 1 |
| Habenicht, UF | 2 |
| Neumann, F | 3 |
| el Etreby, MF | 2 |
| Nikolov, S | 1 |
| Patrashkov, T | 1 |
| Brooks, JR | 1 |
| Berman, C | 1 |
| Nguyen, H | 1 |
| Prahalada, S | 1 |
| Primka, RL | 1 |
| Rasmusson, GH | 1 |
| Slater, EE | 1 |
| Schott, AM | 1 |
| Vial, T | 1 |
| Gozzo, I | 1 |
| Chareyre, S | 1 |
| Delmas, PD | 1 |
| Nabors, WL | 1 |
| Barrows, GH | 1 |
| de Launoit, Y | 1 |
| Veilleux, R | 1 |
| Dufour, M | 1 |
| Delaere, KP | 1 |
| Van Thillo, EL | 1 |
| Mendoza-Valdés, A | 1 |
| Ocampo-del-Carpio, O | 1 |
| De-la-Garza, J | 1 |
| Carlström, K | 1 |
| Stege, R | 1 |
| Srigley, JR | 1 |
| Boivin, JC | 1 |
| Juniewicz, PE | 1 |
| Fetrow, N | 1 |
| Marinelli, J | 1 |
| Wolf, M | 1 |
| Young, E | 1 |
| Lamb, J | 1 |
| Corkery, JC | 1 |
| Bihrle, W | 1 |
| McCaffrey, JA | 1 |
| Whitcomb, FF | 1 |
| Levy, C | 1 |
| Ellis, R | 1 |
| Nabors, W | 1 |
| Chodoff, L | 1 |
| Goodman, PJ | 2 |
| Davis, MA | 2 |
| Benson, R | 2 |
| Goodman, P | 1 |
| Blumenstein, B | 1 |
| Allen, JA | 1 |
| Ayub, M | 1 |
| Levell, MJ | 1 |
| Calais da Silva, F | 1 |
| Debruyne, F | 1 |
| Robinson, P | 1 |
| Suciu, S | 2 |
| Christensen, I | 2 |
| Carvalho, AP | 2 |
| Bond, A | 1 |
| Ongena, P | 2 |
| Christensen, MG | 1 |
| Friis, E | 1 |
| Hornbøl, P | 1 |
| Hvidt, V | 1 |
| Iversen, HG | 1 |
| Krarup, T | 2 |
| Lund, F | 2 |
| Schulze, H | 2 |
| Senge, T | 2 |
| Pinto de Carvalho, AP | 1 |
| McGowan, D | 1 |
| Hwang, YS | 1 |
| Perez, CA | 1 |
| Toscano, V | 1 |
| Concolino, G | 1 |
| Guidez, C | 1 |
| Cariou, G | 1 |
| Coloby, P | 1 |
| Colombel, P | 1 |
| Coulange, C | 1 |
| Grise, P | 1 |
| Poterre, M | 1 |
| Delli Ponti, U | 1 |
| Petracco, S | 1 |
| Schulz, P | 1 |
| Wolf, D | 1 |
| Arbusow, V | 1 |
| Bojar, H | 1 |
| Klobeck, HG | 1 |
| Fittler, F | 1 |
| Goldspiel, BR | 1 |
| Kohler, DR | 1 |
| Cacciatore, M | 2 |
| Romano, C | 2 |
| Cavallo, N | 1 |
| Larsen, JF | 1 |
| Walter, S | 1 |
| Olea, N | 1 |
| Sakabe, K | 1 |
| Soto, AM | 1 |
| Sonnenschein, C | 1 |
| Møller, S | 1 |
| Franzmann, MB | 1 |
| Elder, JS | 1 |
| Gibbons, RP | 1 |
| St-Arnaud, R | 3 |
| Lachance, R | 7 |
| Labrie, C | 2 |
| Plante, M | 2 |
| Lapointe, S | 2 |
| Namer, M | 2 |
| Milsted, RA | 1 |
| Ceda, GP | 1 |
| Ceresini, G | 1 |
| Hoffman, AR | 1 |
| Nightingale, SL | 1 |
| Clissold, SP | 1 |
| Manhès, G | 2 |
| Bergeron, N | 5 |
| Pineault, S | 2 |
| Brochu, M | 3 |
| Turina, E | 1 |
| Keating, MA | 1 |
| Schiff, SF | 1 |
| Balzano, S | 3 |
| Cappa, M | 1 |
| Scarpa, RM | 3 |
| Danielli, E | 1 |
| Campus, G | 2 |
| Pintus, C | 3 |
| Sica, V | 2 |
| Martino, E | 1 |
| Williams, G | 1 |
| Sandow, J | 1 |
| Hewitt, G | 1 |
| Abel, P | 1 |
| Farah, N | 1 |
| Fleming, J | 1 |
| Cox, J | 1 |
| O'Donoghue, EP | 1 |
| Sikora, K | 1 |
| Giguere, M | 11 |
| Lacoursiere, Y | 1 |
| Bergeron, V | 1 |
| Monfette, JE | 1 |
| Tremblay, D | 2 |
| Dupront, A | 1 |
| Meyer, BH | 1 |
| Pottier, J | 2 |
| Givner, ML | 1 |
| Millard, OH | 1 |
| Borsanyi, JP | 6 |
| Schröder, H | 1 |
| Kaldenhoff, H | 1 |
| Canellos, GP | 1 |
| Senn, E | 1 |
| Müller, J | 1 |
| Alioth, H | 1 |
| O'Brien, WM | 1 |
| Lynch, JH | 1 |
| Loviselli, A | 1 |
| Balestrieri, A | 1 |
| Kung, TT | 1 |
| Mingo, GG | 1 |
| Siegel, MI | 1 |
| Watnick, AS | 1 |
| Redding, TW | 1 |
| Johansson, JE | 3 |
| Andersson, SO | 2 |
| Beckman, KW | 2 |
| Zador, G | 2 |
| Moorjani, S | 1 |
| Lupien, PJ | 1 |
| Gagné, C | 1 |
| Brun, D | 1 |
| Giasson, M | 1 |
| Couture, J | 1 |
| de Kernion, JN | 1 |
| Priore, R | 1 |
| Kyprianou, N | 1 |
| Rousseau, L | 1 |
| Couture, M | 1 |
| Stegmayr, B | 1 |
| Schnürer, LB | 1 |
| Kelly, SJ | 1 |
| St Arnaud, R | 1 |
| Santen, RJ | 1 |
| Mowszowicz, I | 1 |
| Portois, MC | 1 |
| Mauvais-Jarvis, P | 1 |
| Harnois, C | 1 |
| Malenfant, M | 1 |
| Lajeunesse, C | 1 |
| Parent, R | 1 |
| Villeneuve, A | 1 |
| Boublil, JL | 1 |
| Kather, R | 1 |
| Cavaglione, G | 1 |
| Lingårdh, G | 1 |
| Luthy, I | 2 |
| Lundgren, R | 1 |
| Geller, J | 1 |
| Guay, J | 1 |
| MacFarlane, JR | 1 |
| Tolley, DA | 1 |
| Raynaud, JP | 1 |
| Moguilewsky, M | 1 |
| Tournemine, C | 1 |
| Coussedière, D | 1 |
| Salmon, J | 1 |
| Husson, JM | 1 |
| Bertagna, C | 1 |
| Pendyala, L | 1 |
| Vomácka, V | 1 |
| Vachalovský, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boos[NCT00175396] | Phase 3 | 400 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
| A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)[NCT00769548] | Phase 3 | 1,322 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| A Prospective Study of Intermittent Androgen Suppression (IAS) in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy[NCT00223665] | Phase 2 | 102 participants (Actual) | Interventional | 1997-01-08 | Completed | ||
| A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer[NCT00005044] | Phase 3 | 1,579 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.[NCT02175212] | Phase 3 | 362 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer[NCT05802121] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer[NCT03541928] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-08-02 | Recruiting | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Postoperative Hypofractionated Radiation Therapy and Hormonal Therapy in Patients With Prostate Cancer: A Phase II Trial[NCT04249154] | Phase 2 | 77 participants (Anticipated) | Interventional | 2019-09-03 | Recruiting | ||
| Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer[NCT02913859] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN[NCT05717660] | Phase 2 | 180 participants (Anticipated) | Interventional | 2023-03-11 | Not yet recruiting | ||
| Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer[NCT02454543] | 452 participants (Anticipated) | Interventional | 2015-05-31 | Active, not recruiting | |||
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer[NCT00116220] | Phase 3 | 206 participants (Actual) | Interventional | 1995-09-30 | Completed | ||
| Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation[NCT02460549] | 9 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2013-12-31 | Terminated (stopped due to enrollment default) | ||
| A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma[NCT01040624] | 77 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Long Term Adjuvant Hormonal Treatment With LHRH Analogue Versus No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Months Combined Androgen Blockade - A Phase III Study[NCT00003026] | Phase 3 | 966 participants (Anticipated) | Interventional | 1997-04-30 | Completed | ||
| A Phase II Study of Dose-Escalated Proton-Based Radiation Therapy Delivered With a Simultaneous Integrated Boost (SIB) to Intraprostatic Tumors (IPT) Visible on Pretreatment Magnetic Resonance Image[NCT03624660] | 100 participants (Anticipated) | Interventional | 2018-09-24 | Recruiting | |||
| Prospective Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration[NCT02963155] | 30 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Randomised Comparison of Short and Protracted Neoadjuvant Hormonal Therapy Prior to Radiation Therapy of High Risk Localized Prostate Cancer[NCT00003734] | Phase 3 | 276 participants (Anticipated) | Interventional | 1998-12-31 | Active, not recruiting | ||
| Effect of Neoadjuvant Degarelix on MRI-guided Transurethral Ultrasound Ablation (TULSA) in Patients With Intermediate-risk Prostate Cancer: A Pilot Study[NCT05917860] | Phase 1 | 15 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy[NCT03296124] | 0 participants (Actual) | Observational | 2017-12-07 | Withdrawn (stopped due to This project currently does not have any subjects enrolled due to other PI priorities.) | |||
| ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.[NCT05786742] | 205 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | |||
| A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE[NCT00002597] | Phase 3 | 2,028 participants (Actual) | Interventional | 1994-10-31 | Completed | ||
| Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859] | Phase 2 | 31 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial[NCT00243646] | Phase 3 | 6 participants (Actual) | Interventional | 2004-08-31 | Terminated (stopped due to poor accrual) | ||
| Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients[NCT02678520] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to PI no longer at institution. Study terminated prior to enrolling subjects.) | ||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies[NCT01515124] | 450 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [NCT00037362] | 0 participants | Observational | 2001-09-30 | Completed | |||
| Phase II Trial of Maximal Androgen Deprivation Followed by Conformal External Beam Radiotherapy With Continued Androgen Deprivation for Clinically Localized Prostate Cancer[NCT00003124] | Phase 2 | 105 participants (Anticipated) | Interventional | 1997-05-31 | Completed | ||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)[NCT02303327] | Phase 3 | 296 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.[NCT01800058] | 68 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer[NCT00932672] | Phase 2 | 45 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to slow recruitment, lack of funding and PI transferred) | ||
| Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial. (PCS-XI)[NCT05820633] | 500 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY[NCT00002889] | Phase 2 | 180 participants (Actual) | Interventional | 1997-05-31 | Completed | ||
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| Phase I Study of 3-Dimensional Conformal Radiotherapy in Patients With Locally Advanced (Stage T2c and T3) Adenocarcinoma of the Prostate[NCT00002480] | Phase 1 | 0 participants | Interventional | 1991-02-28 | Completed | ||
| A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia[NCT00381836] | Phase 2/Phase 3 | 140 participants (Anticipated) | Interventional | 2006-10-31 | Terminated (stopped due to Terminated by sponsor due to general risk that aranesp caused tumor progression) | ||
| Collection of Blood From Patients With Prostate Cancer[NCT00923221] | 1,000 participants (Anticipated) | Observational | 2007-02-28 | Recruiting | |||
| An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT01368055] | 361 participants (Actual) | Interventional | 2011-09-30 | Active, not recruiting | |||
| A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT00693238] | 228 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer[NCT00032825] | Phase 1 | 674 participants (Actual) | Interventional | 2002-03-19 | Completed | ||
| A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer[NCT01420965] | Phase 2 | 7 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Drug supply issues) | ||
| A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma[NCT00001266] | Phase 2 | 70 participants | Interventional | 1990-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. This measure was defined as the percentage of participants with normal BMD scores at baseline who developed Osteopenia after the first cycle of ADT. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | percent of participants (Number) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 13.2 |
Assessment of overall survival measured as median time from completion of first full cycle of IAS until date of death from any cause. (NCT00223665)
Timeframe: From date of first treatment until the date of death or study withdrawal, whichever came first, assessed up to 16 years.
| Intervention | years (Median) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 6.6 |
Monthly Prostate-Specific Antigen (PSA) testing to assess the point at which each patient's disease stops responding to Androgen Deprivation Therapy (ADT). Androgen Independence (AI), also know as Castrate Resistance (CR), was defined as 2 serial rises in PSA while on ADT with Testosterone levels <50 ng/dL. (NCT00223665)
Timeframe: From date of first treatment until the date of development of CR, metastatic progression, or study withdrawal, whichever came first, assessed up to 16 years.
| Intervention | years (Median) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 4.0 |
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health. Percent change was assess for each patient at each time point. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | Percent change of BMD (Number) | |
|---|---|---|
| Post Cycle 1 versus Baseline | Pre Cycle 2 versus Post Cycle 1 | |
| Intermittent Androgen Suppression (IAS) | -1.2 | -0.2 |
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | Percent change in BMD (Number) | |
|---|---|---|
| Post Cycle 1 versus Baseline | Pre Cycle 2 versus Post Cycle 1 | |
| Intermittent Androgen Suppression (IAS) | -3.4 | 1.4 |
Estradiol was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | pg/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Measurement at Month 3 | Measurement at Month 9 | Measurement at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 33.60 | 23.12 | 22.76 | 24.35 |
Executive Function was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Stroop Color Word Interference Task. Subjects are asked to read 100 color words (red, green, blue), followed by identification of color blocks followed by reading the color of the ink and ignoring the word (e.g., the word 'blue' printed in green letters). Assessment was based on the amount of time needed to time to complete the assessment. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | minutes to complete the assessment (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 51.00 | 55.52 | 47.58 | 48.82 |
Spatial Ability was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Wechsler Adult Intelligence Scale-Revised, Block Design sub-test and measures participants' ability to analyze and construct abstract figures from their component parts. The test allows a time limit of 3 minutes per design, for a total of nine designs. Score is based on total number of designs completed (max 9, min 0). (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly completed designs (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Combined Androgen Blockade | 8.65 | 7.20 | 8.82 | 8.47 |
Spatial Ability (Mental Rotation) was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Vandenberg & Kuse (1978) Mental Rotation Test. Subjects are presented with line drawings of complex, three dimensional cubes on a computer screen. The subject must compare the two drawings and decide if they match. Score is based on number of correctly identified figures. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly identified figures (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 16.12 | 13.00 | 16.52 | 15.53 |
Spatial Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT using the Puget Sound Route Learning Test. This test measured the ability to navigate a short route within a room. Three trials were administered followed by three trials of a new route using pictures placed on the floor as landmarks. A delayed recall is administered after twenty minutes. Performance was assessed based on number of correctly recalled sequences after a delay. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | number of correctly recalled sequences (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 19.50 | 22.00 | 23.76 | 24.12 |
Verbal Ability/Fluency was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. Participants were asked to verbally generate as many words beginning with a particular letter (e.g. P) within a 60 second period. Two trials were administered with two different letters. The total number of words generated was recorded for each letter and summed and analyzed. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of words generated (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 24.65 | 26.15 | 26.29 | 25.70 |
Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via the Proactive Interference (PI) task. The PI task involves participants listening to a list of 10 words from the same semantic category (e.g., articles of clothing), and then recalling as many of these words as possible.The procedure is repeated for a total of 4 trials. Assessment is based on the total number of words recalled. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly recalled words (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 21.31 | 22.90 | 22.70 | 22.70 |
Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via Story Recall. This task is based on the well known Wechsler Memory Scale -Revised Logical Memory task. Participants listened to two brief narratives (stories) and were asked to recall as much as possible immediately after hearing each story and following a 20-minute delay. Assessment was based on number of correctly recalled pieces of information after a delay. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | number of correctly recalled data points (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 35.06 | 37.86 | 39.38 | 41.16 |
Visual Working Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This task is based on the Subject Ordered Pointing Task (SOPT). The participant is shown a grid array of 10, 12 or 16 abstract designs and they must choose a new design with each refresh of the screen. Assessment is based on total number of errors. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | total number of errors (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 13.22 | 15.66 | 12.35 | 14.00 |
Testosterone was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | ng/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Measurement at Month 3 | Measurement at Month 9 | Measurement at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 406 | 0.28 | 0.20 | 2.45 |
Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) |
|---|---|
| TAS x 8 Weeks | 24 |
| TAS x 28 Weeks | 23 |
Disease-specific survival time is measured from date of randomization to death due to prostate cancer based on study chair review, with prostate-cancer death defined as (1) primary cause of death certified as due to prostate cancer, (2) complication of therapy, irrespective of disease status, (3) disease progression in the absence of any anti-tumor therapy, or (4) a 1.0 ng/ml-exceeding-rise in serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or after salvage androgen suppression therapy. Death due to other causes is considered a competing risk. All others are censored. DSS is estimated using the cumulative incidence method. Ten-year rate is reported. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) |
|---|---|
| TAS x 8 Weeks | 95 |
| TAS x 28 Weeks | 96 |
Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) |
|---|---|
| TAS x 8 Weeks | 66 |
| TAS x 28 Weeks | 67 |
Time to SBF measured from date of randomization to the date of PSA increase of ≥1.0 ng/mL (from the nadir PSA after completion of protocol-specified therapy) after salvage androgen suppression was started; competing risks LRP, DM, and death without SBF; all others are censored. SBF is estimated using the cumulative incidence method. Ten-year rates are reported. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) |
|---|---|
| TAS x 8 Weeks | 10 |
| TAS x 28 Weeks | 9 |
Time to distant metastasis measured from date of randomization to date of documented distant metastasis; competing risks are BF, LRP, and death without DM; all others are censored. Time to locoregional progression measured from date of randomization to date of documented local or regional progression; competing risks are BF [protocol definition- first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy], DM, and death without LRP; all others are censored. LRP and DM are estimated using the cumulative incidence method. Ten -year rates are reported. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Locoregional progression | Distant metastasis | |
| TAS x 28 Weeks | 4 | 6 |
| TAS x 8 Weeks | 6 | 6 |
"Protocol definition: Time to BF measured from date of randomization to first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored.~Phoenix definition: Time to BF measured from date of randomization to first of (1) the date of documented rise of 2 ng/ml above the post-treatment(RT end date) nadir or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. For both definitions BF is estimated using the cumulative incidence method. Ten year rates reported." (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Protocol definition | Phoenix definition | |
| TAS x 28 Weeks | 59 | 27 |
| TAS x 8 Weeks | 56 | 27 |
Acute drug therapy and radiation (<= 90 days from start of RT) toxicity was graded using the Common Toxicity Criteria (CTC) v.2.0 criteria; late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring schema. Grade refers to the severity of the toxicity. The CTC v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild toxicity, Grade 2 Moderate toxicity, Grade 3 Severe toxicity, Grade 4 Life-threatening or disabling toxicity, Grade 5 Death related to toxicity. The highest grade acute and late toxicity was determined for each patient. (NCT00005044)
Timeframe: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Acute RT and Hormone Toxicity: Grade 1 | Acute RT and Hormone Toxicity: Grade 2 | Acute RT and Hormone Toxicity: Grade 3 | Acute RT and Hormone Toxicity: Grade 4 | Acute RT and Hormone Toxicity: Grade 5 | Late RT Toxicity: Grade 1 | Late RT Toxicity: Grade 2 | Late RT Toxicity: Grade 3 | Late RT Toxicity: Grade 4 | Late RT Toxicity: Grade 5 | |
| TAS x 28 Weeks | 19.5 | 49.8 | 25.7 | 0.1 | 0 | 32.9 | 22.5 | 8.0 | 0.3 | 0 |
| TAS x 8 Weeks | 30.8 | 41.6 | 16.1 | 0 | 0 | 34.0 | 20.5 | 9.7 | 0.1 | 0 |
Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 90 |
| Short Term Androgen Deprivation | 81 |
Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse (NCT02175212)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 177 |
| Short Term Androgen Deprivation | 173 |
Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 94 |
| Short Term Androgen Deprivation | 83 |
Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause. (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 95 |
| Short Term Androgen Deprivation | 86 |
"Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.~Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.~CV events were defined according to the World Health Organization criteria" (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Grade 2 of more rectal toxicity | Grade 2 of more urinary toxicity | Cardiovascular | |
| Long Term Androgen Deprivation | 11.1 | 8.2 | 17.6 |
| Short Term Androgen Deprivation | 7.6 | 7.3 | 7.2 |
Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria. (NCT01040624)
Timeframe: 6 months after the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| HR-A | 1 |
| HR-B | 3 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
The Phoenix definition of biochemical failure was used - an increase in the prostate-specific antigen (PSA) level of >2 ng per milliliter above the nadir. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 26.3 |
| Radiation Therapy Alone | 41.1 |
Clinical relapse is defined as local progression or distant metastases. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 15.0 |
| Radiation Therapy Alone | 21.7 |
Disease-free failure is defined as documentation of progression (local progression, distant failure, and biochemical failure) or death from any cause. Disease-free survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 51.7 |
| Radiation Therapy Alone | 39.5 |
Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 95.7 |
| Radiation Therapy Alone | 92.6 |
Failure is defined as documented metastatic disease. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 5.5 |
| Radiation Therapy Alone | 8.0 |
Local progression defined as documented local progression as determined by clinical exam . Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 10.9 |
| Radiation Therapy Alone | 16.1 |
Overall survival (OS) was calculated from randomization to the date of death from any cause and overall survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From date of randomization to 10 years
| Intervention | percentage of patients (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 61.9 |
| Radiation Therapy Alone | 56.8 |
The rate of prostate rebiopsy at two years is defined as the proportion of patients whose results are positive among all eligible patients who had a repeat biopsy at two years. The rate was estimated separately in each arm. (NCT00002597)
Timeframe: From registration to two years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 20.2 |
| Radiation Therapy Alone | 38.9 |
Second biochemical relapse is as defined as follows (after initiation of salvage hormone therapy): A rise in PSA on at least two consecutive cases above the nadir (after initiation of salvage hormone therapy), with the rises in PSA exceeding 1 ng/ml above the nadir; or failure to reach 4 ng/L or less at 18 months. The rates of second biochemical relapse were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 2.7 |
| Radiation Therapy Alone | 6.1 |
Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | percentage of all lymphocytes (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel + Placebo Pill | 0.101 | 0.081 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 95.4 | 31.9 |
| Group 2: Acyline, Testosterone Gel | 117.8 | 109.0 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 96.3 | 36.5 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | mmol/L (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cholesterol Day 0 | Total cholesterol Day 28 | Total cholesterol Day 56 | LDL choesterol Day 0 | LDL cholesterol Day 28 | LDL cholesterol Day 56 | HDL cholesterol Day 0 | HDL cholesterol Day 28 | HDL cholesterol Day 56 | Triglycerides Day 0 | Triglycerides Day 28 | Triglycerides Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.97 | 5.44 | 4.95 | 2.95 | 3.29 | 2.87 | 1.19 | 1.37 | 1.19 | 1.79 | 1.73 | 1.89 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 4.48 | 4.51 | 4.14 | 2.77 | 2.80 | 2.49 | 1.32 | 1.32 | 1.32 | 0.82 | 0.86 | 0.80 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 4.56 | 4.56 | 4.27 | 2.67 | 2.75 | 2.51 | 1.40 | 1.32 | 1.30 | 1.08 | 1.08 | 1.02 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | picomolar (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 54 | 69 | 54 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 65 | 59 | 64 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 50 | 42 | 50 |
(NCT00729859)
Timeframe: Baseline, 28 days
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.2 | 0.42 |
| Group 2: Acyline, Testosterone Gel | 2.9 | 0.39 |
| Group 3: Acyline, Testosterone Gel, Anastrazole Pill | 2.5 | 0.87 |
HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | HOMA score (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 1.8 | 2.4 | 2.2 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 2.0 | 1.9 | 1.9 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 1.6 | 1.4 | 1.7 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.3 | 0.31 |
| Group 2: Acyline, Testosterone Gel | 4.7 | 0.69 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 4.4 | 1.55 |
QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | QUICKI index (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 0.36 | 0.34 | 0.35 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 0.35 | 0.35 | 0.35 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 0.36 | 0.38 | 0.36 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 34.9 | 37.5 |
| Group 2: Acyline, Testosterone Gel | 23.0 | 22.1 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 27.6 | 25.1 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline testosterone concentration | Day 28 testosterone concentration | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 15.4 | 0.8 |
| Group 2: Acyline, Testosterone Gel | 16.3 | 17.8 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 16.5 | 19.0 |
Defined as freedom from distant metastasis (NCT01800058)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes | No | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 64 | 1 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: 9 - 12 months post-radiotherapy in cases with positivation after basal visit
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 12 | 1 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: Post-neoadjuvant hormone therapy and prior to radiotherapy
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | No Data | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 54 | 8 | 3 |
(Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline). (NCT01800058)
Timeframe: Post-radiotherapy
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | No Data | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 48 | 11 | 6 |
Initially a cutoff point of > 1 or more circulating cells per 7.5 mL of blood will be taken as the reference baseline. (NCT01800058)
Timeframe: Basal
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number of Participants with 0 CTCs | Number of Participants with =>1 CTCs | |
| Circulating Prostatic Tumor Cells in the Peripheral Blood | 60 | 5 |
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
(NCT00693238)
Timeframe: 6 months after the end of radiation therapy
| Intervention | Participants (Number) |
|---|---|
| Low Risk Proton Radiation | 0 |
| Intermediate Risk Proton Radiation | 0 |
110 reviews available for flutamide and Cancer of Prostate
| Article | Year |
|---|---|
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Topics: Anilides; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; Flutamide; | 2018 |
First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cyproterone; Estrogens; Fluta | 2013 |
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Co | 2013 |
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Ag | 2014 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gon | 2014 |
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response | 2015 |
Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing H | 2016 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; N | 2009 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; N | 2009 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; N | 2009 |
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Flutamide; Humans; Male; N | 2009 |
Antiandrogen monotherapy: indications and results.
Topics: Aged; Androgen Antagonists; Anilides; Castration; Flutamide; Humans; Imidazoles; Imidazolidines; Mal | 2002 |
Androgen receptor as a target in androgen-independent prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
[Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Dru | 2002 |
[First line therapy in the treatment of metastatic prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamid | 2003 |
[Antiandrogen in prostate cancer].
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; | 2002 |
[Total androgen blockade].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; | 2002 |
The role of antiandrogen monotherapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Fluta | 2003 |
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Ch | 2003 |
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Cyproterone Acetate; Flutamide; Humans; Imid | 2004 |
[Toxic hepatitis and liver failure under therapy with flutamide].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Biopsy, Needle; Chemical and Drug I | 2004 |
Clinical strategies in the management of biochemical recurrence after radical prostatectomy.
Topics: Androgen Antagonists; Antifungal Agents; Cytochrome P-450 Enzyme System; Disease-Free Survival; Flut | 2003 |
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flu | 2002 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality T | 2004 |
[Hormonal therapy for prostatic cancer--state of the art].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2005 |
[Usefulness and positioning of MAB therapy for prostate cancer].
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Clinical | 2005 |
[Keyrole of endocrinology in the victory against prostate cancer].
Topics: Adrenal Glands; Androgen Antagonists; Antineoplastic Agents, Hormonal; Dehydroepiandrosterone; Fluta | 2006 |
Hormone ablation therapy: lightening the load for today's prostate cancer patient.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modali | 2007 |
New forms and future perspectives in endocrine treatment of prostatic carcinoma.
Topics: Aminoglutethimide; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Estrogen Antagonists; Flu | 1984 |
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Mul | 1995 |
[Application of antiandrogens on prostatic diseases].
Topics: Androgen Antagonists; Chlormadinone Acetate; Clinical Trials as Topic; Flutamide; Humans; Male; Pros | 1994 |
Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality.
Topics: Androgen Antagonists; Autopsy; Combined Modality Therapy; Flutamide; Humans; Incidence; Male; Mass S | 1995 |
Molecular implications of the antiandrogen withdrawal syndrome.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Male; Mutation; Orchiectomy; Prostate-Specific Antige | 1995 |
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Topics: Absorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Estrogens; Flutamide | 1995 |
Casodex: preclinical studies and controversies.
Topics: Androgen Antagonists; Anilides; Animals; Dogs; Endocrine Glands; Flutamide; Genitalia, Male; Humans; | 1995 |
Role of induction androgen deprivation before radical prostatectomy.
Topics: Aged; Androgen Antagonists; Androgens; Clinical Trials as Topic; Flutamide; Humans; Leuprolide; Male | 1995 |
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 1993 |
Role of maximal androgen blockade in advanced prostate cancer.
Topics: Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Orchiectom | 1994 |
[Hepatotoxicity due to flutamide].
Topics: Aged; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Male; Prostatic Neoplasms | 1994 |
Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Male; Neoplasm Metastasis; Prostatic N | 1994 |
Mechanism of action and pure antiandrogenic properties of flutamide.
Topics: Androgen Antagonists; Androgen-Binding Protein; Animals; Antineoplastic Combined Chemotherapy Protoc | 1993 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administratio | 1993 |
Prostate cancer. Primary hormonal treatment.
Topics: Combined Modality Therapy; Cyproterone Acetate; Diethylstilbestrol; Dihydrotestosterone; Estrogens; | 1993 |
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cyproterone Acetate; Flutamide; Humans; Imida | 1993 |
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Clinical Trials as Topic; Flutamide; Humans; Male; Neoplasm | 1996 |
[Progress of endocrine therapy for prostate cancer and results].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Estrogens; Flutamide; | 1996 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Com | 1996 |
Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Gonadot | 1996 |
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Topics: Androgen Antagonists; Anilides; Flutamide; Half-Life; Humans; Imidazoles; Imidazolidines; Male; Nitr | 1997 |
[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Hepatic | 1996 |
[Fulminant liver failure with a fatal outcome due to flutamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Fatal Outcome; Flutamide; Hep | 1997 |
[Significance of neoadjuvant therapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Diethylstilbestrol; E | 1997 |
[Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996].
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Combined Moda | 1997 |
Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Topics: Androgen Antagonists; Anilides; Clinical Trials as Topic; Flutamide; Humans; Imidazoles; Imidazolidi | 1998 |
[Anti-androgen withdrawal syndrome].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; | 1998 |
Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Drug Interactions; Drug M | 1998 |
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cyprotero | 1998 |
The place and the results of monotherapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone | 1998 |
Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; Humans; Imida | 1998 |
[The hepatotoxicity of flutamide].
Topics: Adenocarcinoma, Clear Cell; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Hormonal; Ch | 1998 |
[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Topics: Androgen Antagonists; Anilides; Chlormadinone Acetate; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1998 |
[Total androgen blockade--concept, theory, method and clinical application].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Gonadotropi | 1998 |
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Hum | 1998 |
Antiandrogens as monotherapy for prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cyproterone | 1998 |
Arguments for the long-term use of combined androgen blockade.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Combined Modality | 1998 |
Arguments against the long-term use of combined androgen blockade.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1998 |
[Progress in oral anti-cancer drug therapy for urological cancer].
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Administration Sch | 1999 |
Hormonal manipulation for rising PSA after radical prostatectomy.
Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide | 1999 |
A review of studies of hormonal adjuvant therapy in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Gonadotropin-Releasing Hormone; | 1999 |
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans; | 1999 |
Anti-androgens and other hormonal therapies for prostate cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Biomarkers, Tumor; Flutamide; Humans; Male; Neoplasms, Ho | 1999 |
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flut | 1999 |
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
Topics: Aged; Androgen Antagonists; Cyproterone; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Orchie | 2000 |
Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Inap | 2000 |
[Basic and clinical characteristics of flutamide].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Neoplasms, Hormone-D | 2000 |
Neoadjuvant hormone therapy: the Canadian trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; | 2001 |
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug | 2001 |
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2001 |
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; C | 2001 |
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imid | 2001 |
Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.
Topics: Antifungal Agents; Antineoplastic Agents, Hormonal; Disseminated Intravascular Coagulation; Drug The | 2001 |
Assessing meaningful change in quality of life over time: a users' guide for clinicians.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Competence; Clinical | 2002 |
Antiandrogens.
Topics: Acne Vulgaris; Androgen Antagonists; Animals; Biological Assay; Comb and Wattles; Cyproterone; Femal | 1976 |
Potential test systems for chemotherapeutic agents against prostatic cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgens; Animals; Antineoplastic Agents; Arginase; Dihydrot | 1975 |
Chemotherapy of prostatic cancer.
Topics: Aged; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bromoc | 1975 |
Steroid hormone agonists and antagonists in the treatment of cancer.
Topics: Androgen Antagonists; Androgens; Breast Neoplasms; Epidermal Growth Factor; Estrogen Antagonists; Es | 1992 |
[Endometrioid adenocarcinoma of the prostate. Apropos of a case, review of the literature].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Leuprolide; | 1992 |
A rationale for the use of non-steroidal anti-androgens in the management of prostate cancer.
Topics: Animals; Flutamide; Humans; Male; Prostatic Neoplasms | 1992 |
Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
Topics: Androgen Antagonists; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Humans; Leupro | 1991 |
Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Male; Prostatic Neoplasm | 1991 |
Cancer of the prostate. Mechanisms of action of antiandrogens.
Topics: Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamid | 1991 |
Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Remis | 1991 |
Antiandrogenic substances in the management of prostatic cancer.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Prostatic Neoplasms | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidaz | 1990 |
Flutamide: an antiandrogen for advanced prostate cancer.
Topics: Anilides; Flutamide; Humans; Male; Prostatic Neoplasms | 1990 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
Initiation of LHRH monotherapy for prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; F | 1989 |
Androgen blockade and suppression for prostate carcinoma.
Topics: Androgen Antagonists; Cyproterone; Drug Administration Schedule; Drug Therapy, Combination; Flutamid | 1989 |
Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
Topics: Anilides; Flutamide; Humans; Male; Prostatic Neoplasms | 1989 |
The use of flutamide as monotherapy in the treatment of advanced prostate cancer.
Topics: Anilides; Clinical Trials as Topic; Drug Evaluation; Flutamide; Humans; Male; Prostatic Neoplasms | 1989 |
Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
Topics: Adenocarcinoma; Anilides; Canada; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Hu | 1989 |
Antiandrogens alone or in combination for treatment of prostate cancer: the European experience.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eur | 1989 |
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
Topics: Anilides; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Multicenter Studies as | 1989 |
Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; | 1988 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Female; Flutamide; Glucuronidase; G | 1988 |
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Comb | 1985 |
Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dihydrotestosterone; Fl | 1988 |
Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.
Topics: Androgen Antagonists; Androgens; Cell Differentiation; Combined Modality Therapy; Cyclophosphamide; | 1987 |
New concepts in studying the control of normal and cancer growth of the prostate.
Topics: Androgens; Animals; Blood Proteins; Cell Nucleus; Dogs; Flutamide; Gonadotropins, Pituitary; Humans; | 1987 |
Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dihydrotestosterone; Estrogens | 1986 |
302 trials available for flutamide and Cancer of Prostate
| Article | Year |
|---|---|
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Topics: Androgen Antagonists; Castration; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neop | 2023 |
Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluta | 2017 |
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Dis | 2017 |
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Ho | 2017 |
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Topics: Aged; Androgen Antagonists; Delayed-Action Preparations; Flutamide; Humans; Injections, Intralesiona | 2017 |
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Canada; Chemoradiotherapy; Dose Frac | 2018 |
Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Proliferatio | 2013 |
Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.
Topics: Area Under Curve; Chemistry, Pharmaceutical; Delayed-Action Preparations; Flutamide; Half-Life; Huma | 2014 |
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Flutamide; Humans; Leuprolide; Male; Middle Aged; Prospective Studies; Pros | 2015 |
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cost of Illness; Emotions; Erec | 2015 |
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineopla | 2015 |
Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Proto | 2014 |
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Horm | 2015 |
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenedione; Anilides; Dehydroepiandrosterone; Fl | 2015 |
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Biopsy; Combined Modality Therapy; Di | 2015 |
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Follow-Up Studies; Gosere | 2016 |
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Flutamide; Humans; Male; M | 2016 |
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2016 |
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2008 |
Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Canada; Disease-Free | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Prostatectomy; Prost | 2009 |
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial.
Topics: Aged; Aged, 80 and over; Biopsy; Canada; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; | 2009 |
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2009 |
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2009 |
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; F | 2009 |
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause o | 2009 |
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2010 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Duration of androgen suppression in the treatment of prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-F | 2009 |
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; H | 2010 |
Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Diseases, Metabolic; | 2010 |
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; H | 2009 |
Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studi | 2010 |
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal | 2010 |
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality The | 2011 |
A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2011 |
Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Combined Mod | 2011 |
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Combined Modality Therapy; Estradiol | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry.
Topics: 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Cell Nucleus; Cost-Benefit Analysis; Disea | 2013 |
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineo | 2012 |
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Drug Therapy, Comb | 2012 |
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormon | 2012 |
Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, | 2012 |
Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Dise | 2012 |
The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; D | 2012 |
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Topics: Aged; Androgen Antagonists; Androgens; Biopsy; Chemotherapy, Adjuvant; Endosonography; Flutamide; Fo | 2012 |
Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Body C | 2013 |
Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Flutamide; Humans; | 2002 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survi | 2002 |
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormona | 2003 |
Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer.
Topics: Aged; Androgen Antagonists; Caffeine; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A | 2002 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Disease Progre | 2002 |
Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Arterie | 2002 |
Neoadjuvant flutamide monotherapy for locally confined prostate cancer.
Topics: Aged; Androgen Antagonists; Disease-Free Survival; Fertility Agents, Female; Flutamide; Follow-Up St | 2003 |
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Diploidy; DNA, Neoplasm; F | 2003 |
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2003 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antin | 2003 |
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyprote | 2003 |
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, | 2003 |
Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study.
Topics: Administration, Oral; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; F | 2003 |
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Attention; Biomarker | 2003 |
The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy | 2003 |
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hor | 2003 |
Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Surviva | 2004 |
Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Flutamide; Hum | 2004 |
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide; | 2004 |
[Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
Topics: Aged; Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Dose-Response Relatio | 2004 |
Ten-year survival in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Disease-Free Survival; Double-Blind Method; Flutamide; F | 2003 |
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2002 |
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Topics: Acyclovir; Adenoviridae; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents | 2004 |
Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Brachytherapy; Chemotherapy, Adjuvant; Flu | 2002 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
Topics: Adult; Affect; Aged; Aged, 80 and over; Amyloid beta-Peptides; Androgen Antagonists; Antineoplastic | 2004 |
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Mi | 2004 |
Combined modality treatment in the management of high-risk prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Fin | 2004 |
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progres | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin | 2004 |
The influence of androgen deprivation therapy on metabolism in patients with prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Blood Glucose; Blood Urea Nit | 2005 |
Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma; Combined Modality Therapy; Flut | 2004 |
[Alfa-blockade with doxazosin vs tamsulozin in combination of intermittent androgen blockade in patients with prostate cancer].
Topics: Adrenergic alpha-Antagonists; Aged; Androgen Antagonists; Antineoplastic Agents; Doxazosin; Drug The | 2005 |
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; F | 2005 |
Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; | 2006 |
Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Biotransformation; Chromatography, L | 2006 |
Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutam | 2007 |
Early effects of pharmacological androgen deprivation in human prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Neoplasms, Hormone- | 2007 |
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; | 2007 |
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black People; Cytochrome P-450 CYP3A; C | 2007 |
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Disease-F | 2007 |
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; | 2008 |
Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Hormonal; Double-Blind Method; F | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Flu | 2008 |
The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Comb | 2007 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; | 2008 |
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Mi | 2008 |
Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study.
Topics: Aged; Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neopl | 2008 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Cause of Death; Estradiol; Estrogens; | 2008 |
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; F | 1984 |
Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Combi | 1995 |
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyproterone | 1996 |
Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.
Topics: Aged; Androgens; Chemotherapy, Adjuvant; Combined Modality Therapy; Flutamide; Gonadotropin-Releasin | 1993 |
Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
Topics: Combined Modality Therapy; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Mal | 1994 |
Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 1993 |
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Diploidy; Flutamide; Goserelin; Humans; Ma | 1994 |
Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report.
Topics: Aged; Biomarkers, Tumor; Combined Modality Therapy; Epirubicin; Estramustine; Flutamide; Humans; Mal | 1994 |
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Topics: Aged; Androgens; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; | 1995 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Comb | 1995 |
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Topics: Aged; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged | 1995 |
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas | 1995 |
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies | 1995 |
Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibi | 1995 |
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Mid | 1995 |
UK studies on suramin therapy in hormone resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Flutamide; Humans; Male; Midd | 1995 |
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Topics: Adaptation, Physiological; Aged; Anorexia; Bayes Theorem; Cohort Studies; Drug Monitoring; Drug Resi | 1995 |
A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Confidence Intervals; Double-Blind M | 1993 |
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Goserelin; Humans; Ma | 1995 |
A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy alone for locally advanced prostate cancer. The Radiation Therapy Oncology Group.
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy, High- | 1994 |
A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Prostatectomy; Prostat | 1994 |
Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
Topics: Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follicle Stimulating Hormone; Goserelin; | 1994 |
[Treatment of prostatic carcinoma in clinical stage C. Comparison between radiotherapy plus hormonal therapy after progression and immediate hormonal therapy].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; | 1994 |
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modal | 1993 |
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 1993 |
Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 1993 |
Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1993 |
Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 1994 |
Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Carcinoma in Situ; Case-Control Studies; Combined Modali | 1994 |
Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
Topics: Aged; Combined Modality Therapy; Estramustine; Flutamide; Humans; Male; Orchiectomy; Prognosis; Pros | 1994 |
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver | 1993 |
Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studies; Goserelin; Humans; Mal | 1993 |
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Mid | 1993 |
The use of flutamide in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Huma | 1993 |
Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Flutamide; Goserelin; Humans; Male; Prostatic Neopla | 1993 |
Combination treatment in M1 prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Human | 1993 |
Quality of life in prostatic carcinoma.
Topics: Activities of Daily Living; Flutamide; Goserelin; Humans; Interpersonal Relations; Male; Orchiectomy | 1993 |
Total androgen blockade: the United States experience.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; L | 1993 |
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Stu | 1993 |
[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Topics: Administration, Oral; Aged; Aged, 80 and over; Diarrhea; Drug Administration Schedule; Flutamide; Fo | 1993 |
[Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Dihydrotestosterone; Drug Administration Schedule; Fl | 1993 |
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostati | 1993 |
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.
Topics: Adult; Aged; Androgen Antagonists; Carcinoma; Flutamide; Gonadotropin-Releasing Hormone; Humans; Mal | 1996 |
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; M | 1996 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant | 1996 |
Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; H | 1996 |
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Topics: Aged; Antineoplastic Agents; Flutamide; Humans; Hydrocortisone; Male; Middle Aged; Prospective Studi | 1995 |
[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Fluta | 1995 |
[Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications].
Topics: Actuarial Analysis; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing Hormone; Huma | 1995 |
Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; H | 1996 |
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studie | 1996 |
Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progres | 1996 |
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal | 1996 |
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1996 |
Histopathological effects of androgen deprivation in prostatic cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Fl | 1996 |
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Com | 1996 |
Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cyproterone Acetat | 1996 |
Combination treatment versus LHRH alone in advanced prostatic cancer.
Topics: Age Distribution; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; An | 1996 |
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prospect | 1995 |
Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1994 |
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.
Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Black People; Combined Modality | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1996 |
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Hu | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method | 1996 |
Combined finasteride and flutamide therapy in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 1996 |
Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.
Topics: Appetite; Combined Modality Therapy; Diarrhea; Flutamide; Gonadotropin-Releasing Hormone; Humans; Li | 1996 |
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relat | 1996 |
[Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Chlormadinone Acetate; | 1996 |
[Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Topics: Aged; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Gonadot | 1996 |
[Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Gonadotropin-Relea | 1996 |
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Flutami | 1997 |
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; | 1997 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuva | 1997 |
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, C | 1997 |
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatmen
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Therapy, C | 1997 |
Neoadjuvant hormonal therapy: the Canadian experience.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Canada; Chemotherapy, Adjuvant; Drug Therapy, Combinatio | 1997 |
Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug In | 1996 |
Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Black People; Flutamide; Humans; Male; Middle Aged; Prostate- | 1997 |
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M | 1997 |
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Fl | 1997 |
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
[Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Follow- | 1997 |
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant | 1997 |
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Flutamide; H | 1997 |
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Flushing; | 1997 |
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Belgium; Carcinom | 1997 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 1998 |
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1998 |
Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Disease Pr | 1998 |
European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Androgen Antagonists; Antineoplastic Age | 1998 |
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant | 1998 |
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modal | 1998 |
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cross-Section | 1998 |
Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Finasteride; Flutamide; Gonadotropin-Releasing Hormon | 1998 |
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Neop | 1999 |
Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Anxiety; Depression; Flutamide; Humans; Male; | 1999 |
Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cyproterone Acetate; | 1999 |
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antin | 1999 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agent | 1999 |
[Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Anti | 1999 |
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up Studies; Humans; Leupr | 1999 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; An | 1999 |
Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
Topics: Aged; Androgen Antagonists; Cyproterone; Erectile Dysfunction; Flutamide; Humans; Male; Middle Aged; | 2000 |
Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Nucleus; Cohort Studies; Cytoplasm; Flut | 1999 |
Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Di | 2000 |
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Dru | 2000 |
Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 2000 |
[Endocrine therapy of stage D2 prostate cancer--comparison of drugs used for total androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Chlormad | 2000 |
A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Goserelin | 2000 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease | 2000 |
Comparative study of the clinical efficacy of two dosing regimens of flutamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Health Care Costs; Humans; Male | 2000 |
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2000 |
A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; | 2000 |
4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Europe; Flutamide; F | 2000 |
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Disease Progression; Europe; Flutamide; | 2001 |
Lack of methemoglobinemia with flutamide.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Methemoglobin; Methemoglobinemia; Mi | 2001 |
[Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
Topics: Adrenocorticotropic Hormone; Aged; Androgens; Depression, Chemical; Diethylstilbestrol; Drug Therapy | 2001 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Horm | 2001 |
Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2001 |
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Middle A | 2001 |
Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Estradiol; Estradiol Congeners; Flutamide; Ho | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.
Topics: Adenoviridae; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Genetic Therapy; | 2001 |
Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Delayed-Actio | 2001 |
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
Topics: Androgen Antagonists; Antigen-Presenting Cells; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2001 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Follow-Up | 2002 |
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Cr | 2001 |
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Flutamide therapy for carcinoma of the prostate.
Topics: Aged; Anilides; Clinical Trials as Topic; Diethylstilbestrol; Double-Blind Method; Drug Therapy, Com | 1978 |
Treatment of advanced prostatic cancer with flutamide.
Topics: Adult; Anilides; Clinical Trials as Topic; Diethylstilbestrol; Double-Blind Method; Flutamide; Human | 1979 |
Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer.
Topics: Aged; Anilides; Clinical Trials as Topic; Diethylstilbestrol; Evaluation Studies as Topic; Flutamide | 1976 |
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomark | 1992 |
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Flutamide; Gosere | 1992 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
[Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer].
Topics: Drug Evaluation; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1992 |
Controversies in the treatment of metastatic prostate cancer.
Topics: Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neoplasm Metast | 1992 |
[The role of LH-RH analogues in the treatment of prostate cancer. Report of a conference organized by ICI-Pharma laboratories (part 2)].
Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Orc | 1991 |
Flutamide in hormone-resistant prostatic cancer.
Topics: Acid Phosphatase; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Drug Evaluation; Flutamide; Humans; M | 1990 |
A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug E | 1992 |
Total androgen ablation: European experience. The EORTC GU Group.
Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; | 1991 |
Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate.
Topics: Aged; Buserelin; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Hu | 1991 |
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Prep | 1991 |
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Stu | 1991 |
[Clinical studies of the therapeutic effect of Flucinom in prostatic cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Humans; Male; Mid | 1991 |
The treatment of advanced prostatic carcinoma with total androgenic blockade using bilateral orchidectomy and flutamide: experience at the National Cancer Institute in Mexico.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Male; Mexic | 1991 |
Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Epirubicin; Fl | 1991 |
National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug Tolerance; Flutamide; Gona | 1991 |
Luteinizing hormone releasing hormone agonists: the US experience.
Topics: Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method | 1990 |
Leuprolide with and without flutamide in advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black People; Double | 1990 |
Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Topics: Aged; Anilides; Antineoplastic Agents; Double-Blind Method; Drug Therapy, Combination; Flutamide; Go | 1990 |
Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Evaluati | 1990 |
Combination studies with leuprolide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Double-Blind Method; Flutamide; Gonadotrop | 1990 |
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Stud | 1990 |
Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; | 1990 |
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Gosereli | 1990 |
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Follo | 1990 |
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchi | 1990 |
Complete androgen blockade: data from an EORTC 30853 trial.
Topics: Aged; Anilides; Buserelin; Combined Modality Therapy; Europe; Flutamide; Goserelin; Humans; Male; Mi | 1990 |
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone | 1990 |
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy | 1990 |
Antiandrogens: clinical applications.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic | 1990 |
Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidaz | 1990 |
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Drug Combinations; Drug Evaluation; | 1990 |
[How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
Topics: Buserelin; Clinical Trials as Topic; Flutamide; Goserelin; Humans; Job Description; Male; Nursing St | 1990 |
A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Buserelin; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1990 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busereli | 1990 |
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modalit | 1990 |
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Double-Blind Met | 1990 |
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-U | 1990 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Canada; Flutamide; H | 1990 |
Flutamide for prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flutamide; Gonad | 1989 |
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Met | 1989 |
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Met | 1989 |
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Met | 1989 |
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Met | 1989 |
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
Topics: Anilides; Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Multicent | 1989 |
'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Topics: Aged; Anilides; Buserelin; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Goserelin | 1989 |
Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Buserelin; Clinical Trials as Topic; Cyproterone; Cyp | 1989 |
The use of flutamide as monotherapy in the treatment of advanced prostate cancer.
Topics: Anilides; Clinical Trials as Topic; Drug Evaluation; Flutamide; Humans; Male; Prostatic Neoplasms | 1989 |
Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
Topics: Adenocarcinoma; Anilides; Canada; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Hu | 1989 |
Antiandrogens alone or in combination for treatment of prostate cancer: the European experience.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eur | 1989 |
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
Topics: Anilides; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Multicenter Studies as | 1989 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyp | 1988 |
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
Topics: Acid Phosphatase; Anilides; Bone and Bones; Bone Neoplasms; Dehydroepiandrosterone; Dehydroepiandros | 1985 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Quality of life assessment in prostatic cancer.
Topics: Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prosta | 1988 |
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Topics: Androgen Antagonists; Androgens; Buserelin; Flutamide; Goserelin; Humans; Male; Multicenter Studies | 1988 |
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Mal | 1988 |
[Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
Topics: Aged; Aged, 80 and over; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Estramustine | 1988 |
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Combined Modality | 1986 |
Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Bone Neoplasms; Estramustine; Flutamide; Follow-Up Studies; Humans; | 1988 |
Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.
Topics: Aged; Aged, 80 and over; Anilides; Clinical Trials as Topic; Diethylstilbestrol; Flutamide; Humans; | 1988 |
Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
Topics: Anilides; Carcinoma; Clinical Trials as Topic; Estramustine; Flutamide; Hematologic Diseases; Humans | 1988 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Topics: Aged; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasi | 1988 |
Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Estramustine; Flutamide; Humans; | 1987 |
577 other studies available for flutamide and Cancer of Prostate
| Article | Year |
|---|---|
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
Topics: Androgen Antagonists; Doxorubicin; Formaldehyde; Green Fluorescent Proteins; Humans; Imidazoles; Lig | 2004 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; | 2005 |
4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Humans; Male; Mutation; Prost | 2008 |
Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.
Topics: Administration, Oral; Androgen Receptor Antagonists; Androgens; Animals; Azabicyclo Compounds; Dogs; | 2009 |
Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Boranes; Cell | 2010 |
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Prol | 2010 |
Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Blood-Brain Barrier; Drug Design; Drug Screeni | 2011 |
Aldol derivatives of Thioxoimidazolidinones as potential anti-prostate cancer agents.
Topics: Aldehydes; Androgen Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cr | 2011 |
Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Curcumin; Dr | 2012 |
Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
Topics: Androgens; Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemis | 2016 |
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2023 |
Intracellular distribution of vinclozolin and its metabolites differently affects 5α-dihydrotestosterone (DHT)-induced PSA secretion in LNCaP cells.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; Dihydrotestosterone; Flutamide; Humans; Male; Oxa | 2022 |
Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.
Topics: Androgen Antagonists; Anilides; Chemical and Drug Induced Liver Injury, Chronic; Flutamide; Humans; | 2023 |
Follow up of the prostate cancer treatment based on a novel sensing method for anti-prostate cancer drug (flutamide).
Topics: Antineoplastic Agents; Carbon; Flutamide; Follow-Up Studies; Humans; Male; Prostatic Neoplasms; Repr | 2023 |
The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.
Topics: Cell Line, Tumor; Docetaxel; Flutamide; Humans; Male; Polysaccharides; Prostate; Prostatic Neoplasms | 2023 |
Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.
Topics: Androgen Antagonists; Cell Line, Tumor; Down-Regulation; Flutamide; Humans; Male; Prostatic Neoplasm | 2023 |
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostat | 2019 |
Papain Mediated Synthesized Gold Nanoparticles Encore the Potency of Bioconjugated Flutamide.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Nucleus; Drug Carriers; Drug Delivery System | 2021 |
Folate-Targeted Polyacrylamide/Punicic Acid Nanomicelles for Flutamide Delivery in Prostate Cancer: Characterization, In Vitro Biological Evaluation, and its DFT Study.
Topics: Acrylic Resins; Cell Death; Cell Line, Tumor; Density Functional Theory; Drug Delivery Systems; Fluo | 2020 |
Polyacrylamide-punicic acid conjugate-based micelles for flutamide delivery in PC3 cells of prostate cancer: synthesis, characterisation and cytotoxicity studies.
Topics: Acrylic Resins; Antineoplastic Agents; Cell Survival; Drug Carriers; Flutamide; Humans; Linolenic Ac | 2020 |
Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Topics: Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Cell Proliferation; Coumarins; Flutamide | 2020 |
Haemolytic anaemia induced by flutamide: a case report.
Topics: Aged, 80 and over; Anemia, Hemolytic; Flutamide; Humans; Male; Prostatic Neoplasms | 2023 |
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.
Topics: Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Flu | 2017 |
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Arrhythmias, Cardiac; Califor | 2017 |
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Topics: Affect; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Brain; Cognition | 2018 |
Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, CD34; Antineoplastic Agents | 2018 |
Elaboration of polymersomes versus conventional liposomes for improving oral bioavailability of the anticancer flutamide.
Topics: Animals; Antineoplastic Agents, Hormonal; Biological Availability; Drug Carriers; Drug Compounding; | 2018 |
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Anilides; Antineoplastic Agents, Hor | 2019 |
Extreme Elevation of the Prothrombin Time-International Normalized Ratio due to a Probable Interaction between Warfarin and Flutamide.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Factors | 2019 |
Choice of first-line treatment for metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Estrogens; Flutamide; Goserel | 2013 |
Enhanced delivery system of flutamide loaded chitosan-dextran sulphate nanoparticles for prostate cancer.
Topics: Animals; Cell Death; Cell Line, Tumor; Chitosan; Dextrans; Drug Delivery Systems; Flutamide; Humans; | 2013 |
Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model.
Topics: Androgens; Animals; Antineoplastic Agents, Hormonal; Caseins; Delayed-Action Preparations; Drug Carr | 2013 |
Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Caseins; Caspase 3; Cross-Linking Reagents; Del | 2013 |
Aberrant expression of the PRAC gene in prostate cancer.
Topics: Androgen Antagonists; Androgens; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Ce | 2013 |
[Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Drug Administration | 2014 |
Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Topics: Androgen Antagonists; Androgens; Apoptosis; Carboxypeptidases; Cell Line, Tumor; Flutamide; Humans; | 2014 |
Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chromogranin A; Flutamide; Humans; Male; M | 2014 |
Gene microarray assessment of multiple genes and signal pathways involved in androgen-dependent prostate cancer becoming androgen independent.
Topics: Androgen Antagonists; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Flutamide; Ge | 2014 |
Effect of androgen suppression on bone mineral density in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone D | 2014 |
Preparation and in vitro-in vivo evaluation of surface-modified poly(lactide-co-glycolide) nanoparticles as controlled release carriers for flutamide delivery.
Topics: Androgen Antagonists; Animals; Delayed-Action Preparations; Drug Delivery Systems; Flutamide; Humans | 2015 |
Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury.
Topics: Aged; Alanine Transaminase; Androgen Antagonists; Animals; Antineoplastic Agents; Chemical and Drug | 2015 |
Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
Topics: Androgen Antagonists; beta Catenin; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Fluta | 2015 |
Flutamide-induced photoleukomelanoderma.
Topics: Administration, Cutaneous; Aged; Androgen Antagonists; Benzimidazoles; Biopsy; Biphenyl Compounds; B | 2016 |
Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.
Topics: Androgen Antagonists; Cell Line, Tumor; Computer Simulation; Flutamide; Humans; Hydrogen Bonding; Ma | 2016 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimi | 2017 |
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Flutamide | 2016 |
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamid | 2016 |
High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Ch | 2016 |
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; D | 2016 |
Assessment of Poly (vinyl alcohol) Coated Flutamide Nanoparticulates and their Efficacy on Prostate Cancer Cells.
Topics: Alcohols; Cell Line, Tumor; Drug Carriers; Drug Liberation; Flutamide; Humans; Male; Nanoparticles; | 2017 |
Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Topics: Androgen Antagonists; Antigens, CD; beta Catenin; Cadherins; Cell Line, Tumor; Flutamide; Humans; Ma | 2017 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gas | 2009 |
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flu | 2008 |
PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; K | 2008 |
Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Bindi | 2008 |
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bio | 2008 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; | 2008 |
Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dose-Response Relationship, Drug; | 2009 |
Synthesis and characterization of nonsteroidal-linked M(CO)(3)+ (M = 99mTc, Re) compounds based on the androgen receptor targeting molecule flutamide.
Topics: Drug Stability; Flutamide; Humans; Male; Organotechnetium Compounds; Prostatic Neoplasms; Radiopharm | 2009 |
Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Brachytherapy; Flutamide; Humans; | 2009 |
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Brach | 2009 |
Long-term follow-up after triple treatment of prostate cancer stage pT3.
Topics: Adult; Aged; Androgen Antagonists; Combined Modality Therapy; Disease Progression; Flutamide; Follow | 2009 |
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Topics: Amino Acid Substitution; Anilides; Antineoplastic Agents; Autopsy; Cycloheximide; DNA Primers; Fluta | 2009 |
Suppression of mutant androgen receptors by flutamide.
Topics: Androgen Antagonists; Androgens; Binding, Competitive; Cell Line, Tumor; Dihydrotestosterone; Flutam | 2009 |
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Cyproterone; Flutamide; Humans; Ki | 2009 |
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Topics: Androgen Antagonists; Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Estradiol; Estrogens; F | 2009 |
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Topics: Administration, Oral; Androgen Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents, Hor | 2010 |
Addressing bone loss in the cancer survivor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density; Female; Flutamide; Huma | 2009 |
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotes | 2010 |
"Click" labeling strategy for M(CO)(3) (M = Re, (99m)Tc) prostate cancer targeted flutamide agents.
Topics: Crystallography, X-Ray; Flutamide; Humans; Isotope Labeling; Male; Molecular Conformation; Prostatic | 2010 |
Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Topics: Adenocarcinoma; Adrenal Glands; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Cell Line, | 2010 |
Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.
Topics: Androgen Antagonists; Androgens; Azacitidine; Blotting, Western; CpG Islands; Decitabine; Dihydrotes | 2010 |
Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: the jury must remain out.
Topics: Androgen Antagonists; Clinical Trials as Topic; Flutamide; Gonadotropin-Releasing Hormone; Humans; M | 2010 |
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Carcinoma; Epigenesis, Genetic; Flutamide; Gene Expre | 2010 |
Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Topics: Aged; Androgens; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Flutamide; Goserelin; Hum | 2010 |
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Ther | 2010 |
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadin | 2010 |
Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; | 2010 |
[Spontaneous complete remission in two patients with chronic lymphocytic leukemia].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Flutamide; Human | 2011 |
The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgens; Aniline Compounds; Breast Neoplasms | 2011 |
Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biological Availability; Drug Compounding; Dr | 2011 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E | 2011 |
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Aged, 80 and over; Arachidonic Acid; Aryl Hydr | 2011 |
Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Topics: Androgen Antagonists; Androgens; Blotting, Western; Cell Line, Tumor; Dihydrotestosterone; Estrogens | 2010 |
Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.
Topics: Androgen Antagonists; Carcinoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Down-Regulation; | 2011 |
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineopla | 2012 |
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; | 2011 |
[Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
Topics: Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Multicenter Studies as Topic; | 2011 |
Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.
Topics: Androgen Antagonists; Drug Resistance, Neoplasm; Flutamide; Gene Expression; Gene Expression Profili | 2011 |
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Orchiectomy; Prostat | 2011 |
[Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Flutamid | 2011 |
Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Base Sequence; Cell Line, Tumor; DNA Primers; | 2011 |
A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Topics: Androgen Antagonists; Animals; Binding, Competitive; Carbamates; Cell Line, Tumor; Cell Proliferatio | 2011 |
[Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Neopl | 2011 |
Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Topics: Androgen Antagonists; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cycloheximide; Dihydrotestost | 2011 |
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.
Topics: Algorithms; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cells, Cultured; Disease | 2011 |
[Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats].
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Proliferation; Cytokines; Dr | 2011 |
Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Synergism; Flutamide; Human | 2011 |
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Topics: Analysis of Variance; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; | 2012 |
Editorial comment.
Topics: Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Prostatic Neoplasms; Sexuality; Testoster | 2012 |
Intermittent androgen suppression--ready for prime time?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prostati | 2012 |
Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of Flutamide.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Chromatograph | 2012 |
The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prostatic Neop | 2012 |
Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dr | 2012 |
Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.
Topics: Androgen Antagonists; Androgens; Blotting, Western; Dihydrotestosterone; Estrogens; Estrone; Flutami | 2012 |
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Coculture Techniques; Combi | 2013 |
Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; | 2002 |
Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.
Topics: Acute Kidney Injury; Androgen Antagonists; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 2002 |
Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.
Topics: Androgen Antagonists; Androgens; Apoptosis; Cell Division; Cyproterone Acetate; Dihydrotestosterone; | 2002 |
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Androgen Antagonists; Anilides; Antineoplastic Agents, | 2002 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flu | 2002 |
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
Topics: Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Feasibility Studies; Flutamide; Go | 2002 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans | 2002 |
Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Black or African American; Clinical Trials, P | 2003 |
[Expression of androgen receptor protein in hormone refractory prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Follow-Up | 2003 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; C | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides | 2002 |
Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Dose-Respons | 2003 |
Flutamide-induced photosensitivity: is it a forme fruste of lupus?
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Lupu | 2003 |
Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Diethylstilbestr | 2003 |
Flutamide-induced hepatotoxicity with possible potentiation by simvastatin.
Topics: Aged; Chemical and Drug Induced Liver Injury; Drug Synergism; Flutamide; Humans; Male; Prostatic Neo | 2003 |
[Malignant priapism as a sign of a recurrent prostate cancer. Differential diagnosis of induratio penis plastica].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Dia | 2003 |
[Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Carcinoma, Neuroendocrine; Cell Differentiati | 2003 |
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Calcitriol; Cerulenin; Cycloheximide; Down-Regulation; Enzyme Inhibi | 2003 |
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Topics: Androgens; Blotting, Western; Cell Line, Tumor; Chromones; Culture Media, Conditioned; Dihydrotestos | 2003 |
In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor.
Topics: Androgen Antagonists; Animals; Estradiol; Flutamide; Gonadal Steroid Hormones; Male; Mice; Mice, Nud | 2003 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; | 2003 |
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.
Topics: Animals; Cloning, Molecular; COS Cells; Dihydrotestosterone; Flutamide; Gelsolin; Humans; Male; Mice | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2003 |
Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Flutamide; Humans; Liver; Male; Middle Aged; Prospect | 2003 |
[Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade].
Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Flutamide; Gonadotropin-Releasing Hormone; H | 2003 |
Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Flutamide; Follow-U | 2004 |
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
Topics: Algorithms; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Thera | 2004 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; | 2004 |
Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases.
Topics: Aged; Androgen Antagonists; Flutamide; Gastrointestinal Diseases; Humans; Male; Prostatic Neoplasms | 2004 |
Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Dru | 2004 |
Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Follow-Up | 2004 |
Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chemical and | 2003 |
Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
Topics: Aged; Androgen Antagonists; Drug Therapy, Combination; Fatal Outcome; Flutamide; Goserelin; Hepatic | 2004 |
Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bilirubin; Biomarkers, | 2003 |
Biochemical remission after resection of prostate cancer lung metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; | 2004 |
Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Topics: Active Transport, Cell Nucleus; Base Sequence; Cell Division; Cell Line, Tumor; Drug Interactions; F | 2004 |
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
Topics: Adenocarcinoma; Androgen Antagonists; Apoptosis; Cell Division; Cell Survival; Cysteine Proteinase I | 2004 |
Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Orchie | 2004 |
The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Estrogens, Non-Steroidal; | 2004 |
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
Topics: Amino Acid Sequence; Androgen Antagonists; Animals; Blotting, Western; Cell Nucleus; Chlorocebus aet | 2004 |
Flutamide or thalidomide?
Topics: Communication; Flutamide; Humans; Male; Medication Errors; Prostatic Neoplasms; Thalidomide | 2004 |
Is photopatch testing useful in the investigation of photosensitivity due to flutamide?
Topics: Androgen Antagonists; Dermatitis, Photoallergic; Diagnosis, Differential; Drug Eruptions; Flutamide; | 2004 |
Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locall
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Prospective Stu | 2004 |
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
Topics: Aged; Alcohol Drinking; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Comorbidity | 2004 |
Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Cognition; | 2004 |
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; C | 2004 |
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
Topics: Antibiotics, Antineoplastic; Cell Division; Cell Line, Tumor; Chromones; Drug Interactions; Flutamid | 2004 |
Interstitial pneumonitis related to flutamide monotherapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Humans; Lung Di | 2004 |
Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; Enzyme Induction; Flutamide; Gene Expression Regu | 2004 |
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Topics: Adenosine Triphosphate; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Cell N | 2004 |
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Calcitriol; Cycloheximide; Cytochrome P-450 Enzy | 2005 |
Anemia in patients on combined androgen block therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Combined Modal | 2004 |
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Flutamide; Humans; Leupro | 2004 |
Reversibility of androgen deprivation therapy in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Gonadotro | 2005 |
[Neoadjuvant hormonal therapy for prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Gonadotro | 2005 |
[Experience with therapy of prostate cancer in the Primorye Territory].
Topics: Acetates; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; | 2004 |
Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Apoptosis; Cell Survival; Drug Resistance, Ne | 2005 |
Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system.
Topics: Androgen Antagonists; Androgens; Anemia; Animals; Cyproterone Acetate; Erythropoietin; Flutamide; He | 2005 |
[High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Foll | 2005 |
Castration reduces platelet thromboxane A2 receptor density and aggregability.
Topics: Aged; Androgen Antagonists; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Castrati | 2005 |
Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line, Tumor; Down-Regulation; Flutamid | 2005 |
An index of local sensitivity to nonignorable drop-out in longitudinal modelling.
Topics: Animal Feed; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Hormonal; Cattle; Coc | 2005 |
An index of local sensitivity to nonignorable drop-out in longitudinal modelling.
Topics: Animal Feed; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Hormonal; Cattle; Coc | 2005 |
An index of local sensitivity to nonignorable drop-out in longitudinal modelling.
Topics: Animal Feed; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Hormonal; Cattle; Coc | 2005 |
An index of local sensitivity to nonignorable drop-out in longitudinal modelling.
Topics: Animal Feed; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Hormonal; Cattle; Coc | 2005 |
Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brachytherapy; Cohort Studie | 2005 |
[Toxic hepatitis after flutamide treatment].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carrier State; Chemical and Drug Induce | 2005 |
Coagulopathy, following medical therapy, for carcinoma of the prostate.
Topics: Aged; Blood Coagulation Disorders; Disseminated Intravascular Coagulation; Drug Therapy, Combination | 2005 |
Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives.
Topics: Androgen Antagonists; Fluorine Radioisotopes; Flutamide; Humans; Male; Prostatic Neoplasms; Radionuc | 2005 |
Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Gastrointestinal Diseases; Goserelin; Hu | 2005 |
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.
Topics: Androgen Antagonists; Androgens; Animals; Arsenic; Cell Line; Cell Proliferation; Cell Transformatio | 2005 |
Antiandrogens prevent stable DNA-binding of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Carcino | 2005 |
Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined M | 2005 |
[Experience in treating advanced prostate cancer with bladder outlet obstruction].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, Neoplasm; Flutamide; Humans | 2005 |
Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Cost-Benefit Analysis; Drug Therapy, Combinat | 2005 |
Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model.
Topics: Adenoviridae; Androgens; Animals; Antineoplastic Agents, Hormonal; Binding Sites; Chromatin Immunopr | 2005 |
Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Cell Cycle; Cell Line, Tumor; Cyclin | 2005 |
[Long term survival results in advanced prostate cancer treated with combined androgen blockade].
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Male; M | 2005 |
Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Prostatic Neoplasms; | 2005 |
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Co | 2006 |
The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Apoptosis; Biopsy; Chi-Square Distribution; Combined | 2006 |
Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Animals; Chlorocebus aethiops; COS Cells; Flutamide; Genes, Reporter; Humans; | 2006 |
Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chromatography, High Pressure Liquid; Cytochr | 2006 |
[Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line].
Topics: Androgens; Cell Line, Tumor; Dihydrotestosterone; Flutamide; Humans; Male; Neoplasms, Hormone-Depend | 2006 |
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Longitudinal Studies; Male; Middle Aged; | 2006 |
Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; DNA Mutational Analysis; Drug Stability; Electrop | 2006 |
Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice.
Topics: Alanine Transaminase; Amino Acids; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; C | 2006 |
The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Gonadotropin-Releasing Hormone; | 2006 |
Chiral dimethylamine flutamide derivatives--modeling, synthesis, androgen receptor affinities and carbon-11 labeling.
Topics: Carbon Radioisotopes; Flutamide; Humans; Isotope Labeling; Male; Models, Molecular; Positron-Emissio | 2006 |
Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Dose Fractionation, Radiation; Flutamid | 2006 |
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Cohort Studies; Flutamide; Humans; Male; Middle Aged; Neoplasm | 2006 |
Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Biomarkers, Tumor; Cohort Studies; Drug Therapy, Combina | 2006 |
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Gene Expression | 2006 |
Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
Topics: Androgen Antagonists; Androgens; Cadmium; Cell Line, Transformed; Cell Proliferation; Cell Transform | 2007 |
[Bone metastasis of prostatic cancer imitating Paget's sarcoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neopla | 2006 |
[Histological investigation of prostate cancer treated with hormonal agents].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; H | 2006 |
Androgen decreases osteoprotegerin expression in prostate cancer cells.
Topics: 5-alpha-Dihydroprogesterone; Androgens; Cell Line, Tumor; Flutamide; Gene Expression; Humans; Male; | 2007 |
Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Topics: Androgens; Anilides; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Resistance, Neoplas | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone | 2007 |
Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy, Needle; Drug Resistan | 2007 |
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor | 2007 |
Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Biomarkers, Tumor; Cell Line, Tumor | 2007 |
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Dihyd | 2007 |
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavi | 2008 |
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers, Tumor; Dihydrotestosterone; Disease Progr | 2007 |
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.
Topics: Adenosine Triphosphate; Androgen Antagonists; Animals; Cell Line, Tumor; Cell Survival; Dose-Respons | 2007 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2007 |
Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Androgen Antagonists; Antineoplastic A | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2007 |
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Moda | 2007 |
Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo.
Topics: Androgens; Animals; Cell Line, Tumor; Dihydrotestosterone; DNA Adducts; DNA Damage; Flutamide; Human | 2008 |
Aspirin and hormone therapy for prostate cancer.
Topics: Androgen Antagonists; Aspirin; Atorvastatin; Drug Therapy, Combination; Flutamide; Gonadotropin-Rele | 2007 |
Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Topics: Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Flutamide; Goserelin; Humans; Male; Prosta | 2008 |
Editorial comment on: continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study.
Topics: Aged; Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neopl | 2008 |
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2008 |
Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells.
Topics: Androgen Antagonists; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Homeod | 2008 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonad | 1984 |
A pilot study of flutamide. A new agent in the treatment of advanced prostatic cancer.
Topics: Anilides; Drug Evaluation; Flutamide; Humans; Male; Pilot Projects; Prostatic Neoplasms | 1984 |
Flutamide in the treatment of metastatic carcinoma of the prostate.
Topics: Aged; Anilides; Bone Neoplasms; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 1981 |
Further studies on the effects of flutamide on cortisol metabolism.
Topics: Aged; Anilides; Flutamide; Humans; Hydrocortisone; Male; Middle Aged; Prostatic Neoplasms | 1980 |
Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Topics: Acid Phosphatase; Adenocarcinoma; Animals; Castration; Diethylstilbestrol; Disease Models, Animal; F | 1980 |
Anti-androgens in treatment of prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cyproterone; Flutamide; Humans | 1995 |
Anti-androgens in treatment of prostate cancer.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1995 |
Flutamide hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 1996 |
Prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Chemotherapy, Adjuvant; Flutamide; Humans; Male; Obesit | 1996 |
The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Human | 1995 |
Survey shows M.D.s' ambivalence about maximum androgen blockade.
Topics: Androgen Antagonists; Clinical Trials as Topic; Flutamide; Humans; Male; Prostatic Neoplasms | 1995 |
Adenocarcinoma of the prostate metastatic to the choroid of the eye.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Choroid Neoplasms; Flutamide; Humans; Leuprol | 1995 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1995 |
Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.
Topics: Aged; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Flutamide; Humans; Luteinizing H | 1993 |
Neoadjuvant hormonal deprivation before radical prostatectomy.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormon | 1993 |
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Flutamid | 1994 |
Neoadjuvant hormonal deprivation before radical prostatectomy.
Topics: Aged; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Age | 1993 |
Massive locally extensive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Constipation; Flutamide; Humans; Leuprolide; Male; | 1994 |
Diagnosis of low back pain, secondary to prostate metastasis to the lumbar spine, by digital rectal examination and serum prostate-specific antigen.
Topics: Adenocarcinoma; Aged; Back Pain; Flutamide; Humans; Lumbar Vertebrae; Male; Orchiectomy; Postoperati | 1994 |
Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bo | 1994 |
Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer.
Topics: Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Stag | 1994 |
Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
Topics: Aged; Chemotherapy, Adjuvant; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle | 1994 |
Neoadjuvant hormonal deprivation before radical prostatectomy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 1993 |
Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma in Situ; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1994 |
Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Cy | 1994 |
Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chromogranin A; Chromogranins; Estra | 1994 |
Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
Topics: Adenocarcinoma; Adult; Aged; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1995 |
Clinical trials referral resource. Prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Comb | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor.
Topics: Androgen Antagonists; Base Sequence; Breast Neoplasms; Cell Division; Cell Line; Cell Nucleus; Cytos | 1995 |
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas | 1995 |
Practice trends in the diagnosis and management of prostate cancer in the United States.
Topics: Adult; Aged; Cystoscopy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Staging; | 1995 |
Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Flutamid | 1995 |
Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.
Topics: Amino Acid Sequence; Androgen Antagonists; Animals; Base Sequence; Binding Sites; Flutamide; Haplorh | 1995 |
American studies on suramin therapy in hormone resistant prostate cancer.
Topics: Drug Resistance; Flutamide; Humans; Male; Prostatic Neoplasms; Suramin | 1995 |
Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells.
Topics: Androgen Antagonists; Cadherins; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Flutamide; Fu | 1995 |
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Topics: Aged; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Orchiectomy; Prostate-Sp | 1993 |
Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; H | 1993 |
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Diethylstilbestrol; Flutamide; Hormones; Humans; Male; Middle Aged; Orchiec | 1993 |
Fatal and nonfatal hepatotoxicity associated with flutamide.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera | 1993 |
Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation.
Topics: Aged; Aged, 80 and over; Diethylstilbestrol; Estrogens, Conjugated (USP); Flutamide; Hematuria; Huma | 1993 |
Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Flutamide; Humans; Injections, Intramuscular; | 1993 |
Influence of transrectal hyperthermia on prostate-specific antigen in prostatic cancer and benign prostatic hyperplasia.
Topics: Aged; Combined Modality Therapy; Epirubicin; Flutamide; Humans; Hyperthermia, Induced; Male; Prostat | 1993 |
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Topics: Aged; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate | 1993 |
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.
Topics: Adenocarcinoma; Combined Modality Therapy; Flutamide; Humans; Male; Neoplasm Staging; Prostate-Speci | 1993 |
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
Topics: Aged; Cost-Benefit Analysis; Flutamide; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pros | 1995 |
Methemoglobinemia in a patient receiving flutamide.
Topics: Aged; Cardiopulmonary Bypass; Flutamide; Humans; Male; Methemoglobinemia; Prostatic Neoplasms | 1995 |
Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.
Topics: Androgen Antagonists; Blotting, Northern; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; | 1995 |
[New approaches in the treatment of prostatic cancer].
Topics: Chemotherapy, Adjuvant; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1994 |
[Bilateral testicular metastasis of an adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Orchiectom | 1994 |
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relatio | 1995 |
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Flutamide; Humans; Leupro | 1995 |
Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Flutamide; Humans; Male; Pr | 1995 |
Prostate cancer.
Topics: Adult; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplas | 1994 |
Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Ho | 1993 |
[Fluamide withdrawal syndrome].
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Male; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1994 |
Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Diethylstilbestrol; Flutamide; Humans; Leuprolide; Mal | 1994 |
Response of carcinoma of the prostate to withdrawal of flutamide.
Topics: Flutamide; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen | 1994 |
Fulminant hepatitis after flutamide treatment.
Topics: Acute Disease; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Flutamide; Humans; I | 1994 |
[Clinical significance of the local response to prostatic carcinoma during hormonotherapy].
Topics: Actuarial Analysis; Combined Modality Therapy; Drug Therapy, Combination; Flutamide; Follow-Up Studi | 1993 |
Advanced prostatic carcinoma in a 19-year-old male.
Topics: Adult; Carcinoma; Combined Modality Therapy; Flutamide; Humans; Interferon alpha-2; Interferon-alpha | 1994 |
[Attempt at using chemoluminescence in modern diagnosis and monitoring of therapy in prostatic cancer].
Topics: Biomarkers, Tumor; Flutamide; Humans; Luminescent Measurements; Male; Monitoring, Physiologic; Prost | 1993 |
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Th | 1994 |
Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.
Topics: Androgen Antagonists; Androgens; Cell Cycle; Cell Division; Dihydrotestosterone; Drug Resistance; Fl | 1994 |
Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.
Topics: Cell Differentiation; Clinical Competence; Delphi Technique; Flutamide; Humans; Leuprolide; Luteiniz | 1994 |
[Hepatotoxicity and flutamide].
Topics: Aged; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Male; Prostatic Neoplasms | 1993 |
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 1994 |
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Topics: Amino Acid Sequence; Androgen Antagonists; Binding, Competitive; Blotting, Western; Chloramphenicol | 1994 |
Effect of early exposure of flutamide on subsequent growth of transplantable rat prostatic tumor (dunning R-3327).
Topics: Animals; Cell Division; Dihydrotestosterone; Estradiol; Female; Flutamide; Male; Neoplasm Transplant | 1994 |
Severe reversible neutropenia following treatment of prostate cancer with flutamide.
Topics: Aged; Flutamide; Humans; Male; Neutropenia; Prostatic Neoplasms | 1994 |
Acute cholestatic hepatitis secondary to flutamide therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cholestasis; Flutami | 1994 |
[Objective and subjective response in stage D2 prostate cancer patients with cancer pain].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diethylstilbestrol; Flutamide; Follow-Up Studies; Humans; M | 1994 |
Malignant pleural effusion from prostatic adenocarcinoma resolved with hormonal therapy.
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Leuprolide; Male; Pleural Effusion, Malignant; Pleural Neop | 1994 |
Cost-effectiveness of prostate cancer screening and treatment.
Topics: Androgen Antagonists; Drug Costs; Flutamide; Humans; Male; Prostatic Neoplasms; United States | 1993 |
Temporary prostatic stenting and androgen suppression: a new minimally invasive approach to malignant prostatic retention.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Humans; Male; Prostatic Neoplasms; St | 1993 |
Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer.
Topics: Adrenal Glands; Androgen Antagonists; Androgens; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1993 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Wes | 1993 |
Advanced prostate cancer. The role of high priced hormone therapy.
Topics: Combined Modality Therapy; Cyproterone Acetate; Diagnosis-Related Groups; Drug Costs; Drug Therapy, | 1993 |
Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1993 |
Cholestatic hepatitis following flutamide.
Topics: Adenocarcinoma; Aged; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Flutamide; | 1993 |
Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome.
Topics: Adenocarcinoma; Aged; Biopsy; Flutamide; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Prostatic | 1993 |
What is the correct hormonal treatment for prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releas | 1993 |
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Thera | 1995 |
Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Flutamide-induced liver toxicity including fatal hepatic necrosis.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Live | 1996 |
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Topics: Adenocarcinoma; Androgen Antagonists; Drug Therapy, Combination; Epithelial Cells; Epithelium; Fluta | 1996 |
The use of a removable stent in patients with prostate cancer and obstruction.
Topics: Aged; Antineoplastic Agents, Hormonal; Catheters, Indwelling; Equipment Design; Flutamide; Follow-Up | 1996 |
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Moda | 1995 |
Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma.
Topics: Androgen Antagonists; Animals; Cyproterone Acetate; Flutamide; Male; Neoplasm Proteins; Neoplasms, H | 1996 |
Estimating the cost-effectiveness of flutamide in metastatic cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cost-Benefit Analysis; Flutamide; Human | 1996 |
RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 1996 |
RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 1996 |
Therapeutic options in patients with hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Recep | 1996 |
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
Topics: Amino Acid Sequence; Base Sequence; Blotting, Northern; Cell Line; Chloramphenicol O-Acetyltransfera | 1996 |
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Cost-Benefit Analysis; Disease Pro | 1996 |
Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Foll | 1996 |
[Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Huma | 1996 |
Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormo | 1996 |
Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Apolipoprotein A-I; Body Mass Index; Chole | 1996 |
Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as To | 1996 |
New molecules and treatment modulation in advanced prostatic cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Flutamide; H | 1996 |
Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy.
Topics: Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; | 1996 |
[Fulminant hepatitis caused by flutamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Fatal | 1996 |
Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Follow- | 1996 |
Large Shionogi tumors lose their responsiveness to flutamide treatment.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Division; Flutamide; Humans; Male; Mice; N | 1996 |
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Topics: Aged; Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Resistance, Neo | 1996 |
Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 1996 |
Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression.
Topics: Androgen Antagonists; Androgens; Base Sequence; Blotting, Northern; Cell Division; Dihydrotestostero | 1996 |
Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Case-Control Studies; Chemotherapy, Adjuvant; Flutamide; | 1996 |
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cl | 1997 |
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Finas | 1996 |
[Hepatoxicity caused by flutamide increased by hypotensive situation?].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; | 1996 |
Health-related quality of life among patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Combined Chemothera | 1997 |
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Humans; Male; Midd | 1997 |
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstenedione; Animals; Antineoplastic Agents, Hormo | 1997 |
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progressio | 1997 |
The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Male; | 1997 |
Antiandrogen monotherapy in the management of advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Imidazoles; Imid | 1997 |
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Topics: Androgen Antagonists; Animals; Chromosome Mapping; Dehydroepiandrosterone; Epithelium; Estradiol; Fl | 1997 |
Flutamide photosensitivity.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Male; Photosensitivity Disorders; Prostatic Neoplasms | 1996 |
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Nitri | 1997 |
Hydroxyflutamide may not always be a pure antiandrogen.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Nuclear Receptor Coactivators; Oncogene Proteins; Pro | 1997 |
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Neoplasms, Hormone-D | 1997 |
[Total androgen blockade for prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hor | 1997 |
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic Agents, Hormona | 1997 |
Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
Topics: Alanine Transaminase; Androgen Antagonists; Anilides; Antineoplastic Agents; Flutamide; Humans; Male | 1997 |
Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 1997 |
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cell Differentiation; Dise | 1997 |
Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 1997 |
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.
Topics: Age Factors; Aged; Anemia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Fl | 1997 |
Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Flutamide; Humans; | 1997 |
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Topics: Androgen Antagonists; Anilides; Bucladesine; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclic | 1997 |
Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Subst | 1997 |
Estimated potency of Casodex: a problematic design.
Topics: Androgen Antagonists; Anilides; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compou | 1997 |
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; | 1997 |
Acute renal failure in a patient receiving treatment with suramin.
Topics: Acute Kidney Injury; Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic | 1997 |
[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Flutamide; Human | 1997 |
Finasteride plus flutamide for prostatic carcinoma.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Finasteride | 1997 |
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagno | 1997 |
Flutamide plus castration in patients with previously untreated prostate cancer.
Topics: Androgen Antagonists; Castration; Flutamide; Humans; Male; Prostatic Neoplasms | 1997 |
[Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; | 1997 |
The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease Progression; Disease-Free Survival; Flutamide | 1997 |
[Hepatotoxicity of flutamide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biopsy; Chemical and Drug Induced Liver In | 1997 |
Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Topics: Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Case-Control Studies; C | 1997 |
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agent | 1998 |
Tamoxifen for flutamide/finasteride-induced gynecomastia.
Topics: Aged; Androgen Antagonists; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol | 1997 |
Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 1997 |
Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Amyloidosis; Androgen Antagonists; Antineoplastic Agents, Hormonal; beta 2-Mic | 1997 |
[The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Orchiec | 1997 |
Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Prog | 1998 |
[Fulminant hepatitis associated with treatment with flutamide].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug In | 1997 |
Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Female; Flutamide; Huma | 1998 |
Flutamide photosensitivity--residual vitiliginous lesions.
Topics: Aged; Androgen Antagonists; Dermatitis, Photoallergic; Drug Eruptions; Flutamide; Humans; Male; Pros | 1998 |
Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgens; Blood Chemical Analysis; Bone Neoplasms; C | 1998 |
[Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 1998 |
Flutamide induced lupus.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Lupus Erythematosus, Systemic; Male; | 1998 |
Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Antineoplastic Agent | 1998 |
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brac | 1998 |
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cyproterone Acetate; Drug Interactions; Flutamide; Humans | 1998 |
Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality | 1998 |
Photosensitive drug eruption induced by flutamide.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Carcinoma; Dermatitis, Photoallergic; Diagnos | 1998 |
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
Topics: Androgens; Androstane-3,17-diol; Androstenediol; Anilides; Flutamide; Humans; Male; Mutation; Nitril | 1998 |
Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Hot Flashes; Humans; Leuprolide; | 1998 |
[The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Gonadotro | 1998 |
Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms.
Topics: Acute Disease; Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Chemical and Dr | 1998 |
Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Th | 1998 |
The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Antineoplastic A | 1998 |
Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.
Topics: Aminopyrine N-Demethylase; Androgen Antagonists; Animals; Cell Division; Cells, Cultured; Cytochrome | 1997 |
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Topics: Amino Acid Substitution; Androgen Antagonists; Androgens; Androstenedione; Animals; beta-Galactosida | 1997 |
[Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Flutamide; Humans; Male; Middle Aged; Prostate-Specif | 1998 |
Flutamide-induced liver injury: a case report.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Liver; Male; Prostatic Neoplasms | 1998 |
Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Ne | 1999 |
Interstitial pneumonitis related to leuprorelin acetate and flutamide.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Lung Diseases, Interstitial; M | 1999 |
Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Megestrol Aceta | 1999 |
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Drug Ther | 1993 |
Response of carcinoma of the prostate to withdrawal of flutamide.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Goserel | 1993 |
Bicalutamide versus flutamide in combination therapy.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Nitriles; | 1999 |
Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Cross-Sectional Studies; Flutamide; Humans; M | 1999 |
Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells.
Topics: Androgen Antagonists; Biopsy, Needle; Cell Division; Chemotherapy, Adjuvant; Flutamide; Gonadotropin | 1998 |
Is flutamide effective in patients with bilateral orchiectomy?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Data Interpretatio | 1999 |
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Contraindicat | 1999 |
Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Antigens, Neoplasm; Antineoplastic Agents, Ho | 1999 |
Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; | 1999 |
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Flavon | 1999 |
Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Drug Implants; Drug Therapy, Com | 1999 |
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Base Sequence; Dihydrotestosterone; Estradiol; E | 1999 |
Disclosure statements regarding hormonal treatment of prostate cancer.
Topics: Androgen Antagonists; Conflict of Interest; Flutamide; Humans; Male; Prostatic Neoplasms; Research S | 1999 |
[Flutamide-induced late cutaneous pseudoporphyria].
Topics: Aged; Androgen Antagonists; Biopsy; Diagnosis, Differential; Fluorescent Antibody Technique; Flutami | 1999 |
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Bone Marrow; Bone Marrow Ne | 1999 |
[Fatal hepatic failure following hepatitis caused by flutamide: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Fatal Outcome; | 1999 |
Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)
Topics: Androgen Antagonists; Anilides; Animals; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Tos | 1999 |
[Flutamide and pseudoporphyria].
Topics: Aged; Antineoplastic Agents, Hormonal; Diagnosis, Differential; Drug Eruptions; Flutamide; Humans; M | 1999 |
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 1999 |
Antiandrogen hepatotoxicity in patients with chronic viral hepatitis.
Topics: Aged; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Cyproterone Acetate; Flutamide; | 1999 |
[Risk factor of liver disorders caused by flutamide--statistical analysis using multivariate logistic regression analysis].
Topics: Alanine Transaminase; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Flutamide; Human | 1999 |
[Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; H | 1999 |
Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Topics: Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrotestosterone; Enzyme In | 1999 |
["Evanescent" prostate carcinoma].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy, Needle; Combine | 1999 |
Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Apoptosis; Flutamide; H | 1999 |
Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.
Topics: Antineoplastic Agents, Hormonal; Chromogranin A; Chromogranins; Flutamide; Humans; Immunoenzyme Tech | 1999 |
[Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer].
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Androgen Antagonists; Antineoplastic Agents, Hormonal | 1999 |
Examination of selected food additives and organochlorine food contaminants for androgenic activity in vitro.
Topics: Adenocarcinoma; Androgens; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Cell Survival; Chlord | 2000 |
[A case of prostate cancer treated with combined androgen-blockade].
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Diethylstilbestrol; Flutamide; Humans; | 2000 |
Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 2000 |
Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Carrier Proteins; Flutamide; Gonadal Steroid Hormones; Histone Acetyltransfera | 1999 |
Numb chin syndrome as the presenting symptom of metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma; Chin; Drug Therapy, Combination; Flutamide | 2000 |
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic | 2000 |
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; H | 2000 |
[Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Ch | 2000 |
Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biop | 2000 |
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Cypro | 2000 |
Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Anticarcinogenic Agents; Blotting, Western; Crosses, | 2000 |
Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemother | 2000 |
Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations.
Topics: Androgen Antagonists; Androgens; Animals; Calcium Signaling; Cell Line; Cyproterone Acetate; Dihydro | 2000 |
Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplast | 2000 |
[Fulminant liver failure induced by flutamide].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Liver Failure; Male; Prostatic Neopla | 2000 |
Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2000 |
Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Clinical Trials, Phase II as T | 2000 |
Androgen blockade in prostate cancer.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Meta | 2000 |
[Adenoid cystic carcinoma of the prostate. Clinical case].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Carcinoma, Adenoid Cysti | 2000 |
Enhancement of androgen-dependent transcription and cell proliferation by tributyltin and triphenyltin in human prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Blotting, Northern; Cell Division; DNA, Neoplasm; Flutamide; Humans | 2000 |
Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male | 2000 |
Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Flut | 2000 |
Prediction of organ-confined disease by prostate-specific antigen nadir after neoadjuvant therapy.
Topics: Aged; Androgen Antagonists; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Multivariat | 2000 |
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Binding Sites; Cell Line; COS Cells; Dihyd | 2001 |
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2001 |
Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Black or African Ame | 2001 |
Prostate cancer with multiple lung metastases in a hemodialysis patient.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combinati | 2000 |
[Radical prostatectomy with broadened scope of indications - analysis of early experience].
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Flutamide; Go | 1999 |
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Appetite | 2001 |
Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Top | 2001 |
Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Dihydrotestosterone; DNA- | 2001 |
Chemical andropause and amyloid-beta peptide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Androgen Antagoni | 2001 |
Oncogenic osteomalacia.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Cholecalciferol; Disease Progression; Fatal Outcome; Flutamide | 2000 |
[Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate].
Topics: Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; He | 2001 |
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Topics: Androgen Antagonists; Anilides; Clinical Trials, Phase III as Topic; Cyproterone Acetate; Factor Ana | 2001 |
[Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Drug Administ | 2001 |
M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Bone Neoplasms; Carcinoembryonic Antigen; Cel | 2001 |
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality T | 2001 |
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Topics: Adenoviridae; Androgen Antagonists; Androgen-Binding Protein; Animals; Apoptosis; Arabidopsis Protei | 2001 |
Flutamide-induced acute hepatitis in advanced prostate cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; C | 2001 |
Flutamide-induced hepatotoxicity: report of a case series.
Topics: Adolescent; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Live | 2001 |
[Local staging with magnetic resonance imaging after neoadjuvant hormonal therapy for prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flutamide; Human | 2001 |
Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells.
Topics: Blotting, Western; Flutamide; Humans; Immunoblotting; Male; Oxidation-Reduction; Peptide Hydrolases; | 2001 |
Regulation of u-PA gene expression in human prostate cancer.
Topics: Blotting, Northern; Blotting, Western; Cell Division; Chloramphenicol O-Acetyltransferase; Coloring | 2001 |
[Hepatotoxicity due to flutamide].
Topics: Aged; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Ma | 2001 |
[The effect of combined endocrine therapy on prostate and testis].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Atrophy; Drug Therapy, Combination; Flu | 1999 |
Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study.
Topics: Aged; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Li | 2002 |
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplasti | 2002 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Ac | 2002 |
In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
Topics: Aged; Culture Techniques; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Humans; Lymphatic Meta | 1976 |
Androgen receptors in benign and malignant prostatic tissue.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen Antagonists; Animals; Cyproterone; Dihydrotestostero | 1979 |
Chemotherapy of advanced prostatic cancer today.
Topics: Aged; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Estramustine; Fluorourac | 1976 |
Effect of flutamide on cortisol metabolism.
Topics: Aged; Anilides; Flutamide; Humans; Hydrocortisone; Kinetics; Male; Middle Aged; Prostatic Neoplasms; | 1978 |
Effect of flutamide on estradiol metabolism.
Topics: Anilides; Estradiol; Flutamide; Humans; Male; Prostatic Neoplasms | 1979 |
Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Topics: Adenocarcinoma; Aged; Anilides; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 1979 |
The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.
Topics: Aged; Androgens; Anilides; Flutamide; Gonadotropins, Pituitary; Humans; Male; Middle Aged; Prostatic | 1977 |
Comparison and significance of respiration and glycolysis of prostatic tissue from various species.
Topics: Animals; Diethylstilbestrol; Dogs; Dose-Response Relationship, Drug; Estramustine; Flutamide; Glycol | 1975 |
Histochemical and ultrastructural study of prostatic tissue from baboons treated with antiprostatic drugs.
Topics: Acid Phosphatase; Aminopeptidases; Anilides; Animals; Atrophy; Diethylstilbestrol; Epithelial Cells; | 1976 |
Drug development for carcinoma of the prostate.
Topics: Alkylating Agents; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents; Estroge | 1976 |
Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment.
Topics: Aged; Anilides; Castration; Estrogens; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Ti | 1975 |
Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.
Topics: Aged; Anilides; Biopsy, Needle; Cerebrovascular Disorders; Estradiol; Estrone; Flutamide; Follicle S | 1975 |
Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Drug Resistance; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; L | 1992 |
Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Combined Modality Therapy; Estrogens | 1992 |
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Androgen | 1992 |
NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo.
Topics: Acid Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Cyproterone Acetate; Cytotoxicity Tests, | 1992 |
Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Male; Prostatic Neoplasms | 1992 |
Objective treatment response to endocrine therapy in metastatic prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Combined Modality Therapy; Estrogens; Flutamide; Humans; Lymphatic M | 1992 |
Local hyperthermia for prostatic disease: in vitro studies on human prostatic cancer cell lines.
Topics: Cell Division; Cell Survival; Dihydrotestosterone; DNA, Neoplasm; Flutamide; Humans; Hyperthermia, I | 1992 |
The usefulness of serum acid phosphatase in monitoring patients with advanced prostate carcinoma.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Cyclophosphamide; Estramustine; | 1992 |
Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Chemotherapy, Adjuvant; | 1992 |
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate | 1992 |
Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1992 |
Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.
Topics: Adult; Aged; Combined Modality Therapy; Flutamide; Humans; Leuprolide; Male; Middle Aged; Orchiectom | 1992 |
[Complete androgenic blockade: myth or reality. Study and follow-up of 35 patients with advanced carcinoma of the prostate].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Follow-Up Studie | 1992 |
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasm | 1990 |
Carcinoma of the prostate. Treating disease that has metastasized.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dissemina | 1990 |
Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Topics: Acid Phosphatase; Antigens, Neoplasm; Antineoplastic Agents; APUD Cells; Biomarkers, Tumor; Carcinoe | 1991 |
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; | 1991 |
Proteins C and S in patients with advanced prostatic cancer.
Topics: Buserelin; Carrier Proteins; Complement C4b; Complement Inactivator Proteins; Flutamide; Glycoprotei | 1991 |
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolid | 1991 |
Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Animals; Azasteroids; Diethylstilbestrol; Fina | 1991 |
Flutamide-induced methemoglobinemia.
Topics: Aged; Aged, 80 and over; Flutamide; Humans; Male; Methemoglobinemia; Prostatic Neoplasms | 1991 |
Total androgen ablation: American experience.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Flutamide; Gonadotropin-Releas | 1991 |
Pathologic changes associated with androgen deprivation therapy for prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Therapy, Combinat | 1991 |
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Topics: Androgens; Androstane-3,17-diol; Binding, Competitive; Cell Cycle; Dihydrotestosterone; Dose-Respons | 1991 |
Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
Topics: Androgen Antagonists; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Humans; Imidazoles | 1991 |
Flutamide has no effect on adrenal androgen response to acute ACTH stimulation in patients with prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Aged, 80 and over; Androgens; Drug Therapy, Combination; Flutamid | 1990 |
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Immuno | 1991 |
Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer.
Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents; Drug Administration Sche | 1991 |
Flutamide-related fulminant hepatic failure.
Topics: Bone Neoplasms; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Male; Middle Aged; Prosta | 1991 |
Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
Topics: Anilides; Antineoplastic Agents; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormon | 1990 |
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineo | 1990 |
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neopl | 1990 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Ther | 1990 |
The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line.
Topics: Androgen Antagonists; Androgens; Cell Division; Cell Transformation, Neoplastic; Cyproterone; Cyprot | 1990 |
Complete androgen blockade as primary treatment for advanced metastatic cancer of the prostate.
Topics: Aged; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neopla | 1990 |
The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP.
Topics: Androgens; Antibodies; Cell Division; Dihydrotestosterone; Estradiol; Flutamide; Humans; Male; Nandr | 1990 |
Flutamide-induced liver failure.
Topics: Aged; Anilides; Chemical and Drug Induced Liver Injury; Flutamide; Humans; Liver; Liver Diseases; Ma | 1990 |
Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
Topics: Androgen Antagonists; Carcinoma; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neop | 1990 |
Advances in the treatment of metastatic prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Flutamide; Gonadotrop | 1985 |
Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
Topics: Androgen Antagonists; Anilides; Carcinoma; Castration; Flutamide; Glycoprotein Hormones, alpha Subun | 1986 |
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Topics: Adrenal Glands; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dihydrotestosteron | 1987 |
Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice.
Topics: Androgens; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Female; Flutamide; Male | 1988 |
Flutamide approved for prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; | 1989 |
Androgens do not regulate the growth hormone response to GHRH in elderly men.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Growth | 1989 |
LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Topics: Androgen Antagonists; Buserelin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Pros | 1989 |
"Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Topics: Androgen Antagonists; Anilides; Animals; Cyproterone; Cyproterone Acetate; Dogs; Flutamide; Imidazol | 1989 |
[Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Th | 1989 |
From the Food and Drug Administration.
Topics: Acyclovir; Anilides; Cytomegalovirus Infections; Flutamide; Ganciclovir; Humans; Ifosfamide; Male; M | 1989 |
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutam | 1989 |
re Benefits of combination therapy with flutamide in patients relapsing after castration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Flutamide; Humans; Male; Prostatic Neopl | 1989 |
Long-term experience with flutamide in patients with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Diethylstilbestrol; Flutamide; Humans; Male; Midd | 1989 |
The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aged; Androgens; Anilides; Flutamide; Humans; Male; Mid | 1988 |
Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
Topics: Anilides; Combined Modality Therapy; Cyproterone; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1986 |
Combination therapy in prostate cancer.
Topics: Combined Modality Therapy; Flutamide; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1986 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutam | 1986 |
Treatment of prostatic cancer. Newer forms of androgen deprivation.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestro | 1986 |
The kinetics of antiandrogens in humans.
Topics: Androgen Antagonists; Anilides; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Imidazoles; Imi | 1987 |
Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
Topics: Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; | 1987 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Topics: Adenocarcinoma; Androgens; Anilides; Combined Modality Therapy; Evaluation Studies as Topic; Flutami | 1987 |
Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.
Topics: Aged; Aminoglutethimide; Androstane-3,17-diol; Androstanols; Androsterone; Anilides; Dehydroepiandro | 1987 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstene | 1988 |
Hormonal agents and treatment of cancer.
Topics: Androgens; Breast Neoplasms; Diethylstilbestrol; Dihydrotestosterone; Estrogens; Female; Flutamide; | 1986 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; | 1988 |
The effect of androgen blockade on pulsatile gonadotrophin release and LH response to naloxone.
Topics: Anilides; Flutamide; Follicle Stimulating Hormone; Humans; Hypothalamo-Hypophyseal System; Luteinizi | 1987 |
Short term effects of flutamide administration on hypothalamic-pituitary-testicular axis in man.
Topics: Aged; Anilides; Flutamide; Follicle Stimulating Hormone; Humans; Hypothalamo-Hypophyseal System; Lut | 1988 |
Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Che | 1988 |
Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Topics: Anilides; Animals; Body Weight; Cell Line; Drug Therapy, Combination; Flutamide; Gonadotropin-Releas | 1985 |
The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
Topics: Administration, Oral; Anilides; Flutamide; Humans; Male; Prostatic Neoplasms | 1988 |
Re Benefits of combination therapy with flutamide in patients relapsing after castration.
Topics: Anilides; Combined Modality Therapy; Flutamide; Humans; Male; Orchiectomy; Prostatic Neoplasms | 1988 |
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Topics: Aged; Aged, 80 and over; Anilides; Apolipoproteins B; Combined Modality Therapy; Estrogens; Flutamid | 1988 |
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
Topics: Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Relea | 1988 |
Benefits of combination therapy with flutamide in patients relapsing after castration.
Topics: Aged; Anilides; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hor | 1988 |
Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic C | 1988 |
Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Topics: Acid Phosphatase; Aged; Anilides; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormo | 1987 |
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration.
Topics: Aged; Anilides; Combined Modality Therapy; Drive; Erectile Dysfunction; Flutamide; Humans; Male; Mid | 1988 |
Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency.
Topics: Adenocarcinoma; Aged; Anilides; Fertility; Flutamide; Humans; Male; Middle Aged; Prostate; Prostatic | 1988 |
Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
Topics: Adenocarcinoma; Anilides; Animals; Biological Assay; Drug Therapy, Combination; Flutamide; Gonadotro | 1986 |
Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
Topics: Aged; Anilides; Biological Assay; Combined Modality Therapy; Diethylstilbestrol; Drug Therapy, Combi | 1986 |
Androgen dependence of the Dunning R3327G cell line in monolayer culture.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dihydrotestosterone; Flutamide; | 1987 |
Ocular toxicity of Anandron in patients treated for prostatic cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged; | 1986 |
Manic-like episode following flutamide treatment.
Topics: Aged; Anilides; Bipolar Disorder; Flutamide; Humans; Male; Prostatic Neoplasms | 1986 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Meges | 1986 |
Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide.
Topics: Anilides; Animals; Cells, Cultured; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Resi | 1987 |
Flutamide as primary treatment for metastatic prostatic cancer.
Topics: Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Flutamide; Humans; Male; Middle Aged; Prostatic N | 1987 |
Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Topics: Adrenal Glands; Androgen Antagonists; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releas | 1985 |
Principles of endocrine manipulation in the treatment of prostatic cancer.
Topics: Androgen Antagonists; Animals; Castration; Cyproterone; Estrogens; Flutamide; Gonadotropin-Releasing | 1985 |
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Topics: Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; M | 1985 |
Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues.
Topics: Anilides; Animals; Cells, Cultured; Female; Flutamide; Humans; Kinetics; Male; Mammary Neoplasms, Ex | 1986 |
Flutamide therapy for advanced prostatic cancer: a phase II study.
Topics: Aged; Anilides; Castration; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; Flutamid | 1985 |
Pharmacology and clinical studies with RU 23908 (Anandron).
Topics: Androgen Antagonists; Androstenedione; Animals; Castration; Diethylstilbestrol; Flutamide; Humans; I | 1985 |
[Flutamide in the treatment of advanced carcinoma of the prostate].
Topics: Aged; Anilides; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 1985 |
A new antiprostatic agent for treatment of prostatic carcinoma.
Topics: Adenocarcinoma; Anilides; Flutamide; Gynecomastia; Humans; Male; Neoplasm Metastasis; Prostatic Neop | 1973 |